

0001104659-24-127623S-1 Quoin Pharmaceuticals, Ltd. 2024121120241211162030162030162030 0 0001104659-24-127623 S-1 15 20241211 20241211 Quoin Pharmaceuticals, Ltd. 0001671502 2834 000000000 L3 S-1 33 333-283734 241541778 23 HATA'AS STREET KFAR SABA L3 44425 97299741444 23 HATA'AS STREET KFAR SABA L3 44425 Collect Biotechnology Ltd. 20160721 Collect Biomed Ltd. 20160406 S-1 1 tm2430640d1\_s1.htm FORM S-1 As filed with the Securities and Exchange Commission on December 11, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUOIN PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) A State of Israel 2834 92-2593104 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) A 42127 Pleasant Forest Court Ashburn, VA 20148-7349 (703) 980-4182 (Address, including zip code and telephone number, including area code, of Registrant's principal executive offices) A Dr. Michael Myers Chief Executive Officer Quoin Pharmaceuticals Ltd. 42127 Pleasant Forest Ct Ashburn, VA 20148 Tel: 703-980-4182 (Name, address, including zip code and telephone number, including area code of agent for service) A Copies to: A Peter I. Tsolias Melissa Palat Murawsky Blank Rome LLP Jonathan Irom, Adv. Matthew Rudolph, Adv. Meitar | Law Offices Barry I. Grossman Matthew Bernstein Ellenoff Grossman & Schole LLP One Logan Square 130 North 18th Street Philadelphia, PA 19103 Tel: (215) 569-5500 16 Abba Hillel Silver Rd. Ramat Gan 5250608, Israel Tel: +972-3-610-3100 1345 Avenue of the Americas, 11th Floor New York, NY 10105 Tel: (212) 370-1300 A Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective. A If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, or Securities Act, check the following box. x A If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. A A If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. A A If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. A A Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Securities Exchange Act of 1934, or the Exchange Act. A Large Accelerated Filer A Accelerated Filer A Non-accelerated filer x A Smaller Reporting Company x A A Emerging Growth Company A A If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. A A The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. A A A A The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. A Preliminary Prospectus Subject to Completion, Dated DECEMBER 11, 2024 A A A Up to 19,230,769 Ordinary Shares Represented by American Depository Shares A Up to 19,230,769 Pre-Funded Warrants to Purchase Up to 19,230,769 Ordinary Shares Represented by American Depository Shares A Up to 19,230,769 Series F Warrants to Purchase Up to 19,230,769 Ordinary Shares Represented by American Depository Shares A Up to 19,230,769 Series G Warrants to Purchase Up to 19,230,769 Ordinary Shares Represented by American Depository Shares A Up to 57,692,307 Ordinary Shares Represented by American Depository Shares Issuable Upon Exercise of the Pre-Funded Warrants, Series F Warrants and Series G Warrants A A A We are offering on a reasonable best efforts basis up to 19,230,769 ordinary shares of Quoin Pharmaceuticals Ltd. represented by American Depository Shares (ADSs) together with Series F warrants to purchase an aggregate of up to 19,230,769 ordinary shares represented by ADSs (the Series F Warrants and Series G warrants to purchase an aggregate of up to 19,230,769 ordinary shares represented by ADSs (the Series F Warrants, and together with the Series F Warrants, the Warrants). The assumed combined public offering price for each ADS and accompanying Warrants is \$0.78, which was the closing price of our ADSs as reported by The Nasdaq Capital Market (Nasdaq) on December 9, 2024. Each ADS represents one ordinary share. Each Series F Warrant will have an exercise price equal to 100% of the public offering price per ADS and accompanying Warrants, will be exercisable upon issuance, and will expire two years from the date of issuance. Each Series G Warrant will have an exercise price of equal to 100% of the public offering price per ADS and accompanying Warrants, will be exercisable upon issuance, and will expire five years from the date of issuance. The ADSs and the Warrants will be issued separately and will be immediately separable upon issuance but will be sold together in this offering. This prospectus also relates to the ADSs issuable upon exercise of the Warrants sold in this offering. A We are also offering to each purchaser, if any, whose purchase of ADSs in this offering would otherwise result in the purchaser's beneficial ownership exceeding 4.99% of our outstanding ordinary shares. Each Pre-Funded Warrant will be immediately exercisable for one ADS and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The purchase price of each Pre-Funded Warrant and accompanying Warrants will equal the price at which each ADS and accompanying Warrants are being sold to the public in this offering, minus \$0.0001, and the exercise price of each Pre-Funded Warrant will be \$0.0001 per ADS. The Pre-Funded Warrants and Warrants will be issued separately and will be immediately separable upon issuance but will be purchased together in this offering. For each Pre-Funded Warrant we sell, the number of ADSs we are offering will be decreased on a one-for-one basis. This offering also relates to the ADSs issuable upon exercise of any Pre-Funded Warrants sold in this offering. We refer to the ADSs, Warrants and Pre-Funded Warrants to be sold in this offering.

collectively as the "Securities." For purposes of clarity, each ADS or Pre-Funded Warrant to purchase one ADS is being sold together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS. Our ADSs are listed on Nasdaq under the symbol "QNRX." We have assumed a public offering price of \$0.78 per ADS and accompanying Warrants, which was the closing price of our ADSs on Nasdaq on December 9, 2024. The actual offering price per ADS and accompanying Warrants or Pre-Funded Warrant and accompanying Warrants, will be negotiated between us and the investors, in consultation with the placement agent based on, among other things, our history and our prospects, our past and present operating results, the general condition of the securities markets at the time of this offering and the trading price of our ADS prior to the offering and may be at a discount to the current market price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final offering price. In addition, there is no established public trading market for the Warrants and Pre-Funded Warrants and we do not expect a market to develop. We do not intend to apply for a listing of the Warrants or Pre-Funded Warrants on any national securities exchange. We have engaged Maxim Group LLC to act as our exclusive placement agent (the "Placement Agent" or "Maxim") in connection with this offering. The Placement Agent has agreed to use its reasonable best efforts to arrange for the sale of the Securities offered by this prospectus. The Placement Agent is not purchasing or selling any of the Securities we are offering, and the Placement Agent is not required to arrange the purchase or sale of any specific number of Securities or dollar amount. We have agreed to pay to the Placement Agent the placement agent fees set forth in the table below, which assumes that we sell all of the Securities offered by this prospectus. The Securities are expected to be issued in a single closing and the public offering price per ADS or Pre-Funded Warrant and accompanying Warrants will be fixed for the duration of this offering. We will deliver all Securities to be issued in connection with this offering delivery versus payment ("DVP")/receipt versus payment ("RVP") upon receipt of investor funds received by us. Accordingly, neither we nor the Placement Agent have made any arrangements to place investor funds in an escrow account or trust account since the Placement Agent will not receive investor funds in connection with the sale of the Securities offered hereunder. There is no minimum offering requirement as a condition of closing of this offering. Because there is no minimum offering amount required as a condition to closing this offering, we may sell fewer than all of the Securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of Securities sufficient to pursue our business goals described in this prospectus. Any proceeds from the sale of Securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. See the section entitled "Risk Factors" on page 11 of this prospectus for more information. This offering will terminate on January 11, 2025, unless the offering is fully subscribed before that date or we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will bear all costs associated with the offering. The Securities offered in this prospectus involve a high degree of risk. Before deciding whether to invest in our Securities, you should consider carefully the risks and uncertainties under the heading "Risk Factors" beginning on page 11 of this prospectus.

Per ADS and Accompanying Warrants Per Pre-Funded Warrant and Accompanying Warrants Total(1) Public offering price \$  
\$ Placement Agent's fees (2) \$ \$ \$ \$ Proceeds to us, before expenses (3) \$ \$ \$ \$ (1)Assumes the sale of the maximum amount of Securities offered hereunder. Because there is no minimum number of Securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above. (2)We have agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds raised in this offering. We have also agreed to reimburse the Placement Agent for certain of its offering-related expenses. See "Plan of Distribution" beginning on page 51 of this prospectus for a description of the compensation to be received by the Placement Agent. (3)The amount of the proceeds to us presented in this table does not give effect to any exercise of the Warrants or Pre-Funded Warrants. Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these Securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. Delivery of the Securities is expected to be made on or about January 11, 2024, subject to satisfaction of customary closing conditions. Maxim Group LLC The date of this prospectus is , 2024. Table of Contents About this Prospectus ii PROSPECTUS SUMMARY 1 THE OFFERING 6 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 9 RISK FACTORS 11 USE OF PROCEEDS 16 CAPITALIZATION 17 DILUTION 18 DESCRIPTION OF SHARE CAPITAL 19 DESCRIPTION OF AMERICAN DEPOSITORY SHARES 26 DESCRIPTION OF Warrants WE ARE OFFERING 35 CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS 39 CERTAIN MATERIAL ISRAELI TAX CONSIDERATIONS 46 PLAN OF DISTRIBUTION 51 LEGAL MATTERS 58 EXPERTS 58 ENFORCEABILITY OF CIVIL LIABILITIES 58 WHERE YOU CAN FIND MORE INFORMATION 59 Incorporation of Certain Information By Reference 60 The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the Securities offered under this prospectus. The registration statement, including the exhibits, can be read on our website and the website of the Securities and Exchange Commission. See "Where You Can Find More Information." Information contained in, and that can be accessed through our web site, www.quoinpharma.com, shall not be deemed to be part of this prospectus or incorporated herein by reference and should not be relied upon by any prospective investors for the purposes of determining whether to purchase the Securities offered hereunder. Unless otherwise indicated or the context otherwise requires, all references in this prospectus to the terms "Quoin," "Quoin Ltd.," the "Company," "us," "we," "our," and the "Registrant" refer to Quoin Pharmaceuticals Ltd., an Israeli company, and its consolidated subsidiaries and this offering refers to the offering contemplated in this prospectus. About this Prospectus We and the Placement Agent have not authorized anyone to provide any information or to make any representations other than those contained, or incorporated by reference, in this prospectus or in any free writing prospectuses prepared by us or on our behalf or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the Securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. We are not making an offer to sell these Securities in any jurisdiction where the offer or sale is not permitted or where the person making the offer or sale is not qualified to do so or to any person to whom it is not permitted to make such offer or sale. You should not assume that the information contained in this prospectus (as supplemented or

amended) is accurate on any date subsequent to the date set forth on the front of the document, even though this prospectus (as supplemented or amended) is delivered, or Securities are sold, on a later date. □ We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to this offering. The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any Securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the heading “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.” □ For investors outside the United States: We have not done anything that would permit the offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the Securities described herein and the distribution of this prospectus outside the United States. □ This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled “Where You Can Find More Information.” □ The Quoin logo and other trademarks or service marks of Quoin Ltd. appearing in this prospectus are the property of Quoin Ltd. or Quoin Inc., as applicable. This prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the “” symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. □ II □ □ PROSPECTUS SUMMARY □ The following summary highlights information contained elsewhere in this prospectus or incorporated by reference herein and does not contain all the information that may be important to purchasers of our Securities. Prospective purchasers of our Securities should carefully read the entire prospectus and any applicable prospectus supplement, including the risks of investing in our Securities discussed under the heading “Risk”

Factors contained in this prospectus, the applicable prospectus supplement and under similar headings in the other documents that are incorporated by reference into this prospectus. Prospective purchasers of our Securities should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. □ Company Overview □ We are a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments or cures. Our initial focus is on the development of products, using our proprietary owned and in-licensed drug delivery technologies, that could help address rare skin diseases. Our first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary in-licensed Invisicare® technology, is under development as a potential treatment for Netherton Syndrome (“NS”), a rare hereditary genetic disease. QRX003 is currently being tested in two clinical studies in five clinical sites in the United States (“U.S.”) under an open Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”). An Investigator study in a pediatric NS patient has been initiated in Ireland. We are also developing QRX004 as a potential treatment for Recessive Dystrophic Epidermolysis Bullosa (“RDEB”). In addition, we entered into two separate Research Agreements with the Queensland University of Technology (“QUT”), under which we have obtained an option for global licenses to QRX007 for the potential treatment of NS and QRX008 for the potential treatment of scleroderma, as well as a Research Agreement with the University College Cork (“UCC”) for the development of novel topical formulations of Rapamycin (sirolimus) as potential treatments for a number of rare and orphan diseases for which there are currently no approved therapies or cures. □ Quoin’s mission is to develop and commercialize proprietary therapeutic drug products that treat rare and orphan diseases, particularly those where none currently exists. To achieve this, we plan to: □ — complete the late-stage clinical testing of QRX003 in NS and, if successful, file for marketing approval in the United States and other territories; □ — prepare to commercialize QRX003 by establishing our own sales infrastructure in the U.S. and Europe and entering into distribution partnerships in other territories such as those currently established for Canada, Australia/New Zealand, the Middle East, China, Hong Kong, Taiwan, Latin America, Central and Eastern Europe, Turkey and Singapore; and □ — pursue business development activities by seeking partnering, licensing, merger and acquisition opportunities or other transactions to further expand our pipeline and drug-development capabilities. □ 1 □ Our Current Product Pipeline □ □ \*3 Clinical studies underway

\*\*Clinical trial initiated \*\*\*Clinical testing to commence Q12025 □ Netherton Syndrome □ NS is a rare autosomal recessive genetic disease affecting approximately 6,000 – 8,000 patients in the U.S. and Europe which is caused by a mutation in the SPINK5 gene and has an incidence of approximately 1/200,000 births. The SPINK5 gene encodes a protein, called lympho-epithelial kazal type related inhibitor (“LEKTI”) that serves as a brake system on the activity of certain proteases (enzymes that digest proteins) in the skin called Kallikreins. The absence of the LEKTI protein, as a result of the genetic defect that causes NS, leads to unregulated protease activity in the skin by the Kallikreins, resulting in too few layers of the outer skin (stratum corneum), thereby leading to a highly defective and compromised skin barrier. As a result, patients with NS suffer from a variety of medical issues including regular, severe infections, skin cancer, chronic pruritis, asthma, and allergies among others. □ There are currently no approved therapies to treat NS. In the absence of an approved therapeutic product, patients can only obtain minor symptomatic relief, generally by the regular use of emollients and moisturizing creams and lotions. Other topical agents must be used with caution because the highly compromised skin in NS patients may allow ingredients from some topically applied medications to be excessively absorbed into the bloodstream, which may pose a danger to the patient. Use of topical keratolytic agents, such as urea or lactic acid derivatives, may be limited by skin irritation and is generally reserved for older children or adults. Base line treatment may also include oral antihistamines, which can help to control the itchy, eczematous component, and topical or systemic antibiotics as needed. Oral and topical steroids and systemic biologics may be beneficial in reducing inflammation and the eczematous component of the disease. However, the well-documented side effects of long-term steroid use need to be carefully considered. There is a critical need for a new and effective treatment for NS. □ 2 □ Regulatory Status of QRX003 for the Treatment of NS □ Our lead asset, QRX003, is

currently in late-stage clinical development in the U.S. under an open IND application with the FDA. We submitted an IND in MarchÂ 2022 to the FDA to initiate a clinical study of QRX003 in adult NS patients. We received a â€˜Study MayÂ Proceedâ€™ notification from the FDA on JuneÂ 13, 2022, which cleared us to initiate clinical testing of QRX003 in NS patients. This study is fully up and running and five clinical sites in the U.S. have been opened and are actively recruiting and dosing patients. This study originally was designed as a randomized, double blinded assessment of two different doses of QRX003 versus a placebo vehicle in 18 adult NS patients. The test materials are applied once daily, over a twelve-week period, to pre-selected areas of the patientâ€™s body, primarily the arms and legs. Based on discussions with the FDA, a number of different clinical endpoints are being assessed in the study, including but not limited to, an Investigators Global Assessment (IGA), Patientâ€™s Global Assessment (PaGA) and Pruritis. Â In NovemberÂ 2022, we submitted a protocol for our second clinical study in NS patients to the FDA under our currently open IND (the â€œOpen Label Studyâ€). This study was cleared by the FDA to initiate in DecemberÂ 2022. This study originally was designed to be conducted in ten adult NS patients who are currently receiving, and will continue to do so throughout the study, off-label systemic therapy, primarily systemic biologic therapy. This is an open-label study with no placebo control. Both of these NS clinical studies are running concurrently and utilize the same clinical trial sites and investigators. Â On OctoberÂ 24, 2023, we released positive initial clinical results obtained from the first six evaluable subjects in the Open Label Study. Five of the six subjects reported absence of or negligible pruritis, with one subject reporting no change; three subjects demonstrated improvement with respect to skin appearance on completion of the study and three showing such improvements during the study though not necessarily on completion of the study. In addition, all six subjects reported a favorable impression of QRX003 across a number of key metrics, including: ease of use, time to start working, overall satisfaction, lack of side effects. Â As a result of this positive initial data and the absence of any safety concerns from both studies, on NovemberÂ 8, 2023 we submitted a number of protocol amendments to the FDA, under our open IND, with a view to optimizing both studies and potentially leading to even better clinical outcomes and a more rapid regulatory approval. These protocol amendments included eliminating the lower dose from the double-blinded study, modifying the dosing frequency from once-daily to twice-daily and increasing the number of subjects from 18 to 30. For the Open Label Study, the number of subjects was increased from 10 to 20 and dosing was modified from once-daily to twice-daily. On DecemberÂ 13, 2023, we announced that we were cleared by the FDA to implement these protocol amendments. In FebruaryÂ 2024 we submitted a further protocol amendment to the FDA requesting permission to lower the age of eligibility for participation in both studies to 14Â years and older from 18 years and older. On MarchÂ 4, 2024 we announced that we were cleared to implement this protocol amendment. All protocol amendments have now been implemented and going forward participants in both regulatory studies will be dosed twice-daily with those enrolled in the blinded study receiving either a 4% dose of QRX003 or a placebo, while subjects in the Open Label Study will receive a 4% dose of QRX003 only. In MarchÂ 2022, we submitted a briefing document to the European Medicines Agency (â€œEMAâ€) seeking guidance regarding the clinical and regulatory development of QRX003 for the European Union (â€œEUâ€), to which we received comprehensive and constructive feedback. We also intend to apply for Orphan Drug status in the U.S. and Europe as well as Rare Pediatric Disease designation in the U.S. for QRX003. On JuneÂ 27, 2024 we announced that we will expand our ongoing Netherton Syndrome clinical studies to include international sites. The first international site will be opened at a research hospital in Saudi Arabia. This hospital is currently treating a number of NS patients who will now become eligible for recruitment into our studies. An experienced Clinical Research Organization has been engaged to manage the study locally. Â 3 Â On AugustÂ 6, 2024, we announced the planned initiation of an investigator-led clinical study in New Zealand for QRX003 in pediatric patients with Peeling Skin Syndrome. This rare genetic condition currently has no approved treatments or cures. The first clinical site and patient have been identified, and Quoin is actively evaluating additional clinical sites in other countries. Â On OctoberÂ 22, 2024 we announced the further expansion of our ongoing Netherton Syndrome clinical studies to include to include two additional international sites in the United Kingdom (UK). Both of these sites, Great Ormond Street Hospital and St. Thomasâ€™ Hospital, which are located in London, are highly qualified centers of excellence for treating Netherton Syndrome patients in the UK. Both sites have available cohorts of patients potentially eligible to participate in Quoinâ€™s studies. A globally recognized expert in the treatment of NS patients has been appointed as Principal Investigator for the UK studies and a Clinical Research Organization has been engaged. Â The UK and Saudi Arabia sites will operate under the auspices of Quoinâ€™s open IND application with the FDA. Quoin is also in advanced stage of preparation for the opening of additional sites in several other Western European countries and is concluding a feasibility study in multiple Eastern European countries with both territories having available cohorts of patients with Netherton Syndrome. Â On NovemberÂ 5, 2024, we announced that QRX003 is being tested in a pediatric NS patient at the Childrens Hospital in Dublin,Â Ireland and that we intend to expand this study to include up to three additional pediatric patients with NS in Spain and up to six additional pediatric patients in the UK. The test materials will be applied twice daily to pre-selected areas of the patientâ€™s body. Â Smaller Reporting Company Â We are a â€œsmaller reporting companyâ€ as defined in the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). As a result, we may take advantage of certain reduced disclosure obligations available to smaller reporting companies, including the exemption from compliance with the auditor attestation requirements pursuant to the Sarbanes-Oxley Act of 2002, reduced disclosure about our executive compensation arrangements and the requirements to provide only two years of audited financial statements in our annual reports and registration statements. We will continue to be a â€œsmaller reporting companyâ€ as long as (1)Â we have a public float (i.e., the market value of our ADSs held by non-affiliates) less than \$250 million calculated as of the last business day of our most recently completed second fiscal quarter, or (2)Â our annual revenues are less than \$100 million for our previous fiscal year and we have either no public float or a public float of less than \$700 million as of the end of that fiscal yearâ€™s second fiscal quarter. Decreased disclosures in our SEC filings due to our status as a â€œsmaller reporting companyâ€ may make it harder for investors to analyze our results of operations and financial prospects. Â Company Information Â We were incorporated under the laws of the State of Israel in 1986 under the name Montiger Ltd. Between 1986 and 2021, we underwent several name changes, including the name change to Cellect Biotechnology Ltd. (â€œCellectâ€). On OctoberÂ 28, 2021, Cellect completed the business combination with Quoin Pharmaceuticals,Â Inc., a Delaware corporation (â€œQuoinÂ Inc.â€), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of MarchÂ 24, 2021 (the â€œMerger Agreementâ€), by and among Cellect, QuoinÂ Inc. and CellMSC,Â Inc., a Delaware corporation and wholly-owned subsidiary of Cellect (â€œMerger Subâ€), pursuant to which Merger Sub merged with and into Quoin Inc., with Quoin Inc. surviving as a wholly-owned subsidiary of Cellect (the â€œMergerâ€). Immediately after completion of the Merger, Cellect changed its name to â€œQuoin Pharmaceuticals Ltd.â€ Â Prior to JanuaryÂ 1, 2023, we qualified as a

â€œforeign private issuerâ€ as such term is defined in Rule 405 under the Securities Act. Since January 1, 2023, we have been obligated to file or furnish reports, proxy statements, and other information on U.S. domestic issuer forms with the Securities and Exchange Commission (the â€œSECâ€), which are more detailed and extensive in certain respects, and which must be filed more promptly, than the forms available to a foreign private issuer. The address of our executive corporate offices is 42127 Pleasant Forest Ct., Ashburn, VA 20148, and our telephone number is (703) 980-4182. Our website is [www.quoinpharma.com](http://www.quoinpharma.com). Information contained on or accessible through this website is not incorporated by reference in, or otherwise a part of, this prospectus, and any references to this website are intended to be inactive textual references only. **5** **THE OFFERING** Issuer Quoin Pharmaceuticals Ltd. ADSs offered by us Up to 19,230,769 ADSs at an assumed public offering price of \$0.78 per ADS and accompanying Warrants, which represents the closing price of our ADSs on Nasdaq on December 9, 2024. **6** **Pre-Funded Warrants** offered by us We are also offering up to 19,230,769 Pre-Funded Warrants to purchase up to 19,230,769 ADSs in lieu of ADSs to any purchaser whose purchase of shares of ADSs in this offering would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding ordinary shares immediately following the consummation of this offering. Each Pre-Funded Warrant will be exercisable for one ADS, will have an exercise price of \$0.0001 per ADS, will be immediately exercisable, and will not expire until exercised in full. This prospectus also relates to the offering of the ADSs issuable upon exercise of the Pre-Funded Warrants. For each Pre-Funded Warrant that we sell, the number of ADSs that we are selling will be decreased on a one-for-one basis. **7** **Warrants offered by us** We are also offering (i) up to 19,230,769 Series F Warrants to purchase up to 19,230,769 ADSs and (ii) up to 19,230,769 Series G Warrants to purchase up to 19,230,769 ADSs. Each Series F Warrant will be exercisable for one ADS, will have an exercise price equal to 100% of the combined public offering price per share of ADS and accompanying Warrants, will be exercisable upon issuance, and will expire two years from the date of issuance. Each Series G Warrant will be exercisable for one ADS, will have an exercise price equal to 100% of the combined public offering price per share of ADSs and accompanying Warrants, will be exercisable upon issuance, and will expire five years from the date of issuance. This prospectus also relates to the offering of the ADSs issuable upon exercise of the Warrants. Because we will issue a Series F Warrant and a Series G Warrant for each ADS and for each Pre-Funded Warrant sold in this offering, the number of Warrants sold in this offering will not change as a result of a change in the mix of ADSs and Pre-Funded Warrants sold. **8** **ADSs outstanding prior to this offering** 5,049,720 ADSs (assuming all ordinary shares are represented by ADSs) **9** **ADSs to be outstanding after this offering** 24,280,489 ADSs (assuming all ordinary shares are represented by ADSs, all of the ADSs we are offering under this prospectus are sold, and assuming no sale of Pre-Funded Warrants, which, if sold, would reduce the number of ADSs that we are offering on a one-for-one basis, and no exercise of the Warrants issued in this offering) **10** **Reasonable best efforts offering** We have agreed to offer and sell the Securities offered hereby to the purchasers through the Placement Agent. The Placement Agent has agreed to use its reasonable best-efforts to arrange for the sale of the Securities offered by this prospectus. The Placement Agent is not purchasing or selling any of the Securities we are offering and the Placement Agent is not required to arrange the purchase or sale of any specific number or dollar amount of Securities. See â€œPlan of Distributionâ€ on page 51 of this prospectus. **11** **Use of proceeds** Assuming 19,230,769 ADSs are sold in this offering at an assumed combined public offering price of \$0.78 per ADS and accompanying Warrants, which represents the closing price of our ADS on Nasdaq on December 9, 2024, and assuming no issuance of Pre-Funded Warrants and no exercise of Warrants issued in connection with this offering, we estimate that our net proceeds from the this offering will be approximately 13.4 million, after deducting placement agent fees and estimated offering expenses payable by us. However, this is a best efforts offering with no minimum number of Securities or amount of proceeds as a condition to closing, and we may not sell all or any of these Securities offered pursuant to this prospectus; as a result, we may receive significantly less in net proceeds. **12** **We currently intend to use the net proceeds from the sale of the Securities under this prospectus for general corporate purposes, which may include operating expenses, research and development, including clinical and pre-clinical testing of our product candidates, working capital, future acquisitions and general capital expenditures.** See â€œUse of Proceedsâ€ on page 16 of this prospectus. **13** **Depositary** The Bank of New York Mellon **14** **Transfer Agent and Registrar** Computershare Trust Company, N.A. **15** **Risk factors** See â€œRisk Factorsâ€ beginning on page 11 of this prospectus and the documents incorporated by reference herein for a discussion of factors you should carefully consider before deciding to invest in our Securities. **16** **Listing** Our ADSs are listed on The Nasdaq Capital Market under the symbol â€œQRNX.â€ We do not intend to apply for a listing of the Pre-Funded Warrants or the Warrants on any national securities exchange or other nationally recognized trading system. **17** **The information above is based on 5,049,720 ordinary shares represented by 5,049,720 ADSs outstanding as of December 9, 2024 (assuming all ordinary shares are represented by ADSs), and excludes the following:** 1,943,787 ordinary shares represented by 1,943,787 ADSs issuable upon the exercise of outstanding options at a weighted-average exercise price of \$4.29 per ADS; and 8,988,346 ordinary shares represented by 8,988,346 ADSs issuable upon the exercise of outstanding warrants at a weighted-average exercise price of \$2.10 per ADS. **18** **Unless otherwise indicated, all information in this prospectus assumes no exercise of the outstanding options or warrants described above after December 9, 2024, including, for the avoidance of doubt, any Pre-Funded Warrants or Warrants.** We may enter into privately negotiated agreements with the holders of certain existing outstanding warrants to purchase up to 8,988,346 ADSs (the â€œPrior Warrantsâ€) to, among other things, reduce the exercise price of such Prior Warrants and to extend the current expiration date of the Prior Warrants. There can be no assurance that we will amend the Prior Warrants or as to the final terms of any amendments to the Prior Warrants. **19** **CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS** Certain information contained, or incorporated by reference, in this prospectus may contain â€œforward-looking statementsâ€ within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by the use of forward-looking terminology such as â€œmay,â€ â€œwill,â€ â€œexpect,â€ â€œanticipate,â€ â€œestimate,â€ â€œcontinue,â€ â€œbelieve,â€ â€œshould,â€ â€œintend,â€ â€œprojectâ€ or other similar words, but are not the only way these statements are identified. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on

assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Â Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things: Â Â·our limited operating history and the difficulties encountered by a small developing company; Â Â·our history of losses and need for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; Â Â·our lack of revenue generated from product sales since inception, and potential inability to be profitable; Â Â·uncertainties of cash flows and inability to meet working capital needs; Â Â·our ability to obtain regulatory approvals; Â Â·our ability to generate favorable pre-clinical and clinical trial results; Â Â·our ability to identify and develop potential product candidates; Â Â·additional costs or delays associated with unsuccessful clinical trials; Â Â·the inability to predict the timing of revenue from sales of a future product; Â Â·the extensive regulatory requirements and future developmental and regulatory challenges we will still face even if we obtain approval for a product candidate; Â Â·our ability to obtain or maintain orphan drug designation or data exclusivity for our product candidates; Â Â·our ability to obtain Orphan Disease and Rare Pediatric Disease designations for our product candidates; Â 9 Â Â·the potential oversight of programs or product candidates that may be more profitable or more successful; Â Â·our manufacturing processes may not be validated and our methodology may not be accepted by the scientific community; Â Â·the ability to conduct clinical trials, because of difficulties enrolling patients or other reasons; Â Â·the requirements of being a publicly traded company may strain our resources; Â Â·potential adverse effects resulting from failure to maintain effective internal controls; Â Â·our ability to comply with the applicable continued listing requirements of Nasdaq; Â Â·the potential negative impact on our securities price and trading volume if securities or industry analysts do not publish reports about us or if they adversely change their recommendations about our business; Â Â·failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of our ADSs; Â Â·the potential volatility of the market price for our ADSs; Â Â·the potential dilution of our shareholdersâ™ potential ownership due to future issuances of share capital; Â Â·the requirement for holders of ADSs to act through the depositary to exercise their rights; Â Â·the potential limitations on ADS holders with respect to the transfer of their ADSs; and Â Â·the risks of securities class action litigation. Â The risks and uncertainties included here are not exhaustive or necessarily in order of importance. Other sections of this prospectus, including âœRisk Factorsâ€ beginning onÂ pageÂ 11, our Annual Report on FormÂ 10-KÂ for the year ended DecemberÂ 31, 2023, and other reports that we file with the SEC include additional factors that could affect our businesses and financial performance. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors. You are urged to carefully review and consider the various disclosures made throughout this prospectus which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. Â You should not put undue reliance on any forward-looking statements. Although the forward-looking statements in this prospectus are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Â In addition, certain sections of this prospectus contain information obtained from independent industry sources and other sources that we have not independently verified. Â 10 Â Â RISK FACTORS Â Investing in our Securities involves a high degree of risk. Before making an investment in our Securities, you should carefully consider the risk factors discussed below as well as other information we include or incorporate by reference in this prospectus, including the risks and uncertainties discussed under âœRisk Factorsâ€ in our Annual Report on FormÂ 10-K for the fiscal year ended December 31, 2023 and our Quarterly Report on FormÂ 10-Q for the nine months ended SeptemberÂ 30, 2024, each of which has been filed with the SEC and is incorporated by reference in this prospectus, as well as any updates thereto contained in subsequent filings with the SEC or any free writing prospectus. All of these risk factors are incorporated herein in their entirety. If any of the following risks occur, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that case, the market price of our Securities could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially harm our business, operating results and financial condition and could result in a complete loss of your investment. Â Risks Related to this Offering Â This is a reasonable best efforts offering, in which no minimum number or dollar amount of Securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans. Â The Placement Agent has agreed to use its reasonable best efforts to solicit offers to purchase the Securities in this offering. The Placement Agent has no obligation to buy any of the Securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the Securities. There is no required minimum number of Securities that must be sold as a condition to completion of this offering, and there can be no assurance that the offering contemplated hereby will ultimately be consummated. Even if we sell Securities offered hereby, because there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount is not presently determinable and may be substantially less than the maximum amount set forth above. We may sell fewer than all of the Securities offered hereby, which may significantly reduce the amount of proceeds received by us. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise additional funds, which may not be available or available on terms acceptable to us. Â Because there is no minimum required for the offering to close, investors in this offering will not receive a refund in the event that we do not sell an amount of Securities sufficient to pursue the business goals outlined in this prospectus. Â We have not specified a minimum offering amount nor have or will we establish an escrow account in connection with this offering. Because there is no escrow account and no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to fulfill our objectives due to a lack of interest in this offering. Further, because there is no escrow account in operation and no minimum investment amount, any proceeds from the sale of Securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. Investor funds will not be returned under any circumstances whether during or after the offering. Â 11 Â Â You may experience immediate and substantial dilution in the net tangible book value of the shares you purchase in this offering and may experience additional dilution in the future. Â The public offering price per ADS and accompanying Warrants and the public offering price of each Pre-Funded Warrant and accompanying Warrants may be substantially higher than the as adjusted net tangible book value per ADS after giving

effect to this offering. Assuming the sale of 19,230,769 ADSs at an assumed public offering price of \$0.78 per ADS and accompanying Warrants (which is based on the closing price of our ADSs on Nasdaq on December 9, 2024), assuming no sale of any Pre-Funded Warrants in this offering, and after deducting the Placement Agent fees and commissions and estimated offering expenses payable by us, you will incur immediate dilution in as adjusted net tangible book value of approximately \$0.03 per ADS. As a result of the dilution to investors purchasing Securities in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of the liquidation of our company. See the section entitled "Dilution" below for a more detailed discussion of the dilution you will incur if you participate in this offering. To the extent shares are issued under outstanding options and warrants at exercise prices lower than the public offering price of our ADSs or Pre-Funded Warrants in this offering, you will incur further dilution. This offering may cause the trading price of our ADSs to decrease. The price per ADS, together with the number of ADSs we propose to issue and ultimately will issue if this offering is completed, may result in an immediate decrease in the market price of our ADSs. This decrease may continue after the completion of this offering. Sales of substantial amounts of our ADSs in the public market, or the perception that such sales might occur, could adversely affect the market price of our ADSs. You may experience future dilution as a result of future equity offerings. In order to raise additional capital, we may in the future offer additional ADSs or other securities convertible into or exchangeable for our ADSs that could result in further dilution to investors purchasing our ordinary shares represented by ADSs in this offering or result in downward pressure on the price of our ADSs. We may sell ADSs or other securities in any other offering at prices that are higher or lower than the prices paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders. In addition, we may enter into privately negotiated agreements with the holders of certain existing outstanding warrants to purchase up to 8,988,346 ADSs to, among other things, reduce the exercise price of such Prior Warrants and to extend the current expiration date of the Prior Warrants. There can be no assurance that we will amend the Prior Warrants or as to the final terms of any amendments to the Prior Warrants. Our management will have broad discretion over the use of the net proceeds from this offering, you may not agree with how we use the proceeds, and the proceeds may not be invested successfully. We have not designated any portion of the net proceeds from this offering to be used for any particular purpose. Accordingly, our management will have broad discretion as to the use of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest the net proceeds in a way that does not yield a favorable, or any, return for our company. Our management's judgment may not result in positive returns on your investment and you will not have the opportunity to evaluate the economic, financial or other information upon which our management bases its decisions. We will need to raise additional funding to fund our working capital needs or consummate potential future acquisitions. Additional financing may not be available on acceptable terms, or at all. Failure to obtain additional capital may force us to limit or terminate our operations. Even if we sell all Securities offered hereby, the expected net proceeds of this offering will not be sufficient for us to fund the working capital needs of our business or potential strategic acquisitions we may pursue in the future. We will continue to seek funds through equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Additional funding may not be available to us on acceptable terms, or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. 12 There is no public market for the Pre-Funded Warrants or the Warrants being offered in this offering. There is no established public trading market for the Pre-Funded Warrants or the Warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the Pre-Funded Warrants or the Warrants on any securities exchange or nationally recognized trading system. Without an active market, the liquidity of the Pre-Funded Warrants or the Warrants will be limited. Holders of our Pre-Funded Warrants or the Warrants will have no rights as holders of ordinary shares represented by ADSs until such warrants are exercised. Until you acquire ordinary shares represented by ADSs upon exercise of your Pre-Funded Warrants or Warrants, you will have no rights with respect to ADSs issuable upon exercise of your Pre-Funded Warrants or Warrants. Upon exercise of your Pre-Funded Warrants or Warrants, you will be entitled to exercise the rights of a holder of ordinary shares represented by ADSs only as to matters for which the record date occurs after the exercise date. The Warrants may not have any value. Each Warrant has an exercise price equal to 100% of the public offering price per ADS and accompanying Warrants in this offering. In the event the market price per our ADS does not exceed the exercise price of the Warrants during the period when the Warrants are exercisable, the Warrants may not have any value. Provisions of the Warrants offered by this prospectus could discourage an acquisition of us by a third party. Certain provisions of the Warrants offered by this prospectus could make it more difficult or expensive for a third party to acquire us. The Warrants prohibit us from engaging in certain transactions constituting "fundamental transactions" unless, among other things, the surviving entity assumes our obligations under the Warrants. Further, the Warrants provide that, in the event of certain transactions constituting "fundamental transactions," with some exceptions, holders of such warrants will have the right, at their option, to require us to purchase such Warrants from the holders for consideration of the same type as that offered to the holders of ordinary shares in such transaction in an amount determined pursuant to a formula set forth in such warrants. These and other provisions of the Warrants offered by this prospectus could prevent or deter a third party from acquiring us even where the acquisition could be beneficial to you. Purchasers who purchase our Securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement. In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement including, but not limited to: (i) a covenant to not enter into variable rate financings for a period of 180 days following the closing of the offering, subject to certain exceptions; (ii) a covenant to not enter into any equity financings for 90 days from closing of the offering, subject to certain exceptions. 13 Risks Related to Ownership of Our ADSs and Ordinary Shares Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our ADSs. Our ADSs are listed on the Nasdaq Capital Market, which imposes, among other requirements, a minimum bid requirement. On April 29, 2024, we received a deficiency letter from the Listing Qualifications Department of Nasdaq notifying us that for the preceding 31 consecutive business days

(MarchÂ 14, 2024 through AprilÂ 26, 2024), our ADSs did not maintain a minimum closing bid price of \$1.00 (â€œMinimum Bid Price Requirementâ€) per ADS as required by Nasdaq Listing RuleÂ 5550(a)(2). In accordance with Nasdaq Listing RuleÂ 5810(c)(3)(A), we had a compliance period of 180 calendar days, or until OctoberÂ 28, 2024, to regain compliance with Nasdaq Listing RuleÂ 5550(a)(2). On OctoberÂ 16, 2024, the Company submitted a letter to Nasdaq requesting an additional 180-day grace period to regain compliance with the Minimum Bid Price Requirement. On OctoberÂ 29, 2024, the Company received a letter from the Listing Qualifications Department of Nasdaq granting the Company an additional 180 calendar day grace period, or until AprilÂ 28, 2025, to regain compliance. The Staffâ€™s determination in granting the Company the extension was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the Minimum Bid Price Requirement, and the Companyâ€™s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse split, if necessary. Compliance may be achieved without further action if the closing bid price of the Companyâ€™s ADS is at or above \$1.00 for a minimum of ten consecutive business days at any time during the second compliance period, in which case Nasdaq will notify the Company if it determines the Company is in compliance and the matter will be closed; however Nasdaq could require the closing bid price to equal or to exceed the \$1.00 minimum bid price requirement for more than 10 consecutive business days before determining that the Company complies. If compliance cannot be demonstrated by AprilÂ 28, 2025, the Staff will provide written notification that the Companyâ€™s securities will be delisted. At that time, the Company may appeal the Staffâ€™s determination to a Hearings Panel. Â If we cannot regain compliance with the Minimum Bid Price Requirement or if we otherwise fail to meet any of Nasdaqâ€™s listing standards, our ADSs will be subject to delisting. If that were to occur, our ADSs would be subject to rulesÂ that impose additional sales practice requirements on broker-dealers who sell our securities. The additional burdens imposed upon broker-dealers by these requirements could discourage broker-dealers from effecting transactions in our ADSs. This would adversely affect the ability of investors to trade our ADSs and would adversely affect the value of our ADSs. Delisting from Nasdaq would cause us to pursue eligibility for trading of our ADSs on other markets or exchanges, or on an over-the-counter market. In such case, our stockholdersâ€™ ability to trade or obtain quotations of the market value of our ADSs would be severely limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger spreads in the bid and ask prices of these securities. There can be no assurance that our ADSs, if delisted from the Nasdaq, would be listed on a national securities exchange, a national quotation service or the over-the-counter markets. Delisting from the Nasdaq could also result in negative publicity, adversely affect the market liquidity of our ADSs, decrease securities analystsâ€™ coverage of us or diminish investor, supplier and employee confidence. Â 14 Â Â The delisting of our ADSs from Nasdaq may make it more difficult for us to raise capital on favorable terms in the future, or at all. Such a delisting would likely have a negative effect on the price of our ADSs and would impair your ability to sell or purchase our ADSs when you wish to do so. Further, if our ADSs were to be delisted from Nasdaq, our ADSs would cease to be recognized as a covered security, and we would be subject to additional regulation in each state in which we offer our securities. Moreover, there is no assurance that any actions that we take to restore our compliance with the Nasdaq Minimum Bid Price Requirement would stabilize the market price or improve the liquidity of our ADSs, prevent our ADSs from falling below the Nasdaq minimum bid price required for continued listing again or prevent future non-compliance with other applicable Nasdaq listing requirements, including maintaining minimum levels of stockholdersâ€™ equity or market values of our ADSs, our ADSs could be delisted. Â 15 Â Â USE OF PROCEEDS Â We estimate that we will receive net proceeds from this offering of approximately \$13.4 million (assuming the sale of the maximum number of Securities offered hereby), based upon an assumed public offering price of \$0.78 per ADS and accompanying Warrants (which is the closing price of our ADS on Nasdaq on DecemberÂ 9, 2024), after deducting the estimated placement agent fees and estimated offering expenses payable by us and assuming no issuance of any Pre-Funded Warrants and no exercise of the Warrants. However, because this is a reasonable best efforts offering with no minimum number of Securities or amount of proceeds as a condition to closing, the actual offering amount, placement agent fees, and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover pageÂ of this prospectus, and we may not sell all or any of the Securities we are offering. As a result, we may receive significantly less in net proceeds. Based on the assumed offering price set forth above, we estimate that our net proceeds from the sale of 75%, 50%, and 25% of the Securities offered in this offering would be approximately \$9.9Â million, \$6.4Â million, and \$2.9Â million, respectively, after deducting the estimated placement agent fees and estimated offering expenses payable by us, and assuming no issuance of any Pre-Funded Warrants and assuming no exercise of the Warrants. We will only receive additional proceeds from the exercise of the Warrants we are selling in this offering if the Warrants are exercised for cash. We cannot predict when or if these Warrants will be exercised. It is possible that these Warrants may expire and may never be exercised. Â These estimates exclude the proceeds, if any, from the exercise of the Warrants offered hereby. If all of the Warrants offered hereby were to be exercised in cash, we would receive additional proceeds of approximately \$30.0 million. We cannot predict when or if these Warrants will be exercised. It is possible that these Warrants may expire and may never be exercised. Additionally, these Warrants contain a cashless exercise provision that permit exercise of such Warrants on a cashless basis at any time when there is no effective registration statement under the Securities Act covering the issuance of the underlying shares. Â We currently intend to use these net proceeds for general corporate purposes, which may include operating expenses, research and development, including clinical and pre-clinical testing of our product candidates, working capital, future acquisitions and general capital expenditures. We have not determined the amount of net proceeds to be used specifically for any of such purposes. Â The expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve and change. The amounts and timing of our actual expenditures, specifically with respect to working capital, may vary significantly depending on numerous factors. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. We have no current agreements, commitments or understandings for any material acquisitions or licenses of any products, businesses or technologies that are definitive or probable to close. Unforeseen events or changed business conditions may result in application of the proceeds of the offering in a manner other than as described in this prospectus. Our shareholders may not agree with the manner in which our management chooses to allocate and spend the net proceeds. Moreover, our management may use the net proceeds for corporate purposes that may not result in our being profitable or increase our market value. Â Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. Â 16 Â Â

CAPITALIZATION  $\Delta$  The following table sets forth our cash and capitalization as of September 30, 2024 on:  $\Delta$  an actual basis; and  $\Delta$  an as adjusted basis, assuming our sale of the maximum number of Securities offered hereby in this offering at an assumed public offering price of \$0.78 per ADS and accompanying Warrants, based on the closing price of our ADSs on Nasdaq on December 9, 2024, resulting in net proceeds to us of approximately \$13.4 million, after deducting the placement agent fees and estimated offering expenses payable by us, and assuming no sale of Pre-Funded Warrants and no exercise of Warrants.  $\Delta$  The as adjusted information set forth in the table below is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering as determined at pricing. You should read the information in this table together with our audited financial statements and related notes and  $\Delta$  Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, incorporated by reference in this prospectus.  $\Delta$   $\Delta$  As of September 30, 2024  $\Delta$   $\Delta$  Actual  $\Delta$   $\Delta$  As Adjusted  $\Delta$   $\Delta$  (Unaudited)  $\Delta$  Cash and Short-Term Investments  $\Delta$  \$10,306,888  $\Delta$   $\Delta$  \$23,671,888  $\Delta$  Liabilities:  $\Delta$   $\Delta$   $\Delta$   $\Delta$   $\Delta$  Non-Current Liabilities  $\Delta$  2,473,733  $\Delta$   $\Delta$  2,473,733  $\Delta$  Shareholders' Equity:  $\Delta$   $\Delta$   $\Delta$   $\Delta$   $\Delta$  Ordinary shares, no par value per share, 100,000,000 ordinary shares authorized and 5,049,720 ordinary shares (represented by 5,049,720 ADSs) issued and outstanding actual and 24,280,489 ordinary shares (represented by 24,280,489 ADSs) issued and outstanding as adjusted  $\Delta$   $\Delta$   $\Delta$  Additional paid-in capital  $\Delta$  58,296,199  $\Delta$   $\Delta$  71,661,199  $\Delta$  Accumulated deficit  $\Delta$  (52,854,518)  $\Delta$   $\Delta$  (52,854,518) Total shareholders' equity  $\Delta$  \$5,441,681  $\Delta$   $\Delta$  \$18,806,681  $\Delta$  Total capitalization  $\Delta$  \$7,915,414  $\Delta$   $\Delta$  \$21,280,414  $\Delta$  The information above is based on 5,049,720 ordinary shares, represented by 5,049,720 ADSs outstanding as of September 30, 2024 (assuming all ordinary shares are represented by ADSs) and excludes the following:  $\Delta$   $\Delta$  278,011 ordinary shares represented by 278,011 ADSs issuable upon the exercise of outstanding options at a weighted-average exercise price of \$25.34 per ADS; and  $\Delta$   $\Delta$  8,988,346 ordinary shares represented by 8,988,346 ADSs issuable upon the exercise of outstanding warrants at a weighted-average exercise price of \$2.10 per ADS.  $\Delta$   $\Delta$  17  $\Delta$   $\Delta$  Dilution  $\Delta$  If you invest in our Securities in this offering, your interest will be diluted immediately to the extent of the difference between the public offering price paid by the purchasers of the ADSs or Pre-Funded Warrants sold in this offering and the pro forma as adjusted net tangible book value per ADS after this offering.  $\Delta$  Our historical net tangible book value of our ADSs as of September 30, 2024, was approximately \$4.9 million, or approximately \$0.98 per ADS. Net tangible book value per share represents the amount of our total tangible assets less total liabilities divided by the total number of our ADSs outstanding as of September 30, 2024.  $\Delta$  After giving effect to the sale by us in this offering of 19,230,769 ADSs at a price of \$0.78 per ADS and accompanying Warrants, based on the closing price of our ADSs on Nasdaq on December 9, 2024, after deducting the Placement Agent fees and estimated offering expenses payable by us, and assuming no sale of any Pre-Funded Warrants in this offering and no exercise of any Warrants, our as adjusted net tangible book value as of September 30, 2024, would have been approximately \$18.3 million, or approximately \$0.75 per ADS. This represents an immediate decrease in net tangible book value of approximately \$0.23 per ADS to our existing security holders and an immediate dilution in as adjusted net tangible book value of approximately \$0.03 per ADS to purchasers of ADSs in this offering. The final public offering price will be determined through negotiation between us, the Placement Agent, and prospective investors in the offering and may be at a discount to the current market price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final public offering price. The following table illustrates this per share dilution:  $\Delta$  Assumed public offering price per ADS  $\Delta$   $\Delta$   $\Delta$  \$0.78  $\Delta$  Historical net tangible book value per ADS as of September 30, 2024  $\Delta$  \$0.98  $\Delta$   $\Delta$   $\Delta$  Decrease in as adjusted net tangible book value per ADS attributable to new investors participating in this offering  $\Delta$  \$(0.23)  $\Delta$   $\Delta$   $\Delta$  As adjusted net tangible book value per ADS after this offering  $\Delta$   $\Delta$   $\Delta$  \$0.75  $\Delta$  Dilution per ADS to new investors purchasing ADSs in this offering  $\Delta$   $\Delta$   $\Delta$  \$0.03  $\Delta$   $\Delta$   $\Delta$  \$0.10 increase in the assumed public offering price to \$0.88 per ADS and accompanying Warrants, based on the closing price of our ADSs on Nasdaq on December 9, 2024, would increase our as adjusted net tangible book value as of September 30, 2024 after this offering to approximately \$20.1 million, or approximately \$0.83 per ADS, and would change the dilution to investors in this offering to approximately \$0.05 per ADS, assuming the sale by us of 19,230,769 ADSs and accompanying Warrants, assuming no sale of any Pre-Funded Warrants and no exercise of any Warrants, and after deducting the Placement Agent fees and estimated offering expenses payable by us. A \$0.10 decrease in the assumed initial public offering price to \$0.68 per ADS and accompanying Warrants, based on the closing price of our ADSs on Nasdaq on December 9, 2024, would decrease our as adjusted net tangible book value as of September 30, 2024 after this offering to approximately \$16.5 million, or approximately \$0.68 per ADS, and would not be dilutive to investors in this offering, assuming the sale by us of 19,230,769 ADSs and accompanying Warrants, assuming no sale of any Pre-Funded Warrants and no exercise of any Warrants, and after deducting the Placement Agent fees and estimated offering expenses payable by us.  $\Delta$  We may also increase or decrease the number of securities we are offering. A 2,000,000 increase in the number of ADSs sold by us in the offering would increase our as adjusted net tangible book value as of September 30, 2024 after this offering to approximately \$19.8 million, or approximately \$0.75 per ADS, and would be dilutive to investors in this offering by approximately \$0.03 per ADS, assuming the assumed public offering price remains the same, assuming no sale of any Pre-Funded Warrants and no exercise of any Warrants, and after deducting the Placement Agent fees and estimated offering expenses payable by us. A 2,000,000 decrease in the number of ADSs sold by us in the offering would decrease our as adjusted net tangible book value as of September 30, 2024 after this offering to approximately \$16.8 million, or approximately \$0.76 per ADS, and would change the dilution to investors in this offering to approximately \$0.02 per ADS, assuming the assumed public offering price remains the same, assuming no sale of any Pre-Funded Warrants and no exercise of any Warrants, and after deducting the Placement Agent fees and estimated offering expenses payable by us.  $\Delta$  The table and discussion above are based on 5,049,720 ordinary shares, represented by 5,049,720 ADSs outstanding (assuming all ordinary shares are represented by ADSs) as of September 30, 2024 and excludes the following:  $\Delta$   $\Delta$  278,011 ordinary shares represented by 278,011 ADSs issuable upon the exercise of outstanding options at a weighted-average exercise price of \$25.34 per ADS; and  $\Delta$   $\Delta$  8,988,346 ordinary shares represented by 8,988,346 ADSs issuable upon the exercise of outstanding warrants at a weighted-average exercise price of \$2.10 per ADS.  $\Delta$  The information discussed above is illustrative only and will adjust based on the actual public offering price, the actual number of ADSs that we offer in this offering, and other terms of this offering determined at pricing. Except as indicated otherwise, the discussion and table above assumes no sale of Pre-Funded Warrants, which, if sold, would reduce the number of ADSs that we are offering on a one-for-one basis.  $\Delta$   $\Delta$  18  $\Delta$   $\Delta$  DESCRIPTION OF SHARE CAPITAL  $\Delta$  The following are summaries of material provisions of our articles of association and the Israeli Companies Law, 5759-1999 (the  $\Delta$  Companies Law $\Delta$ ), insofar as they relate to the material terms of

our ordinary shares. Â Purposes and Objects of the Company Â Our purpose is set forth in SectionÂ 2 of our articles of association and includes every lawful purpose. Â Voting Rights Â Holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of shareholders at a shareholders meeting. Shareholders may vote at shareholders meetings either in person, by proxy or by written ballot. Israeli law does not allow public companies to adopt shareholder resolutions by means of written consent in lieu of a shareholders meeting. The board of directors shall determine and provide a record date for each shareholders meeting and all shareholders at such record date may vote. Unless stipulated differently in the Companies Law or in the articles of association, all shareholdersâ€™ resolutions shall be approved by a simple majority vote. As a general rule, an amendment to our articles of association requires the prior approval of a simple majority of our shares represented and voting at a general meeting. Â Transfer of Shares Â Our ordinary shares that are fully paid for are issued in registered form and may be freely transferred under our articles of association, unless the transfer is restricted or prohibited by applicable law or the rulesÂ of a stock exchange on which the shares are traded. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our articles of association or Israeli law, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel. Â Amendment of Share Capital Â Our articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution duly passed by our shareholders at a annual or special general meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings and profits, or an issuance of shares for less than their nominal value (which would be applicable to our company should our articles be changed so as to permit the issue of shares having a nominal value, however our shares currently have no nominal value), require a resolution of our board of directors and court approval. Â Dividends and Liquidation Rights Â We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the companyâ€™s articles of association provide otherwise. The Companyâ€™s Articles of Association do not require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by the Board. Â 19 Â Pursuant to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according to our then last reviewed or audited financial statements (less the amount of previously distributed dividends, if not reduced from the earnings), provided that the end of the period to which the financial statements relate is not more than six months prior to the date of the distribution. If we do not meet such criteria, then we may distribute dividends only with court approval; as a company listed on an exchange outside of Israel, however, court approval is not required if the proposed distribution is in the form of an equity repurchase, provided that we notify our creditors of the proposed equity repurchase and allow such creditors an opportunity to initiate a court proceeding to review the repurchase. If within 30 days such creditors do not file an objection, then we may proceed with the repurchase without obtaining court approval. In each case, we are only permitted to distribute a dividend if the Board and, if applicable, the court determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. Â In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future. Â Exchange Controls Â There are currently no Israeli currency control restrictions on payments of dividends or other distributions with respect to our ordinary shares or the proceeds from the sale of the shares, except, under certain circumstances, for shareholders who are subjects of countries that are, or have been, in a state of war with Israel. Israeli residents have an obligation to file reports with the Bank of Israel regarding certain transactions. However, legislation remains in effect pursuant to which currency controls can be imposed by administrative action at any time. Â Shareholders Meetings Â Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year and in any event no later than 15 months after the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to as special meetings. The Board may call special meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that a board of directors is required to convene a special meeting upon the written request of (1)Â any two or more of our directors, (2)Â one quarter of the directors then in office; or (3)Â as a company listed on an exchange in the U.S., one or more shareholders holding, in the aggregate either (a)Â 10% or more of our issued and outstanding share capital and 1% of our outstanding voting rights, or (b)Â 10% or more of our outstanding voting rights. Â Under Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting of the shareholders may request that the board of directors include a matter in the agenda of a general meeting of the shareholders to be convened in the future, provided that it is appropriate to discuss such a matter at the general meeting. Notwithstanding the foregoing, as a company listed on an exchange outside of Israel, a matter relating to the appointment or removal of a director may only be requested by one or more shareholders holding at least 5% of the voting rights at the general meeting of the shareholders. Â 20 Â Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings of a company are the shareholders of record on a date to be decided by the board of directors which for us, as a company listed on an exchange outside Israel, may be between four and sixtyÂ days prior to the date of the meeting. Â The Companies Law and our articles of association require that resolutions regarding the following matters must be passed at a general meeting of our shareholders: Â Â·amendments to our articles of association; Â Â·appointment, terms of service or termination of service of our auditors; Â Â·appointment and dismissal of external directors, if and to the extent any are required to be appointed under the Companies Law; Â Â·approval of acts and transactions requiring general meeting approval pursuant to the Companies Law; Â Â·increases or reductions of our authorized share capital; Â Â·a merger; and Â Â·the exercise of our board of directorsâ€™ powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management. Â The Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes, among other things, the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting. Under the Companies Law and our amended and restated articles of association, shareholders are not permitted to take action by way of written consent in lieu of a meeting. Â Quorum Â Our articles of association provide that the quorum required for our general meetings of shareholders consists of two or

more shareholders present in person, by proxy or by other voting instrument in accordance with the Companies Law and our articles of association, who hold or represent, in the aggregate, at least 33 1/3% (of the total outstanding voting rights (the quorum requirement for domestic filing companies under Nasdaq current corporate governance rules) unless the Company qualifies as a foreign private issuer under U.S. federal securities laws and the general meeting is convened pursuant to a resolution of the Board, in which case the requisite quorum will be 25% of the Company's shares entitled to vote at a general meeting of the shareholders. **21** **Vote Requirements** Our articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our articles of association. Under the Companies Law, certain actions require the approval of a special majority, including: (i) an extraordinary transaction with a controlling shareholder or in which the controlling shareholder has a personal interest, (ii) the terms of employment or other engagement of a controlling shareholder of the company or a controlling shareholder's relative (even if such terms are not extraordinary) and (iii) certain compensation-related matters described above under "Management Compensation Committee" Compensation Policy under the Companies Law. Under our articles of association, the alteration of the rights, privileges, preferences or obligations of any class of our shares (to the extent there are classes other than ordinary shares) requires the approval of a simple majority of the class so affected (or such other percentage of the relevant class that may be set forth in the governing documents relevant to such class), in addition to a majority of all classes of shares voting together as a single class at a shareholder meeting. **Dissolution** Generally under Israeli law, a resolution for the voluntary winding up of a company requires the approval of holders of 75% of the voting rights represented at the meeting, in person, by proxy or by written ballot and voting on the resolution. In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares (including holders of entitlements to shares, after deducting the nominal value (if any) of such shares and the price which would have been paid in order to exercise the right to such shares), in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future. **Access to Corporate Records** Under the Companies Law, all shareholders of a company generally have the right to review minutes of the company's general meetings, its register of shareholders and material shareholders, articles of association, financial statements and any document it is required by law to file publicly with the Israeli Companies Registrar. Any of our shareholders may request to review any document in our possession that relates to any action or transaction with a related party, interested party, or office holder that requires shareholder approval under the Companies Law. We may deny a request to review a document if we determine that the request was not made in good faith, that the document contains a trade secret or patent, or that the document's disclosure may otherwise prejudice our interests. **Acquisitions under Israeli Law** **Full Tender Offer** A person wishing to acquire shares of a public Israeli company, and who would as a result hold over 90% of the target company's issued and outstanding share capital, is required by the Companies Law to make a tender offer to all of the company's shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company, and who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares, is required to make a tender offer to all of the shareholders who hold shares of that class for the purchase of all of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law, provided that a majority of the offerees that do not have a personal interest in such tender offer, have accepted the tender offer. Alternatively, if shareholders who do not accept the tender offer represent less than 2% of the company's issued and outstanding share capital (or less than 2% of the applicable class of shares), approval by a majority of the offerees that do not have a personal interest in such tender offer is not required to complete the tender offer. A shareholder whose shares are so transferred may petition the court regarding the fair value to be paid in consideration of such shares, within six months from the date of acceptance of the full tender offer; this right of petition applies to all offeree shareholders, unless the acquirer stipulated in the tender offer that a shareholder accepting the offer may not seek appraisal rights, and prior to the acceptance of the full tender offer, the acquirer and the company disclosed the information required by law in connection with a full tender offer. To the extent a court so petitioned determines that the offered value was less than the fair value per share, the court may order the difference to be paid. **22** **Special Tender Offer** The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer complying with the relevant provisions of the Companies Law if, as a result of the acquisition, the purchaser would become a holder of 25% or more of the voting rights in the company, if there did not previously exist a holder of 25% or more of the voting rights in the company, or if, as a result of the acquisition, the purchaser would become a holder of more than 45% of the voting rights in the company, if there did not previously exist a holder of more than 45% of the voting rights in the company. This requirement does not apply if the acquisition: (a) occurs in the context of a private placement by the company that received shareholder approval as a private placement giving the offeree 25% or 45% of the company's voting rights (as the case may be); (b) is from a holder of 25% or more of the voting rights in the company and results in the acquirer becoming a holder of 25% or more of the voting rights in the company; or (c) is from a holder of more than 45% of the voting rights in the company and results in the acquirer becoming a holder of more than 45% of the voting rights in the company. In the event that a special tender offer is made, the target company's board of directors is required to express its opinion on the advisability of the offer, or may abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. A special tender offer must be directed to all offerees, and the offerees may give notice of their agreement or opposition to the special tender offer. The special tender offer will be consummated only if: (a) at least 5% of the voting rights attached to the company's outstanding shares will be acquired by the offeror, and (b) among those shareholders who gave notice of their position (excluding any controlling shareholders of the offeror, holders of 25% or more of the voting rights in the target company, and any person having a personal interest in the acceptance of the tender offer, including relatives or corporations under the control of any of the above), the number of shares whose holders agreed to the offer exceeds the number of shares whose holders objected to the offer. If a special tender offer is accepted by the procedure described above, then shareholders who did not respond to or who objected the offer may accept the offer within four days of the last day set for the acceptance of the offer. An office holder in a company which is the target of a special tender offer who, in his or her capacity as an office holder, performs an act or omits to act for in order to cause the failure of an existing or foreseeable special tender offer, or to impair the likelihood of its acceptance, is liable to the offeror and offerees for

damages, unless such office holder acted in good faith and had reasonable grounds to believe that such act or omission was beneficial to the company. As a safe harbor, office holders of the target company may negotiate with a potential purchaser in order to improve the terms of a special tender offer, or negotiate with third parties in order to obtain a competing offer. ¶ 23 ¶ In the event that a special tender offer is accepted, the purchaser, any person or entity controlling or controlled by the purchaser, or under common control with the purchaser, may not make a subsequent tender offer for the purchase of shares of the target company, and may not enter into a merger with the target company, for a period of one¶ year from the date of the offer, unless the purchaser or such person or entity undertakes to effect such an offer or merger as a special tender offer in compliance with the Companies Law requirements. ¶ Merger ¶ The Companies Law permits merger transactions if approved by each party¶'s board of directors and, unless certain conditions described under the Companies Law are met, by each party¶'s shareholders by a majority vote as described below. ¶ For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares voted at the shareholders meeting held by shareholders who are not the other party to the merger, or held by any person who holds 25% or more of the outstanding shares or the right to appoint 25% or more of the directors of the other party to the merger (including relatives or entities in control of the above), vote against the merger. If the transaction would have been approved but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the relative value of the merger parties and the consideration offered to the shareholders. If the non-surviving entity of the merger has more than one class of shares, the merger must be approved by each class of shareholders. If a merger is with a company¶'s controlling shareholder, or if a controlling shareholder has a personal interest in the merger, then the merger will be subject to the special majority approval required for an extraordinary transaction with a controlling shareholder. In the context of mergers (as well as other related party transactions), a ¶controlling shareholder¶ under Israeli law is deemed to include any shareholder holding 25% or more of the voting rights in the company if no other shareholder owns more than 50% of the voting rights in the company, and two or more shareholders with a personal interest in the approval of the same transaction are deemed to be one shareholder for such purpose. ¶ The Companies Law requires the board of directors of a merging company to discuss and determine whether, in its view, there exists a reasonable concern that as a result of the proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors, and if not, the board of directors may not approve the merger. The Companies Law requires each merging company to inform its secured creditors of the proposed merger plan. Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of any of the parties to the merger, and may further give instructions to secure the rights of creditors. ¶ A merger may not be completed unless at least 50¶ days have passed from the date that a proposal for approval of the merger is filed with the Israeli Registrar of Companies, and 30¶ days have passed from the date the merger was approved by the shareholders of each merging company. ¶ 24 ¶ ¶ Antitakeover Measures ¶ The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights, distributions or other matters, and shares having preemptive rights. As of the date of the registration statement of which this prospectus forms a part, we do not have any authorized or issued classes of shares other than our ordinary shares. In the future, if we do create and issue a class of shares other than ordinary shares, such class of shares, depending on the specific rights that may be attached to them, may delay or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization of a new class of shares will require an amendment to our articles of association which requires the prior approval of the holders of a majority of our shares at a general meeting. Shareholders voting in such meeting will be subject to the restrictions provided in the Companies Law as described above. ¶ 25 ¶ ¶ DESCRIPTION OF AMERICAN DEPOSITORY SHARES ¶ The Bank of New York Mellon (the ¶Depositary¶), as depositary, has registered and delivered American Depository Shares, also referred to as ADSs. Each ADS represents one ordinary share (or a right to receive one ordinary share) deposited with The Bank of New York Mellon in Manchester, United Kingdom, as custodian for the Depositary. The Depositary¶'s corporate trust office at which the ADSs will be administered is located at 240 Greenwich Street, New York, New York 10286. The Bank of New York Mellon¶'s principal executive office is located at 240 Greenwich Street, New York, New York 10286. ¶ ADSs may be held either (a)¶ directly (1)¶ by having an American Depository Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs or (2)¶ by having uncertificated ADSs, or (b)¶ indirectly by holding a security entitlement in ADSs through a broker or other financial institution that is a direct or indirect participant in The Depositary Trust Company, also called DTC. If ADSs are held directly by the holder, then that holder is registered as such, and is referred to in our description here an ADS holder. An indirect holder of ADSs indirectly must rely on the procedures of the holder¶'s broker or other financial institution to assert the rights of ADS holder described in this Exhibit. ¶ Registered holders of uncertificated ADSs will receive statements from the depositary confirming their holdings. ¶ We will not treat registered ADS holders as one of our shareholders, and they will not have shareholder rights. Israeli law governs shareholder rights. The depositary will be the holder of the ordinary shares underlying ADSs. A registered holder of ADSs will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs. ¶ The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR. ¶ Dividends and Other Distributions ¶ How will you receive dividends and other distributions on the shares? ¶ The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. ¶ Cash.¶ The depositary will convert any cash dividend or other cash distribution we pay in non-U.S. currency on the ordinary shares into U.S. dollars, if it can do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency, and it will not be liable for any interest. ¶ Before making a distribution, the depositary will deduct any withholding taxes, or other required governmental charges. See ¶Certain Material U.S. Federal Income Tax Considerations¶ below. The depositary will distribute only

whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution. **Â 26 Â Shares.** The depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution. The depositary will only distribute whole ADSs. It will sell ordinary shares which would require it to deliver a fraction of an ADS (or ADSs representing those shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed ordinary shares (or ADSs representing those shares) sufficient to pay its fees and expenses in connection with that distribution. **Â Rights to purchase additional shares.** If we offer holders of our securities any rights to subscribe for additional ordinary shares or any other rights, the depositary may (1) exercise those rights on behalf of ADS holders, (2) distribute those rights to ADS holders or (3) sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse. In that case, you will receive no value for them. The depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights relate and distribute those securities or, in the case of ordinary shares, new ADSs representing the new ordinary shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer. **Â Other Distributions.** The depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with non-U.S. currency. Alternatively, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws may restrict the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer. **Â The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders.** We have no obligation to register ADSs, shares, rights or other securities under the **Â Securities Act.** We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you. **Â 27 Â Deposit, Withdrawal and Cancellation** **Â How are ADSs issued?** The depositary will deliver ADSs upon deposits of ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs and will deliver the ADSs to or upon the order of the person or persons that made the deposit. **Â How can ADS holders withdraw the deposited securities?** ADS holders may surrender ADSs for the purpose of withdrawal at the Depositaryâ€™s account at DTCC (BNYMâ€™s DTC participant #2504). Upon payment of its cancellation fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the ordinary shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates in accordance with the Cancellation Instruction provided to The Bank of New York Mellon. **Â How do ADS holders interchange between certificated ADSs and uncertificated ADSs?** ADS holders may surrender ADS to the depositary for the purpose of exchanging ADS for uncertificated ADSs. The depositary will cancel that ADS and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADS evidencing those ADSs. **Â Voting Rights** **Â ADS holders may instruct the depositary how to vote the number of deposited ordinary shares their ADSs represent.** If we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholdersâ€™ meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. **Â The depositary will try, as far as practical, subject to the laws of Israel and the provisions of our articles of association or similar documents, to vote or to have its agents vote the ordinary shares or other deposited securities as instructed by ADS holders.** If we do not request the depositary to solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so. **Â Except by instructing the depositary as described above, ADS holders will not be able to exercise voting rights, unless they surrender your ADSs and withdraw the ordinary shares.** However, ADS holders may not know about the meeting sufficiently in advance to withdraw the ordinary shares. In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as instructed. **Â We cannot assure that ADS holders will receive the voting materials in time to ensure that they can instruct the depositary to vote ordinary shares.** In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that ADS holders may not be able to exercise voting rights and there may be nothing they can do if your ordinary shares are not voted as requested. **Â 28 Â In order to give ADS holders a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request the Depositary to act, we agree to give the depositary notice of any such meeting and details concerning the matters to be voted upon at least thirtyÂ days in advance of the meeting date.** **Â Fees and Expenses** **Â Persons depositing or withdrawing shares or ADS holders must pay:** **Â For:** \$5.00 (or less) per ADS (or portion of ADS) **Â Issuance of ADSs, including issuances resulting from a distribution of ordinary shares or rights or other property** **Â Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates** **Â \$0.05 (or less) per ADS** **Â Any cash distribution to ADS holders** **Â A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the ordinary shares had been deposited for issuance of ADSs** **Â Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders** **Â \$0.05 (or less) per ADSs per calendarÂ year** **Â Depositary services** **Â Registration or transfer fees** **Â Transfer and registration of ordinary shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw ordinary shares** **Â Expenses of the Depositary**

Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement); converting foreign currency to U.S. dollars. Taxes and other governmental charges the Depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes. As necessary. Any charges incurred by the Depositary or its agents for servicing the deposited securities. As necessary. The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid. 29. From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions. The depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary's obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request. Payment of Taxes. ADS holders are responsible for any taxes or other governmental charges payable on their ADSs or on the deposited securities represented by any of their ADSs. The depositary may refuse to register any transfer of ADSs or allow a withdrawal of the deposited securities represented by your ADSs, until such taxes or other charges are paid. It may apply payments owed to the ADS holder or sell deposited securities represented by the ADSs to pay any taxes owed and the ADS holder will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.

Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities. The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do by an ADS holder surrendering ADSs and subject to any conditions or procedures the depositary may establish. If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs. 30. If there is any change in the deposited securities such as a sub-division, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful and to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the net proceeds upon surrender of the ADSs. If there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange for new ADSs identifying the new deposited securities. If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently worthless, the depositary may call for surrender or of those ADSs or cancel those ADSs upon notice to the ADS holders.

Amendment and Termination. How may the deposit agreement be amended? We may agree with the depositary to amend the deposit agreement and the ADSs without consent of the ADS holders for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, ADS holders are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended. How may the deposit agreement be terminated? The depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if 60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment; we delist our ordinary shares from an exchange on which they were listed and do not list the ordinary shares on another exchange; we appear to be insolvent or enter insolvency proceedings all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities; there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or there has been a replacement of deposited securities. If the deposit agreement will terminate, the depositary will notify ADS holders at least 90 days before the termination date. At any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date. 31. After the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is not required to register any transfer of ADSs or distribute any dividends or other

distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except as described in this paragraph. **Limitations on Obligations and Liability** **Limits on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs** **The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:** **are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith;** **are not liable if we are or it is prevented or delayed by law or circumstances beyond our or its control from performing our or its obligations under the deposit agreement;** **are not liable if we or it exercises discretion permitted under the deposit agreement;** **are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;** **have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;** **are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and** **may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person.** **In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.** **Requirements for Depositary Actions** **Before the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require:** **payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any ordinary shares or other deposited securities;** **satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and** **compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.** **The depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so.** **Right to Receive the Ordinary Shares Underlying ADSs** **ADS holders have the right to cancel their ADSs and withdraw the underlying ordinary shares at any time except:** **when temporary delays arise because:** (1) **the depositary has closed its transfer books or we have closed our transfer books;** (2) **the transfer of ordinary shares is blocked to permit voting at a shareholders meeting; or** (3) **we are paying a dividend on our shares;** **when you owe money to pay fees, taxes and similar charges; or** **when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.** **This right of withdrawal may not be limited by any other provision of the deposit agreement.** **Pre-release of ADSs** **The deposit agreement permits the depositary to deliver ADSs before deposit of the underlying shares. This is called a pre-release of the ADSs. The depositary may also deliver ordinary shares upon cancellation of pre-released ADSs (even if the ADSs are canceled before the pre-release transaction has been closed out). A pre-release is closed out as soon as the underlying ordinary shares are delivered to the depositary. The depositary may receive ADSs instead of ordinary shares to close out a pre-release. The depositary may pre-release ADSs only under the following conditions:** (1) **before or at the time of the pre-release, the person to whom the pre-release is being made represents to the depositary in writing that it or its customer owns the ordinary shares or ADSs to be deposited;** (2) **the pre-release is fully collateralized with cash or other collateral that the depositary considers appropriate; and** (3) **the depositary must be able to close out the pre-release on not more than five business days** <sup>™</sup> **notice. In addition, the depositary will limit the number of ADSs that may be outstanding at any time as a result of pre-release, although the depositary may disregard the limit from time to time if it thinks it is appropriate to do so.** **Direct Registration System** **In the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, or DRS, and Profile Modification System, or Profile, will apply to the ADSs. DRS is a system administered by DTC that facilitates interchange between registered holdings of uncertificated ADSs and holdings of security entitlements in ADSs through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer.** **In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code).** **In the deposit agreement, the parties agree that the depositary's reliance on and compliance with instructions received by the depositary through the DRS/Profile system and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary.** **Shareholder communications; inspection of register of holders of ADSs** **The depositary will make available for your inspection at its office all communications from us that we make generally available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you upon our request. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs.** **DESCRIPTION OF Warrants WE ARE OFFERING** **The following summary of certain terms and provisions of Pre-Funded Warrants and Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the forms of such warrants, which are filed as exhibits to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in such forms of warrants for a complete description of the terms and conditions of the Pre-Funded Warrants and Warrants. The Pre-Funded Warrants will be issued separately from the accompanying Warrants, and may be transferred separately immediately thereafter.** **Pre-Funded Warrants Being Offered in this Offering** **Duration and Exercise Price** **Each Pre-Funded Warrant offered hereby will have an initial exercise price equal to \$0.0001 per ADS. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The exercise price and number of ADSs issuable upon exercise is subject to appropriate proportional adjustment in the event of share dividends, share splits, reorganizations or similar events affecting our ADSs and the exercise price.** **Exercisability** **The Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice and, within the earlier of (i) one trading day and (ii) the number of trading days comprising the standard settlement period with respect to the ADSs as in effect on the date of delivery of the notice of exercise thereafter, payment in full for the number of ADSs purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder may not exercise any portion of the**

Pre-Funded Warrant to the extent that the holder, together with its affiliates and any other persons acting as a group together with any such persons, would beneficially own more than 4.99% of the number of ordinary shares outstanding immediately after exercise (the "Beneficial Ownership Limitation"). A Cashless Exercise A The Pre-Funded Warrants may also be exercised, in whole or in part, at such time by means of a "cashless exercise" in which the holder shall be entitled to receive upon such exercise (either in whole or in part) the net number of ADSs determined according to a formula set forth in the Pre-Funded Warrants. A Fractional Shares A No fractional ADSs will be issued upon the exercise of the Pre-Funded Warrants. Rather, we will, at our election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price or round up to the next whole ADS. A 35 A Transferability A Subject to applicable laws, a Pre-Funded Warrant may be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments of transfer and funds sufficient to pay any transfer taxes payable upon such transfer. A Trading Market A There is no trading market available for the Pre-Funded Warrants on any securities exchange or nationally recognized trading system. We do not intend to list the Pre-Funded Warrants on any securities exchange or nationally recognized trading system. The ADSs issuable upon exercise of the Pre-Funded Warrants are currently listed on The Nasdaq Capital Market under the symbol "QNRX." A Rights as a Shareholder A Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder's ownership of the underlying ordinary shares represented by ADSs, the holders of the Pre-Funded Warrants do not have the rights or privileges of holders of our ordinary shares represented by ADSs, including any voting rights, until they exercise their Pre-Funded Warrants. A Fundamental Transaction A In the event of a fundamental transaction, as described in the Pre-Funded Warrants and generally including any reorganization, recapitalization or reclassification of our Ordinary Shares, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding Ordinary Shares, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction. A Warrants Being Offered in this Offering A Duration and Exercise Price A Each Warrant offered hereby will be a warrant to purchase one ADS and will be immediately exercisable. The Series F Warrants will have an initial exercise price equal to \$0.78 per ADS and will expire on the second anniversary of the original issuance date. The Series G Warrants will have an initial exercise price equal to \$0.78 per ADS and will expire on the fifth anniversary of the original issuance date. The exercise price and number of ADSs issuable upon exercise is subject to appropriate proportional adjustment in the event of share dividends, share splits, reorganizations or similar events affecting our ADSs and the exercise price. A 36 A Exercisability A The Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice and, within the earlier of (i) one trading day and (ii) the number of trading days comprising the standard settlement period with respect to the ADSs as in effect on the date of delivery of the notice of exercise thereafter, payment in full for the number of ADSs purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder may not exercise any portion of the Warrant to the extent that the holder, together with its affiliates and any other persons acting as a group together with any such persons, would beneficially own more than 4.99% of the number of ordinary shares outstanding immediately after exercise (the "Beneficial Ownership Limitation"). A Cashless Exercise A If, at the time a holder exercises its Warrants, a registration statement registering the issuance of the ADSs underlying the Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of ADSs determined according to a formula set forth in the Warrants. A Fractional Shares A No fractional ADSs will be issued upon the exercise of the Warrants. Rather, we will, at our election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price or round up to the next whole ADS. A Transferability A Subject to applicable laws, a Warrant may be transferred at the option of the holder upon surrender of the Warrant to us together with the appropriate instruments of transfer and funds sufficient to pay any transfer taxes payable upon such transfer. A Trading Market A There is no trading market available for the Warrants on any securities exchange or nationally recognized trading system. We do not intend to list the Warrants on any securities exchange or nationally recognized trading system. The ADSs issuable upon exercise of the Warrants are currently listed on The Nasdaq Capital Market under the symbol "QNRX." A 37 A Rights as a Shareholder A Except as otherwise provided in the Warrants or by virtue of such holder's ownership of the underlying ordinary shares represented by ADSs, the holders of the Warrants do not have the rights or privileges of holders of our ordinary shares represented by ADSs, including any voting rights, until they exercise their Warrants. A Fundamental Transaction A In the event of a fundamental transaction, as described in the Warrants and generally including any reorganization, recapitalization or reclassification of our Ordinary Shares, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding Ordinary Shares, the holders of the Warrants will be entitled to receive upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Warrants immediately prior to such fundamental transaction. Additionally, in the event of a fundamental transaction, we or any successor entity will, at the option of the holder of a Warrant exercisable at any time concurrently with or within 30 days after the consummation of the fundamental transaction (or, if later, the date of the public announcement thereof), purchase the Warrant from the holder by paying to the holder an amount of consideration equal to the value of the remaining unexercised portion of such Warrant on the date of consummation of the fundamental transaction based on the Black-Scholes option pricing model, determined pursuant to a formula set forth in the Warrants. The consideration paid to the holder will be the same type or form of consideration that was offered and paid to the holders of ordinary shares in connection with the fundamental transaction; provided that if no such consideration was offered or paid, the holders of ordinary shares will be deemed to have received ordinary shares of the successor entity in such fundamental transaction for purposes of this provision of the Warrants. A 38 A CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS A The following summary is included herein for general information and is not intended to be, and should not be considered to be, legal or tax advice. Each holder should consult with his or her own tax advisor as to the particular u.s. federal income tax consequences of the purchase, ownership and sale of ordinary shares, american depository shares and warrants, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws. A Subject to the limitations described in the next paragraph, the following discussion summarizes the material u.s. federal income tax consequences to a "U.S. Holder" arising from the

purchase, ownership and disposition of the ordinary shares, ADSs and warrants. For this purpose, a U.S. Holder is a beneficial owner of ordinary shares or ADSs or warrants that is: (1) an individual citizen or resident of the United States, including an alien individual who is a lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal income tax laws; (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States, any state therein, or the District of Columbia; (3) an estate, the income of which is includable in gross income for U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust; and (5) a trust that has a valid election in effect to be treated as a U.S. person to the extent provided in U.S. Treasury regulations. A non-U.S. Holder is a beneficial owner of ordinary shares or ADSs or warrants that is not a U.S. Holder. This summary is for general information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations that may be relevant to a decision to purchase our ordinary shares or ADSs or warrants. This summary generally considers only U.S. Holders that will own our ordinary shares or ADSs or warrants as capital assets (generally, property held for investment). Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences to a person that is a non-U.S. Holder, nor does it describe the rules applicable to determine a taxpayer's status as a U.S. Holder. This summary is based on the provisions of the Code, final, temporary and proposed U.S. Treasury regulations promulgated thereunder, administrative and judicial interpretations thereof, and the Convention Between the Government of the United States of America and the Government of the State of Israel with Respect to Taxes on Income (the U.S.-Israel Double Tax Treaty), all as in effect as of the date hereof and all of which are subject to change, possibly on a retroactive basis, and all of which are open to differing interpretations. We will not seek a ruling from the Internal Revenue Service, or IRS, with regard to the U.S. federal income tax treatment of an investment in our ordinary shares or ADSs or warrants and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below. This discussion does not address all of the tax considerations that may be relevant to a particular U.S. Holder based on such holder's particular circumstances, or to U.S. Holders that are subject to special treatment under U.S. federal income tax law, including: (1) banks, life insurance companies, regulated investment companies, or other financial institutions or financial services entities; (2) brokers or dealers in securities or foreign currency; (3) persons who acquired our ordinary shares or ADSs or warrants in connection with employment or other performance of services; (4) U.S. Holders that are subject to the U.S. alternative minimum tax; (5) U.S. Holders that hold our ordinary shares or ADSs or warrants as a hedge or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for U.S. federal income tax purposes; (6) tax-exempt entities; (7) real estate investment trusts; (8) U.S. Holders that expatriate out of the United States or former long-term residents of the United States; or (9) U.S. Holders having a functional currency other than the U.S. dollar. This discussion does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly, indirectly or constructively, at any time, ordinary shares or ADSs or warrants representing 10% or more of our voting power or value. This discussion also does not address any U.S. state or local or non-U.S. tax considerations, any U.S. federal estate, gift, generation-skipping, transfer, or alternative minimum tax considerations, or any U.S. federal tax consequences other than U.S. federal income tax consequences. <sup>39</sup> If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our ordinary shares or ADSs or warrants, the tax treatment of such entity or arrangement treated as a partnership and each person treated as a partner thereof generally will depend upon the status and activities of the entity and such person. A holder that is treated as a partnership for U.S. federal income tax purposes and partners thereof should consult their own tax advisors regarding the U.S. federal income tax considerations applicable to the purchase, ownership and disposition of our ordinary shares or ADSs or warrants. Each prospective investor is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing, holding or disposing of our ordinary shares or ADSs or warrants, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws. <sup>40</sup> U.S. Tax Status of the Company Although the Company is incorporated under Israeli law, as a result of the consummation of the Merger, the Company should be treated, pursuant to Section 7874 of the Code, as a U.S. corporation for all purposes under the Code. As a result, since the Company is and will be treated as a U.S. corporation for U.S. federal income tax purposes and, we do not intend to treat the Company as a passive foreign investment company, as such rules apply only to non-U.S. corporations that are treated as such for U.S. federal income tax purposes. Since the Company is a taxable corporation in Israel, it would likely be subject to income taxation in both the United States and Israel on the same income, which could reduce the amount of income available for distribution to shareholders. The ability of the Company to take foreign tax credits against its U.S. tax liability in respect of taxes paid in Israel may be limited. The remainder of this discussion assumes that the Company is treated as a U.S. corporation for all U.S. federal income tax purposes. If, for some reason (e.g., future repeal of Section 7874 of the Code), we were no longer treated as a U.S. corporation under the Code, the U.S. federal income tax consequences described herein could be materially and adversely affected. <sup>41</sup> Taxation of Pre-Funded Warrants The position of the IRS is that when the holder of an option to purchase property is economically compelled to exercise the option based on all the facts and circumstances, the option holder is treated as the beneficial owner of the underlying property for U.S. federal income tax purposes. Economic compulsion to exercise an option or warrant to acquire stock can result when the exercise price of the option or warrant is nominal in relation to the value of the stock subject to the option or warrant at the time of issuance of such option or warrant. The purchase price of each Pre-Funded Warrant will comprise substantially all of the value of the ADSs representing our ordinary shares underlying the Pre-Funded Warrant at the time the Pre-Funded Warrants are sold. As a result, the discussion of the U.S. federal income taxation of warrants in this prospectus treats holders of Pre-Funded Warrants as economically compelled to exercise the Pre-Funded Warrants and receive ordinary shares represented by ADSs. Accordingly, references to ordinary shares or ADSs in this section, <sup>42</sup> Certain Material U.S. Federal Income Tax Considerations, include Pre-Funded Warrants as if the Pre-Funded Warrant holders receive ordinary shares represented by ADSs at the time such Pre-Funded Warrant holders purchase the Pre-Funded Warrants. Additionally, references to warrants in this section, <sup>43</sup> Certain Material U.S. Federal Income Tax Considerations, means the Warrants only and not the Pre-Funded Warrants. There can be no assurance that the IRS or a court will not take a contrary position on the U.S. federal income taxation of the Pre-Funded Warrants. Each prospective investor in Pre-Funded Warrants is urged to consult his or her own tax advisor regarding the U.S. federal income tax consequences of the Pre-Funded Warrants. <sup>44</sup> Taxation of Dividends Paid on Ordinary Shares or ADSs We do not intend to pay dividends in the foreseeable future. In the event that we do pay dividends, a U.S. Holder will be required to include in

gross income as ordinary income the amount of any distribution paid on ordinary shares or ADSs (including the amount of any Israeli tax withheld on the date of the distribution), to the extent that such distribution does not exceed our current or accumulated earnings and profits, as determined for U.S. federal income tax purposes. The amount of a distribution which exceeds our current and accumulated earnings and profits will be treated first as a non-taxable return of capital, reducing the U.S. Holder's tax basis for the ordinary shares or ADSs to the extent thereof, and then as capital gain. Corporate holders generally will not be allowed a deduction for dividends received. A In general, preferential tax rates for qualified dividend income and long-term capital gains are applicable for U.S. Holders that are individuals, estates or trusts. For this purpose, qualified dividend income means, inter alia, dividends received from a domestic corporation. As indicated above, we believe we should be treated as a domestic corporation and our dividends will therefore be qualified dividend income. A U.S. Holder will not be entitled to the preferential rate: (1) if the U.S. Holder has not held our ordinary shares or ADSs for at least 61 days of the 121-day period beginning on the date which is 60 days before the ex-dividend date, or (2) to the extent the U.S. Holder is under an obligation to make related payments on substantially similar property. Any days during which the U.S. Holder has diminished its risk of loss on our ordinary shares or ADSs are not counted towards meeting the 61-day holding period. Finally, U.S. Holders who elect to treat the dividend income as investment income pursuant to Code section 163(d)(4) will not be eligible for the preferential rate of taxation. A The amount of a distribution with respect to our ordinary shares or ADSs will be measured by the amount of the fair market value of any property distributed, and for U.S. federal income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by us in NIS will be included in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includable in the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income tax purposes equal to such U.S. dollar value. If the U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise disposes of it, any subsequent gain or loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss. A U.S. Holders' eligibility to claim a foreign tax credit with respect to any Israeli withholding tax imposed on dividends paid by us may be limited. The foreign tax credit rules are complex, and their application in connection with Section 7874 of the Code in the presence of the U.S.-Israel Double Tax Treaty, are not entirely clear at this time. U.S. Holders should consult their own tax advisors with respect to any benefits they may be entitled to under the foreign tax credit rules and the U.S.-Israel Double Tax Treaty, and to determine whether, and to what extent, they are entitled to such credits. A 41 A Taxation of the Disposition of Ordinary Shares or ADSs or Warrants A Upon the sale, exchange or other taxable disposition of our ordinary shares or ADSs or warrants, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder's tax basis for the ordinary shares or ADSs or warrants in U.S. dollars and the amount realized on the disposition in U.S. dollars (or its U.S. dollar equivalent determined by reference to the spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency). The gain or loss realized on the sale, exchange or other disposition of ordinary shares or ADSs or warrants will be long-term capital gain or loss if the U.S. Holder has a holding period of more than one year at the time of the disposition. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of receiving currency other than U.S. dollars upon the disposition of their ordinary shares. A Gain realized by a U.S. Holder on a sale, exchange or other disposition of ordinary shares or ADSs or warrants will generally be treated as U.S. source income for U.S. foreign tax credit purposes. A loss realized by a U.S. Holder on the sale, exchange or other disposition of ordinary shares or ADSs or warrants is generally allocated to U.S. source income. The deductibility of a loss realized on the sale, exchange or other disposition of ordinary shares or ADSs or warrants is subject to limitations. A A U.S. Holder's eligibility to claim a foreign tax credit with respect to any Israeli withholding tax imposed on gain from the sale or other disposition of our ordinary shares or ADSs or warrants may be limited. The foreign tax credit rules are complex, and their application in connection with Section 7874 of the Code in the presence of the U.S.-Israel Double Tax Treaty are not entirely clear at this time. U.S. Holders should consult their own tax advisors with respect to any benefits they may be entitled to under the foreign tax credit rules and the U.S.-Israel Double Tax Treaty. A Exercise or Lapse of a Warrant A Except as discussed below with respect to a cashless exercise of a warrant, a U.S. Holder generally will not recognize gain or loss upon the exercise of a warrant for cash. An ordinary share or ADS acquired pursuant to the exercise of a warrant for cash generally will have a tax basis equal to the U.S. Holder's tax basis in the warrant, increased by the amount paid to exercise the warrant. The holding period of such share or ADS generally begins on the day after the date of exercise of the warrant and will not include the period during which the U.S. Holder held the warrant. A The tax consequences of a cashless exercise of a warrant are not clear under current tax law. A cashless exercise may be tax-free, either because the exercise is not a gain realization event or because the exercise is treated as a recapitalization for U.S. federal income tax purposes. In either tax-free situation, a U.S. Holder's basis in the ordinary shares or ADSs received upon exercise of a warrant would equal the holder's basis in the warrant. If the cashless exercise were not treated as a gain realization event, a U.S. Holder's holding period in the ordinary shares or ADSs received upon exercise of a warrant would be treated as commencing on the date following the date of exercise (or possibly the date of exercise) of the warrant. If the cashless exercise were treated as a recapitalization, the holding period of the ordinary shares or ADSs received upon exercise of a warrant would include the holding period of the warrant. A It is also possible that a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In such event, a U.S. Holder would recognize gain or loss with respect to the portion of the exercised warrants treated as surrendered to pay the exercise price of the warrants (the surrendered warrants). The U.S. Holder would recognize capital gain or loss in an amount equal to the difference between the fair market value of the surrendered warrants and the U.S. Holder's tax basis in such warrants. In this case, a U.S. Holder's tax basis in the ordinary shares or ADSs received upon exercise of a warrant would equal the sum of the fair market value of the surrendered warrants and the U.S. Holder's tax basis in the warrants exercised (except for any such tax basis allocable to the surrendered warrants). A U.S. Holder's holding period for the ordinary shares or ADSs received upon exercise of a warrant would commence on the date following the date of exercise (or possibly the date of exercise) of the warrant. A 42 A Due to the absence of authority on the U.S. federal income tax treatment of a cashless exercise, there can be no assurance which, if any, of the alternative tax consequences and holding periods described above would be adopted by the IRS or a court. Accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of a cashless exercise. A If a warrant is allowed to lapse unexercised, a U.S. Holder generally will recognize a capital loss equal to such holder's tax basis in the warrant. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of the exercise of a warrant, including with respect to whether the exercise is a taxable event,

and their holding period and tax basis in the ordinary shares or ADSs received. A Tax on Investment Income A U.S. Holders who are individuals, estates or trusts will generally be required to pay a 3.8% Medicare tax on their net investment income (including dividends on and gains from the sale or other disposition of our ordinary shares and ADSs or warrants), or in the case of estates and trusts on their net investment income that is not distributed. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder's total adjusted income exceeds applicable thresholds. A Tax Consequences for Non-U.S. Holders of Ordinary Shares or ADSs or Warrants A Taxation of Dividends Paid on Ordinary Shares or ADSs A In general, any distributions we make to a non-U.S. Holder on ordinary shares or ADSs, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the non-U.S. Holder's conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such non-U.S. Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form W-8BEN or W-8BEN-E, as applicable). Any distribution on our ordinary shares or ADSs not constituting a dividend for U.S. federal income tax purposes will be treated first as reducing (but not below zero) the non-U.S. Holder's adjusted tax basis in its shares of such stock and, to the extent such distribution exceeds the non-U.S. Holder's adjusted tax basis in such stock, as gain realized from the sale or other disposition of such stock, which will be treated as described under "Gain on Sale, Exchange or Other Taxable Disposition of Ordinary Shares, ADSs, and Warrants" below. The full amount of any distributions to you may, however, be subject to U.S. withholding tax unless the applicable withholding agent elects to withhold a lesser amount based on a reasonable estimate of the amount of the distribution that would be treated as a dividend for U.S. federal income tax purposes. In addition, if we determine that we are classified as a "United States real property holding corporation" (see "Gain on Sale, Exchange or Other Taxable Disposition of Ordinary Shares, ADSs, and Warrants" below), we will withhold 15% of any distribution that exceeds our current and accumulated earnings and profits. A 43 A Dividends we pay to a non-U.S. Holder that are effectively connected with such non-U.S. Holder's conduct of a trade or business within the United States (and if a tax treaty applies are attributable to a U.S. permanent establishment or fixed base maintained by the non-U.S. Holder) will generally not be subject to U.S. withholding tax, provided such non-U.S. Holder complies with certain certification and disclosure requirements (usually by providing an IRS Form W-8ECI). Instead, such dividends will generally be subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to U.S. Holders. If the non-U.S. Holder is a corporation, dividends that are effectively connected income may also be subject to a "branch profits tax" at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty). A Exercise or Lapse of a Warrant A The U.S. federal income tax treatment of a non-U.S. Holder's exercise of a warrant or the lapse of a warrant held by a non-U.S. Holder generally will correspond to the U.S. federal income tax treatment of the exercise or lapse of a warrant by a U.S. Holder, as described under "Exercise of a Warrant" above. Accordingly, a non-U.S. Holder generally will not be subject to U.S. federal income tax on the exercise of a warrant in exchange for ordinary shares or ADSs. However, if a cashless exercise of warrants results in a taxable exchange, as described above in "Exercise of a Warrant" above, the rules described below under "Gain on Sale, Exchange or Other Taxable Disposition of Ordinary Shares, ADSs, and Warrants" would apply. A Gain on Sale, Exchange or Other Taxable Disposition of Ordinary Shares, ADSs, and Warrants A non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax on the proceeds from the disposition of, our ordinary shares or ADSs or warrants, unless: A the gain is effectively connected with the conduct of a trade or business by the non-U.S. Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the non-U.S. Holder); A the non-U.S. Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or A we are or have been a "United States real property holding corporation" for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the non-U.S. Holder held our ordinary shares or ADSs, and, in the case where our ordinary shares or ADSs are regularly traded on an established securities market, the non-U.S. Holder has owned, directly or constructively, more than 5% of our regularly-traded stock at any time within the shorter of the five-year period preceding the disposition or such non-U.S. Holder's holding period for the stock disposed of by the non-U.S. holder. There can be no assurance that our ordinary shares or ADSs will be treated as regularly traded on an established securities market for this purpose. A Gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates. Any gains described in the first bullet point above of a non-U.S. Holder that is a foreign corporation may also be subject to an additional "branch profits tax" at a 30% rate (or lower applicable treaty rate). Gain described in the second bullet point above will generally be subject to a flat 30% U.S. federal income tax, although the gain may be offset by some United States source capital losses realized during the same taxable year. Non-U.S. Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties. A 44 A If the third bullet point above applies to a non-U.S. Holder, gain recognized by such holder on the sale, exchange or other disposition of our ordinary shares, ADSs, or warrants will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our ordinary shares, ADSs, or warrants from such holder may be required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. We will be classified as a United States real property holding corporation if the fair market value of our "United States real property interests" equals or exceeds 50% of the sum of the fair market value of our worldwide real property interests plus our other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes. Non-U.S. Holders are urged to consult their own tax advisors regarding the application of these rules. A Payments to Foreign Financial Institutions A The Foreign Account Tax Compliance Act ("FATCA") generally provides that a 30% withholding tax may be imposed on payments of U.S. source income, such as U.S. source dividends, to certain non-U.S. entities unless such entities enter into an agreement with the IRS to disclose the name, address and taxpayer identification number of certain U.S. persons that own, directly or indirectly, interests in such entities, as well as certain other information relating to such interests. Non-U.S. Holders are encouraged to consult with their own tax advisors regarding the possible implications and obligations of FATCA. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of ordinary shares or ADSs on or after January 1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. A Information Reporting and Withholding A A U.S. Holder may be subject to backup withholding at a rate of 24% with respect to dividends and proceeds from a disposition of ordinary shares or ADSs or

warrants. In general, backup withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will not apply with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations. Â In general, non-U.S. Holders will not be subject to backup withholding with respect to the payment of dividends and proceeds from a disposition of ordinary shares or ADSs or warrants, provided that the applicable withholding agent does not have actual knowledge or reason to know the holder is a United States person, and the holder either certifies its non-U.S. status, such as by furnishing a valid IRS FormÂ W-8BEN, W-8BEN-E or W-8ECI, or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any payments of dividends on our ordinary shares or ADSs paid to the non-U.S. holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our ordinary shares or ADSs or warrants within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our ordinary shares or ADSs or warrants conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup withholding or information reporting. Â Backup withholding is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a holder, provided that the required information is timely furnished to the IRS. Â 45 Â CERTAIN MATERIAL ISRAELI TAX CONSIDERATIONS Â The following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our ordinary shares or ADSs or warrants (all referred to in this section as "the Shares"). You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign, including Israeli, or other taxing jurisdiction. Â The following is a summary of the material tax consequences under Israeli law concerning the purchase, ownership and disposition of our Shares. Â This discussion does not purport to constitute a complete analysis of all potential tax consequences applicable to investors upon purchasing, owning or disposing of our Shares. In particular, this discussion does not take into account the specific circumstances of any particular investor (such as traders in securities, not for profit organizations, pension funds and other tax-exempt entities, financial institutions, certain financial companies, broker-dealers, partnerships and other transparent entities, investors that own, directly or indirectly, 10% or more of our outstanding voting rights, all of whom are subject to special tax regimes not covered under this discussion). To the extent that issues discussed herein are based on legislation that has yet to be subject to judicial or administrative interpretation, there can be no assurance that the views expressed herein will accord with any such interpretation in the future. The discussion below is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli law, which change could affect the tax consequences described below. The discussion should not be construed as legal or professional tax advice and does not cover all possible tax considerations. Â You are urged to consult your own tax advisors as to the Israeli or other tax consequences of the purchase, ownership, and disposition of the Shares, including, in particular, the effect of any foreign, state or local taxes. Â General Corporate Tax Structure in Israel Â Israeli resident companies are generally subject to corporate tax on their taxable income at the rate of 23% for the 2024 taxÂ year. Capital gains derived by an Israeli resident company are generally subject to the prevailing corporate tax rate. Â Taxation of Shareholders Â Capital Gains Â Capital gains tax is imposed on the disposition of capital assets by an Israeli resident and on the disposition of such assets by a non-Israeli resident if those assets are either (i)Â located in Israel; (ii)Â are shares or a right to a share in an Israeli company, or (iii)Â represent, directly or indirectly, rights to assets located in Israel, unless an exemption is available or unless an applicable double tax treaty between Israel and the sellerâ€™s country of residence provides otherwise. The Israeli Income Tax Ordinance distinguishes between "Real Gain" and the "Inflationary Surplus". "Real Gain" is the excess of the total capital gain over Inflationary Surplus generally computed on the basis of the increase in the Israeli Consumer Price Index between the date of purchase and the date of disposition. Inflationary Surplus is not subject to tax. Â 46 Â Taxable capital gain accrued by individuals on the sale of the Shares are taxed at the rate of 25%. However, if the individual shareholder is a "Substantial Shareholder" at the time of sale or at any time during the preceding 12-month period, such gain will be taxed at the rate of 30%. In this regard, broadly, a "Substantial Shareholder" is considered to be a person who alone, or together with his relative or another person who collaborates with him on a regular basis based on a contract, holds, directly or indirectly, at least 10% of any our means of control. In this context "means of control" generally includes the right to vote, receive profits, nominate a director or an officer, receive assets upon liquidation, or instruct someone who holds any of these rights regarding the manner in which he or she is to exercise such right(s), and all regardless of the source of such rights. Â The term "Israeli resident" is generally defined under Israeli tax legislation with respect to individuals as a person whose center of life is in Israel. The Israeli tax legislation provides that in order to determine the center of life of an individual, account will be taken of the individualâ€™s family, economic and social connections, including: (a)Â place of permanent home; (b)Â place of residential dwelling of the individual and the individualâ€™s immediate family; (c)Â place of the individualâ€™s regular or permanent occupation or the place of his permanent employment; (d)Â place of the individualâ€™s active and substantial economic interests; and (e)Â place of the individualâ€™s activities in organizations, associations and other institutions. The center of life of an individual will be presumed to be in Israel if: (a)Â the individual was present in Israel for 183Â days or more in the taxÂ year; or (b)Â the individual was present in Israel for 30Â days or more in the taxÂ year, and the total period of the individualâ€™s presence in Israel in that taxÂ year and the two previous taxÂ years is 425Â days or more. The presumption in this paragraph may be rebutted either by the individual or by the assessing officer. Â Capital gains derived by corporations are generally subject to tax at the ordinary corporate tax rate (currently 23%). Under Israeli tax legislation, a corporation will be considered as an "Israeli Resident" if it meets one of the following criteria: (a)Â it was incorporated in Israel; or (b)Â the control and management of its business are exercised in Israel. Â Despite the above, capital gains generated from the sale of our Shares by a non-Israeli shareholder may be exempt from Israeli tax under the Israeli tax legislation provided that the following cumulative conditions are met: (i)Â the Shares were purchased by the shareholder upon or after the registration of the Shares on the non-Israeli stock exchange (i.e., JulyÂ 29, 2016); (ii)Â the shareholder does not have a permanent establishment maintained in Israel to which the generated capital gain is attributed; and (iii)Â so long as neither the shareholder nor the particular capital gain is otherwise subject to the Israeli Income Tax Law (Inflationary Adjustments) 5745-1985. However, a seller of our Shares that is a non-Israeli resident corporation will not be entitled to this exemption if Israeli residents: (i)Â have a controlling interest, directly or indirectly, alone or together with another (i.e., together with a relative, or together with someone who is not a relative

but with whom, according to an agreement, there is regular cooperation in material matters of the company, directly or indirectly), or together with another Israeli resident, of more than 25% in any of the means of control of such non-Israeli corporation or (ii)Â are the beneficiaries of, or are entitled to, 25% or more of the income or profits of such non-Israeli corporation, whether directly or indirectly. In addition, this exemption would not be available to a person whose gains from selling or otherwise disposing of our Shares are deemed to be business income. Â Likewise, capital gains generated from the sale of our Shares by a non-Israeli shareholder who purchased the Shares before the registration of the Shares on the non-Israeli stock exchange may also be exempt from Israeli tax under the Israeli tax legislation provided that the following cumulative conditions are met: (i)Â the Shares were purchased on JanuaryÂ 1, 2009 or afterwards; (ii)Â the Shares were not purchased from a related party (as defined for this purpose) or as part of an exempted reorganization for Israeli tax purposes; (iii)Â the Shares are not registered for trade on an Israeli stock exchange at the date of the sale; (iv)Â on the day of the purchase of the Shares and in the twoÂ preceding years - most of the value of the assets held by the Israeli company, directly or indirectly, are not rights in, or attached or related to, or in connection with the use of or proceeds from, real estate rights or a real estate corporations, as defined under the Real Estate Taxation Law 5723-1963, and any other rights to real estate, rights to use state natural resources such as minerals or rights to use benefits derived from the real estate in Israel; and (v)Â the capital gain is not allocated to a permanent establishment that the non-Israeli resident maintains in Israel. Â 47 Â Â In addition, the sale of the Shares may be also exempt from Israeli capital gains tax under the provisions of an applicable double tax treaty. For example, the tax treaty between the Government of the United States of America and the Government of the State of Israel with respect to Taxes on Income, as amended, (the "U.S.-Israel Double Tax Treaty") generally exempts a shareholder who is a United States resident (for purposes of the treaty) holding the shares as a capital asset and is entitled to claim the benefits afforded to such a resident by the U.S.-Israel Double Tax Treaty ("Treaty U.S. Resident") from Israeli capital gain tax in connection with the sale of our Shares, provided that: (i)Â the Treaty U.S. Resident owns, directly or indirectly, less than 10% of our voting power at any time within the 12-month period preceding such sale, subject to certain conditions; (ii)Â the Treaty U.S. Resident, if an individual, was present in Israel for a period or periods of less than 183Â days in the aggregate during the relevant taxableÂ year; (iii)Â the capital gain from the sale was not derived through a permanent establishment of the Treaty U.S. Resident which is maintained in Israel, under certain terms; (iv)Â the capital gain from the sale is not attributed to royalties; and (v)Â the capital gain from the sale is not attributed to real estate located in Israel. A Treaty U.S. Resident not exempt from Israeli capital gains tax may be limited under U.S. law in its ability to claim a credit for such taxes against the U.S. federal income tax imposed with respect to such sale, exchange or disposition even if such Treaty U.S. Resident is eligible for benefits under the U.S.-Israel Double Tax Treaty. The U.S.-Israel Double Tax Treaty does not relate to U.S. state or local taxes. Â There may be some other circumstances in which exemptions (or partial exemptions) may apply, so that any non-Israeli shareholder who does not meet the aforementioned exemption criteria (whether under the Israeli internal tax law or the relevant tax treaty) should consult their own tax advisors. Â Regardless of whether non-Israeli shareholders may be liable for Israeli capital gains tax on the sale of our Shares, the payment of the consideration for such sale may be subject to withholding of Israeli tax at source and holders of our Shares may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale. Specifically, in transactions involving a sale of all of the shares of an Israeli resident company, in the form of a merger or otherwise, the Israel Tax Authority may require shareholders who are not liable for Israeli capital gains tax on such a sale to sign declarations on forms specified by the Israel Tax Authority, provide documents (including, for example, a certificate of residency) or obtain a specific exemption from the Israel Tax Authority to confirm their status as non-Israeli residents and, in the absence of such declarations or exemptions, the Israel Tax Authority may require the purchaser of the shares to withhold tax at source. Â The purchaser, the Israeli stockbroker or the financial institution through which the Shares are held, is obligated, subject to the abovementioned exemptions, to withhold tax on the amount of consideration paid upon the sale of Shares at a rate of 25% (for individuals) or 23% (for corporations). Â Upon the sale of traded securities, a detailed return, including a computation of the tax due, generally need to be filed and an advance payment must be paid to the Israel Tax Authority on JanuaryÂ 31 and JulyÂ 31 of every calendar year in respect of sales of traded securities made within the previous sixÂ months. This will apply to the sale of our Shares. However, if all tax due was withheld at source according to applicable provisions of the Israeli Income Tax Ordinance and regulations promulgated thereunder, such return need not be filed, and no advance payment must be paid. Capital gains are also reportable on annual income tax returns. Â 48 Â Â Dividends Â Dividends distributed by an Israeli company to a shareholder who is an Israeli resident individual will generally be subject to income tax at a rate of 25%. However, a 30% tax rate will apply if the dividend recipient is a Substantial Shareholder, as defined above, at the time of distribution or at any time during the preceding 12-month period. If the recipient of the dividend is an Israeli resident corporation, dividends will generally be exempted from Israeli income tax provided that the income from which such dividend is distributed was derived or accrued within Israel. Â Dividends distributed by an Israeli company to a non-Israeli resident (either an individual or a corporation) are generally subject to Israeli withholding tax at the rate of 25% (30% if the dividend recipient is a Substantial Shareholder at the time of distribution or at any time during the preceding 12-month period). Dividends paid on publicly traded shares, to non-Israeli residents or Israeli resident individual, are generally subject to Israeli withholding tax at a rate of 25%, so long as the shares are registered with a nominee company (whether or not the recipient is a substantial shareholder), unless a lower rate is provided under an applicable tax treaty (provided that a certificate from the ITA allowing for a reduced withholding tax rate is obtained in advance). However, a distribution of dividends to non-Israeli residents is generally subject to a withholding tax at the source at a rate of 15%, or such lower rate as may be provided in an applicable tax treaty, if the dividend is distributed from income attributed to a "Benefited or Approved Enterprise," and 20% if the dividend is distributed from income attributed to "Preferred Enterprise" as such term is defined in the Law for the Encouragement of Capital Investments, 5719-1959, or such lower rate as may be provided in an applicable tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced withholding tax rate). For example, under the U.S.-Israel Double Tax Treaty, the following tax rates will apply in respect of dividends distributed by an Israeli resident company to a Treaty U.S. Resident: (i)Â if the Treaty U.S. Resident is a corporation that holds during that portion of the taxableÂ year which precedes the date of payment of the dividend and during the whole of its prior taxableÂ year (if any), at least 10% of the outstanding shares of the voting stock of the Israeli company paying the dividend and not more than 25% of the gross income of such Israeli company for such prior taxableÂ year (if any) consists of certain types of interest or dividends, the maximum tax rate is 12.5%; (ii)Â if both the conditions mentioned in clause (i)Â above are met and the dividend is paid from an Israeli resident company's income which was entitled to a reduced tax rate under the Law for the Encouragement of Capital Investments, 1959,

Â , 2024, subject to satisfaction or waiver of customary closing conditions. Â We have agreed to indemnify the Placement Agent and specified other persons against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the Placement Agent may be required to make in respect thereof. Â Fees and Expenses Â This offering is being conducted on a âœreasonable best effortsâ basis and the Placement Agent has no obligation to buy any of the Securities from us or to arrange for the purchase or sale of any specific number or dollar amount of Securities. We have agreed to pay the Placement Agent a fee based on the aggregate proceeds as set forth in the table below (assuming the sale of all of the Securities we are offering): Â Â Â Per ADS and Accompanying WarrantsÂ Â Per Pre-Funded Warrant and Accompanying WarrantsÂ Â TotalÂ Public offering priceÂ \$Â Â Â \$Â Â Â \$Â Â Placement Agentâ™s feesÂ \$Â Â Â \$Â Â Â \$Â Â Proceeds to us, before expenses (1)Â \$Â Â Â \$Â Â Â \$Â Â Â (1)The amount of the proceeds to us presented in this table does not give effect to any exercise of the Warrants or Pre-Funded Warrants. Â We have agreed to pay to the Placement Agent a cash fee equal to 7% of the aggregate gross proceeds raised in this offering. Because there is no minimum offering amount required as a condition to closing in this offering, the actual aggregate cash placement fee, if any, is not presently determinable and may be substantially less than the maximum amount set forth above. The Placement Agent may retain other brokers or dealers to act as sub-agents on their behalf in connection with this offering and may pay any sub-agent a fee with respect to any Securities placed by such placement agent. Â 51 Â Â In addition, we will bear the costs in connection with the offering and have also agreed to reimburse the Placement Agent for its expenses relating to this offering, including, but not limited to, fees, expenses and disbursements relating to background checks of our officers and directors and the fees and expenses of counsel for the Placement Agent, up to a maximum reimbursement allowance of \$125,000. We have agreed to the payment of \$25,000 to be applied against the Placement Agentâ™s expenses (the âœAdvanceâ). Upon acceptance of the engagement by the Placement Agent, the Company delivered to Maxim the Advance. Such Advance will be applied against the Placement Agentâ™s expenses in connection with the offering, and to the extent not actually incurred, such Advance shall be reimbursed to us. Â Regulation M Compliance Â The Placement Agent may be deemed to be an underwriter within the meaning of SectionÂ 2(a)(11) of the Securities Act, and any commissions received by them and any profit realized on the resale of the shares sold by them while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, a placement agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, RuleÂ 415(a)(4)Â under the Securities Act and RuleÂ 10b-5 and Regulation M under the Exchange Act. These rulesÂ and regulations may limit the timing of purchases and sales of Securities by the placement agents acting as principal. Under these rulesÂ and regulations, the placement agents: Â Â·may not engage in any stabilization activity in connection with our securities; and Â Â·may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution. Â Lock-Up Agreements Â Our directors and officers have entered into lock-up agreements. Under these agreements, these individuals have agreed, subject to specified exceptions, not to sell or transfer any ADSs or securities convertible into, or exchangeable or exercisable for, our ADSs during a period ending six (6)Â months after the completion of this offering, without first obtaining the written consent of the placement agent, subject to certain exceptions. Specifically, these individuals have agreed, in part, not to: Â Â·offer, pledge, sell, contract to sell or otherwise dispose of Quoinâ™s securities or any securities convertible into or exercisable or exchangeable for ordinary shares; Â Â·enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our securities, whether any such transaction is to be settled by delivery of our securities, in cash or otherwise; Â Â·make any demand for or exercise any right with respect to the registration of any of our securities; and Â Â·publicly disclose the intention to make any offer, sale, pledge or disposition of, or to enter into any transaction, swap, hedge, or other arrangement relating to any of our securities. Â Notwithstanding these limitations, our securities may be transferred under limited circumstances, including, without limitation, by gift, will or intestate succession. Â 52 Â Â We have agreed with the Placement Agent to be subject to a lock-up period of 90 days following the date of closing of the offering pursuant to this prospectus. This means that

during the applicable lock-up period, subject to certain limited exceptions, we may not: (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents, or (ii) file or cause to be filed any registration statement or amendment or supplement thereto, other than the preliminary prospectus or the prospectus related to this offering, a registration statement on Form S-8 in connection with any employee benefit plan, or the filing of any amendment or supplement to any existing registration statement solely for the purpose of revising any required disclosure in such registration statement and not for the purpose of increasing the offering size pursuant to any such registration statement. In addition, subject to certain exceptions, we have agreed not to effect or enter into an agreement to effect any issuance of securities in a Variable Rate Transaction (as defined in the placement agency agreement) for a period of 180 days following the closing date of this offering, subject to certain exceptions. **Determination of Offering Price** The public offering price of the Securities we are offering, including the exercise price of the Warrants, was negotiated between us and the investors, in consultation with the Placement Agent based on the trading of our ADSs prior to the offering, among other things. Other factors considered in determining the public offering price of the Securities we are offering include our history and prospects, the industry in which we operate, our past and present operating results, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, the previous experience of our executive officers, general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant. **Listing** Our ADSs are listed on The Nasdaq Capital Market under the trading symbol "QNRX". We do not plan to list the Pre-Funded Warrants or the Warrants on The Nasdaq Capital Market or any other securities exchange or trading market. **Other Activities and Relationships** The Placement Agent and certain of its affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The Placement Agent and certain of its affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. In the ordinary course of their various business activities, the Placement Agent and certain of its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the Placement Agent or its affiliates enter into a lending relationship with us, they will routinely hedge their credit exposure to us consistent with their customary risk management policies. The Placement Agent and its affiliates may hedge such exposure by entering into transactions that consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the ADSs offered hereby. Any such short positions could adversely affect future trading prices of the ADSs offered hereby. The Placement Agent and certain of its affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. **53** **This prospectus in electronic format may be made available on a website maintained by the Placement Agent, and the Placement Agent may distribute this prospectus electronically.** **The foregoing does not purport to be a complete statement of the terms and conditions of the placement agency agreement or the securities purchase agreement entered into in connection with this offering, copies of which have been filed as exhibits to the registration statement of which this prospectus is a part. See "Where You Can Find More Information."** **Offer Restrictions Outside the United States** Other than in the United States, no action has been taken by us or the Placement Agent that would permit a public offering of the securities offered by us in any jurisdiction where action for that purpose is required. The securities offered by us in this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offering of the securities offered by us under this prospectus be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by us under this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. **Notice to Prospective Investors in Israel** This document does not constitute a prospectus under the Israeli Securities Law and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only at, and any offer of the securities is directed only at, investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and "qualified individuals", each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. **Notice to Prospective Investors in Canada** The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. **54** **Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal advisor.** **Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts** (NI 33-105), the placement agents are not required to comply with the disclosure requirements of NI 33-105 regarding placement agents conflicts of interest in connection with this offering. **Notice to Prospective Investors in European Economic Area** In relation to each Member State of the European Economic Area which has implemented

the Prospectus Directive (each, a "Relevant Member State") an offer to the public of any securities may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any securities may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State: (i) to any legal entity which is a qualified investor as defined in the Prospectus Directive; (ii) to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer; or (iii) in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by us or any placement agents of a prospectus pursuant to Article 3 of the Prospectus Directive. For the purposes of this provision, the expression "offer to the public" in relation to any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State, and the expression "2010 PD Amending Directive" means Directive 2010/73/EU. A 55. A. Notice to Prospective Investors in United Kingdom A. Each placement agent has represented and agreed that: A. it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (the FSMA) received by it in connection with the issue or sale of the securities in circumstances in which Section 21(1) of the FSMA does not apply to us; and A. it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United Kingdom. A. Notice to Prospective Investors in Switzerland A. The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (the SIX) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. A. Neither this document nor any other offering or marketing material relating to the offering, or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (CISA). Accordingly, no public distribution, offering or advertising, as defined in CISA, its implementing ordinances and notices, and no distribution to any non-qualified investor, as defined in CISA, its implementing ordinances and notices, shall be undertaken in or from Switzerland, and the investor protection afforded to acquirers of interests in collective investment schemes under CISA does not extend to acquirers of securities. A. Notice to Prospective Investors in Australia A. No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (ASIC), in relation to the offering. A. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the Corporations Act) and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. A. Any offer in Australia of the securities may only be made to persons (the Exempt Investors) who are "sophisticated investors" (within the meaning of section 708(8) of the Corporations Act), "professional investors" (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the securities without disclosure to investors under Chapter 6D of the Corporations Act. A. 56. A. The securities applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring securities must observe such Australian on-sale restrictions. A. This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. A. Notice to Prospective Investors in the Cayman Islands A. No invitation, whether directly or indirectly, may be made to the public in the Cayman Islands to subscribe for our securities. A. Notice to Prospective Investors in Taiwan A. The securities have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the securities in Taiwan. A. Notice to Prospective Investors in Hong Kong A. The contents of this prospectus have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this prospectus, you should obtain independent professional advice. Please note that (i) our shares may not be offered or sold in Hong Kong, by means of this prospectus or any document other than to "professional investors" within the meaning of Part I of Schedule 1 of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) (SFO) and any rules made thereunder, or in other circumstances which do not result in the document being a "prospectus" within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong) (CO) or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO, and (ii) no advertisement, invitation or document relating to our shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere) which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect

to the shares which are or are intended to be disposed of only to persons outside Hong Kong or only to àœprofessional investorsâ within the meaning of the SFO and any rulesÂ made thereunder. Â Notice to Prospective Investors in the Peopleâ™s Republic of China Â This prospectus may not be circulated or distributed in the PRC and the shares may not be offered or sold, and will not offer or sell to any person for re-offering or resale directly or indirectly to any resident of the PRC except pursuant to applicable laws, rulesÂ and regulations of the PRC. For the purpose of this paragraph only, the PRC does not include Taiwan and the special administrative regions of Hong Kong and Macau. Â 57 Â LEGAL MATTERS Â Certain legal matters as to United States law in connection with this offeringÂ will be passed upon for us by Blank RomeÂ LLP. The validity of the securities and other matters of Israeli law will be passed upon for us by Meitar | Law Offices, Ramat Gan,Â Israel. Certain legal matters related to the offering will be passed upon for the Placement Agent by Ellenoff GrossmanÂ & Schole LLP. Â EXPERTS Â The consolidated financial statements as of and for the years ended DecemberÂ 31, 2023 and 2022 incorporated by reference in this registration statement have been audited by Marcum LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. Â ENFORCEABILITY OF CIVIL LIABILITIES Â To the extent any of our shareholders may seek to enforce a U.S. judgment in Israel against us or our executive officers and directors, or to assert U.S. securities law claims in Israel, shareholders may have difficulties enforcing such a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal securities laws, in Israel. Â We have been informed by our legal counsel in Israel that it may be difficult to assert U.S. securities laws claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws because Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact which can be a time-consuming and costly process. Matters of procedure will also be governed by Israeli law. Â We have irrevocably appointed Quoin Pharmaceuticals,Â Inc., as our agent to receive service of process in any action against us in any U.S. federal or state court arising out of this offering or any purchase or sale of securities in connection with this offering. Subject to specified time limitations and legal procedures,Â Israeli courts may enforce a U.S. judgment in a civil matter which is non-appealable, including a judgment based upon the civil liability provisions of the Securities Act or the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that, among other things: Â Â·the judgment was rendered by a court of competent jurisdiction, according to the laws of the state in which the judgment is given; Â Â·the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted; and Â Â·the judgment is not contrary to public policy of Israel. Â 58 Â Â Even if such conditions are met, an Israeli court may not declare a foreign civil judgment enforceable if: Â Â·the prevailing law of the foreign state in which the judgment is rendered does not allow for the enforcement of judgments of Israeli courts (subject to exceptional cases); Â Â·the defendant did not have a reasonable opportunity to be heard and to present his or her evidence, in the opinion of the Israeli court; Â Â·the enforcement of the civil liabilities set forth in the judgment is likely to impair the security or sovereignty of Israel; Â Â·the judgment was obtained by fraud; Â Â·the judgment was rendered by a court not competent to render it according to the rulesÂ of private international law prevailing in Israel; Â Â·the judgment conflicts with any other valid judgment in the same matter between the same parties; or Â Â·an action between the same parties in the same matter was pending in any Israeli court or tribunal at the time at which the lawsuit was instituted in the foreign court. Â If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.Â WHERE YOU CAN FIND MORE INFORMATION Â We have filed with the SEC a registration statement on FormÂ S-1Â under the Securities Act with respect to the securities offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed with the registration statement. For further information about us and the securities offered hereby, we refer you to the registration statement and the exhibits filed with the registration statement. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. The SEC also maintains an internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC.Â The address of that website isÂ [www.sec.gov](http://www.sec.gov). Â We are required to file periodic reports, proxy statements, and other information with the SEC pursuant to the ExchangeÂ Act. These reports, proxy statements, and other information will be available on the website of the SEC referred to above. Â 59 Â Â We also maintain a website atÂ [www.quoinpharma.com](http://www.quoinpharma.com), through which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.Â Information contained on or accessed through our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. Â Incorporation of Certain Information By Reference Â The SEC allows us to àœincorporate by referenceâ information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus. Â We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File No.Â 001-37846): Â Â·Our Annual Report on FormÂ 10-K for the fiscal year ended DecemberÂ 31, 2023 filed with the SEC on MarchÂ 14, 2024; Â Â·Our Quarterly Report on FormÂ 10-Q for the quarter ended MarchÂ 31, 2024 filed with the SEC on MayÂ 9, 2024, our Quarterly Report on FormÂ 10-Q for the quarter ended JuneÂ 30, 2024 filed with the SEC on AugustÂ 8, 2024, and our Quarterly Report on FormÂ 10-Q for the quarter ended SeptemberÂ 30, 2024 filed with the SEC on NovemberÂ 8, 2024; Â Â·Our Current Reports on FormÂ 8-K filed with the SEC on JanuaryÂ 30, 2024, MarchÂ 6, 2024, MarchÂ 8, 2024, AprilÂ 9, 2024, MayÂ 3, 2024, SeptemberÂ 30, 2024, OctoberÂ 31, 2024 and DecemberÂ 10, 2024; Â Â·Our Definitive Proxy Statement on Schedule 14A filed with the SEC on OctoberÂ 24, 2024; and Â We also incorporate

by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made (i) on or after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of such registration statement, and (ii) on or after the date of this prospectus but prior to the termination of the offering (i.e., until the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement of which this prospectus forms a part has been withdrawn). Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. <sup>60</sup> We will furnish without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to: Quoin Pharmaceuticals Ltd. 42127 Pleasant Forest Ct. Ashburn, VA 20148 Telephone: (703) 980-4182 Attention: Corporate Secretary. You may also access these documents, free of charge, on the SEC's website at [www.sec.gov](http://www.sec.gov) or on our website at <https://investors.quoinpharma.com/financial-information/sec-filings>. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus or any accompanying prospectus supplement. In accordance with Rule 412 of the Securities Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. You should rely only on information contained in, or incorporated by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference into this prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such an offer or solicitation. <sup>61</sup> Up to 19,230,769 Ordinary Shares Represented by American Depository Shares. Up to 19,230,769 Pre-Funded Warrants to Purchase Up to 19,230,769 Ordinary Shares Represented by American Depository Shares. Up to 19,230,769 Series F Warrants to Purchase Up to 19,230,769 Ordinary Shares Represented by American Depository Shares. Up to 19,230,769 Series G Warrants to Purchase Up to 19,230,769 Ordinary Shares Represented by American Depository Shares. Up to 57,692,307 Ordinary Shares Represented by American Depository Shares Issuable Upon Exercise of the Pre-Funded Warrants, Series F Warrants and Series G Warrants. <sup>62</sup> Preliminary

<sup>63</sup> Sole Placement Agent. <sup>64</sup> Maxim

Group LLC. The date of this prospectus is <sup>65</sup>, 2024. <sup>66</sup> PART II

INFORMATION NOT REQUIRED IN PROSPECTUS. Item 13. Other Expenses of Issuance and Distribution. The following table sets forth the various costs and expenses, other than the placement agent's fees and expenses, to be paid in connection with the offering of securities described in this registration statement. All the amounts shown are estimates except the SEC registration fee. SEC registration fee \$6,890. Printing and mailing expenses \$50,000. Legal fees and expenses \$200,000. Accounting fees and expenses \$57,500. Transfer agent and registrar fees \$80,000. Miscellaneous \$65,610. Total \$460,000. Item 14. Indemnification of Directors and Officers. Under the Companies Law, a company may not exculpate an Office Holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an Office Holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our articles of association include such a provision. An Israeli company may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders. Under the Companies Law, an Israeli company may indemnify an Office Holder in respect of the following liabilities and expenses incurred for acts performed by him or her as an Office Holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification, which ours do: A financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator's award approved by a court. However, if an undertaking to indemnify an Office Holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be reasonably foreseen based on the company's activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; A reasonable litigation expenses, including attorneys' fees, incurred by the Office Holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (a) no indictment was filed against such Office Holder as a result of such investigation or proceeding; and (b) no financial liability, such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction; II-1 A reasonable litigation expenses, including attorneys' fees, incurred by the Office Holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the Office Holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent; and A expenses, including reasonable litigation expenses and legal fees, incurred by an Office Holder in relation to an administrative proceeding instituted against such Office Holder, or certain compensation payments made to an injured party imposed on an Office Holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law, 1968 (the "Israeli Securities Law"). Under the Companies Law and the Israeli Securities Law, a company may insure an Office Holder against the following liabilities incurred for acts performed by him or her as an Office Holder if and to the extent provided in the company's articles of association: A a breach of the duty of loyalty to the company, provided that the Office Holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; A a breach of duty of care to the company or to a third party, including a breach arising out of the negligent conduct of the Office Holder; and A a financial liability imposed on the Office Holder in favor of a third party. Under our articles of association, we may insure an Office Holder against the

forementioned liabilities as well as the following liabilities: (i) a breach of duty of care to the company or to a third party; (ii) any other action against which we are permitted by law to insure an Office Holder; (iii) expenses incurred and/or paid by the Office Holder in connection with an administrative enforcement procedure under any applicable law including Parts 8(3), 8(4) and 9(1) of the Israeli Securities Law, and a proceeding according to Section D of Chapter 4 in Part 9 of the Companies Law, including reasonable litigation expenses and attorney fees; (iv) a payment to a person injured by a violation of Section 52BBB(a)(1)(a) of the Israeli Securities Law; and (v) expenses incurred in connection with a proceeding under the Economic Competition Law 5748-1988, including reasonable litigation expenses and attorney fees.

II-2 Under the Companies Law, an Israeli company may not indemnify, exculpate or insure an Office Holder against any of the following: (i) a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the Office Holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; (ii) a breach of duty of care committed intentionally or recklessly, excluding a breach arising solely out of the negligent conduct of the Office Holder; (iii) an act or omission committed with intent to derive illegal personal benefit; or (iv) a fine, civil fine, or other financial sanction levied against the Office Holder. Under the Companies Law, exculpation, indemnification and insurance of Office Holders in a public company must be approved by the compensation committee and the board of directors and, with respect to directors and the Chief Executive Officers or under certain circumstances, also by the shareholders. However, under regulations promulgated under the Companies Law, the insurance of Office Holders does not require shareholder approval and may be approved by only the compensation committee, if the engagement terms are determined in accordance with the limitations set forth in the company's compensation policy, which was approved by the shareholders by the requisite special majority, provided that the insurance policy is on market terms and the insurance policy is not likely to materially impact the company's profitability, assets or obligations. Our articles of association permit us to exculpate, indemnify and insure our Office Holders to the fullest extent permitted or to be permitted by the Companies Law and the Israeli Securities Law. Upon the recommendation of our compensation committee, our board of directors has approved, and our shareholders have approved, at the annual general meeting held on April 12, 2022, the form of indemnification and release agreements to be entered into with each of our current and future directors and executive officers exculpating them, to the fullest extent permitted by law and our articles of association, and undertaking to indemnify them to the fullest extent permitted by law and our articles of association. This indemnification will be limited to events determined as foreseeable by the board of directors based on our activities, and to an amount or according to criteria determined by the board of directors and our compensation committee as reasonable under the circumstances. The maximum indemnification amount set forth in our indemnification and release agreements during any period of three years in the aggregate for all of the covered directors and executive officers, is limited to an amount equal to the higher of: (i) \$35,000,000 and (ii) 25% of our total shareholders' equity as reflected in our most recent financial statements as of the time of the actual payment of indemnification is made. In the opinion of the SEC, indemnification of directors and other Office Holders for liabilities arising under the Securities Act, however, is against public policy and therefore unenforceable. We have obtained directors' and officers' liability insurance for the benefit of our Office Holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Companies Law.

II-3 Item 15. Recent Sales of Unregistered Securities

Agreements with Altium Growth Fund, LP and Warrant Exercises

On October 28, 2021, the Company completed a private placement transaction with Altium Growth Fund, LP ("Altium" or "Investor") for an aggregate purchase price of approximately \$17.0 million (comprised of a set off of approximately \$5.0 million of bridge notes from bridge financing earlier in 2021 (the "Bridge Notes"), and approximately \$12.0 million in cash) (the "Primary Financing"), which resulted in net proceeds of approximately \$10.1 million. The Company issued 28,508 ADSs to Altium. The Company also issued to Altium, effective as of March 13, 2022 (i) a Series A Warrant to purchase 28,508 ADSs (the "Series A Warrant") (ii) a Series B Warrant to purchase 28,508 ADSs (the "Series B Warrant") and (iii) a Series C Warrant to purchase 15,931 ADSs (the "Series C Warrant") and, together with the Series A Warrant and the Series B Warrant, the "Investor Warrants"). The exercise price for the Investor Warrants was \$597 per ADS, with the Series A Warrant having a five-year maturity, and the Series B Warrant and the Series C Warrant having a two-year maturity. The Company had the right to require the mandatory exercise of the Series C Warrant, subject to an effective registration statement being in place for the resale of the shares underlying such warrant and the satisfaction of equity market conditions, as defined in the Series C Warrant. In the period from April 22, 2022 to June 30, 2022, the Investor exercised the Series B Warrant in full pursuant to the alternate cashless exercise rights of such warrant, resulting in the issuance of a total of 28,508 ADSs to the Investor. The market related conditions to require the mandatory exercise of the Series C Warrant were not met during the period up to July 14, 2022. On July 14, 2022, the Company entered into an agreement with Quoin Inc. and Altium (the "Altium Agreement"), pursuant to which the parties agreed to, among other things, (i) amend certain terms of the Series A Warrant and the Investor Exchange Warrants previously issued to Altium to reduce the exercise price to \$0.00 per ADS with respect to a total of 33,333 ADSs, (ii) cancel the Series C Warrant and the remaining portion of the Series A Warrant previously issued to Altium, and (iii) terminate the Purchase Agreements, pursuant to which the warrants were previously issued to Altium. The incremental fair value of the modified warrants was approximately \$491,000, which was charged against the gross proceeds of the 2022 Offering (see below) as the modification was done in contemplation of the offering. As of August 2, 2022, Altium exercised all of its warrants to purchase ADSs at \$0.00 per ADS exercise price, and the Company issued a total of 33,333 ADSs to Altium.

Noteholder Warrant Exercises

Commencing in October 2020, Quoin Inc. issued promissory notes (the "2020 Notes") to five noteholders, including our directors, Messrs. Langer and Culverwell (collectively, the "2020 Noteholders"). The 2020 Notes were issued at a 25% original issue discount with an aggregate face value of \$1,213,313 with interest at a rate of 20% per annum. The 2020 Notes were mandatorily convertible into ADSs based on the valuation negotiated in the Primary Financing. The 2020 Noteholders also received warrants exercisable at any time after the issuance date for a number of shares of Quoin Inc.'s common stock equal to 100% of the as if converted shares as if the 2020 Notes principal and interest were convertible at the lowest price any securities are sold, convertible, or exercisable into in the Primary Financing or the next round of financing (whichever is lower). At the closing of the Cellect/Quoin merger, ADSs were issued to the 2020 Noteholders upon the conversion of the principal of the 2020 Notes. In addition, effective as of March 13, 2022, Quoin Ltd. exchanged Quoin Inc. warrants held by the 2020 Noteholders for warrants on substantially the same terms as the Investor Exchange Warrants, exercisable for 2,449 ADSs, in the aggregate, at the exercise price of \$597 per ADS (the "Noteholder Warrants"). The Noteholder Warrants became exercisable immediately upon issuance and were

to expire five years from March 13, 2022. The exercise price of the warrants held by the 2020 Noteholders was also reduced to \$0.00 as of July 14, 2022 as a result of the Altium Agreement. The change in the exercise price of the Noteholder Warrants resulted in a deemed dividend of approximately \$65,000. From July to September 2022, the 2020 Noteholders exercised all their warrants to purchase ADSs at \$0.00 per ADS exercise price, and a total of 2,449 ADSs were issued to such noteholders. II-4 Axella In addition, in August 2022, we issued 3,683 ADSs to one of the principals of Axella Research LLC (âœAxellaâ€), a provider of regulatory and pre- clinical/clinical services to us with respect to QRX003 and QRX004, to settle in full the outstanding liability to Axella for accrued fees under our consulting agreements with Axella. We believe that each of such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D promulgated under the Securities Act. No underwriter or underwriting discount or commission was involved in any such transaction. Item 16.Exhibits and Financial Statement Schedules (a) Exhibits. The exhibits to the registration statement are listed in the Exhibit Index to this registration statement and are incorporated herein by reference. (b) Financial Statement Schedules All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the consolidated financial statements and related notes thereto. Item 17.Undertakings The Registrant hereby undertakes that: (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i)To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the âœSecurities Actâ€); (ii)To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the âœCalculation of Registration Feeâ table in the effective registration statement; and (ii)To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. provided, however, that paragraphs (1)(i), (1)(ii) and (1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the âœExchange Actâ€), that are incorporated by reference in the registration statement. (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. (4)That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. (5)That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: (i)Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; (ii)Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; (iii)The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and (iv)Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. (6)That, for purposes of determining any liability under the Securities Act: (i)the information omitted from the form of prospectus filed as part of the registration statement in reliance upon Rule 430A and contained in the form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of the registration statement as of the time it was declared effective; and (ii)each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. (7)For purposes of determining any liability under the Securities Act of 1933, each filing of the registrantâ€™s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit planâ€™s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. (8)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the indemnification provisions described herein, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. II-7

EXHIBITÂ INDEX Â Exhibit No. Â Â ExhibitÂ Description 1.1\* Â FormÂ of Placement Agency Agreement. Â Â Â 2.1 Â Agreement and Plan of Merger and Reorganization, dated as of MarchÂ 24, 2021, by and among Cellect Biotechnology Ltd., CellMSC,Â Inc. and Quoin Pharmaceuticals,Â Inc. (incorporated by reference to ExhibitÂ 10.1 of the FormÂ 6-K filed with the SEC on MarchÂ 24, 2021). Â Â Â 2.2 Â Amendment made as of SeptemberÂ 24, 2021, to the Agreement and Plan of Merger and Reorganization, dated as of MarchÂ 24, 2021, by and among Cellect Biotechnology Ltd., CellMSC,Â Inc., and Quoin Pharmaceuticals,Â Inc. (incorporated by reference to ExhibitÂ 99.2 to FormÂ 6-K filed with the SEC on SeptemberÂ 27, 2021). Â Â Â 2.3 Â Amended and Restated Share Transfer Agreement, dated MayÂ 27, 2021 by and between Cellect Biotechnology Ltd. and EnCellX Inc. (incorporated by reference to ExhibitÂ 2.2 to Registration Statement on FormÂ F-4 filed with the SEC on JuneÂ 16, 2021). Â Â Â 2.4 Â Amendment made as of SeptemberÂ 26, 2021, to the Amended and Restated Share Transfer Agreement dated as of MayÂ 27, 2021, by and between EnCellX,Â Inc. and Cellect Biotechnology Ltd. (incorporated by reference to ExhibitÂ 99.3 to FormÂ 6-K filed with the SEC on SeptemberÂ 27, 2021). Â Â Â 2.5 Â Securities Purchase Agreement, dated as of MarchÂ 24, 2021, by and among Cellect Biotechnology Ltd., Quoin Pharmaceuticals,Â Inc. and the investors named on the Schedule of Buyers attached thereto (incorporated by reference to ExhibitÂ 10.4 of the FormÂ 6-K filed with the SEC on MarchÂ 24, 2021). Â Â Â 2.6 Â Securities Purchase Agreement, dated as of MarchÂ 24, 2021, by and among Quoin Pharmaceuticals,Â Inc. and the investors listed on the Schedule of Buyers attached thereto (incorporated by reference to ExhibitÂ 10.6 of the FormÂ 6-K filed with the SEC on MarchÂ 24, 2021). Â Â Â 2.7 Â Amendment Agreement, dated as of SeptemberÂ 17, 2021, by and among Quoin Pharmaceuticals,Â Inc., Cellect Biotechnology,Â Ltd., and Altium Growth Fund, L.P. (incorporated by reference to ExhibitÂ 99.1 of the FormÂ 6-K filed with the SEC on SeptemberÂ 17, 2021). Â Â Â 2.8 Â Letter Agreement, dated SeptemberÂ 17, 2021, between Quoin Pharmaceuticals,Â Inc. and Cellect Biotechnology,Â Ltd. (incorporated by reference to ExhibitÂ 99.2 of the FormÂ 6-K filed with the SEC on SeptemberÂ 17, 2021). Â Â Â 2.9 Â Second Amendment Agreement, dated as of MarchÂ 13, 2022, by and among Quoin Pharmaceuticals,Â Inc., Quoin Pharmaceuticals Ltd., and Altium Growth Fund, L.P. (incorporated by reference to ExhibitÂ 4.1 to FormÂ 6-K filed with the SEC on MarchÂ 28, 2022). Â Â Â 2.10 Â Waiver Agreement, dated JuneÂ 6, 2022, by and among Quoin Pharmaceuticals Ltd., Quoin Pharmaceuticals,Â Inc. and Altium Growth Fund, LP (incorporated by reference to ExhibitÂ 10.2 to FormÂ 6-K filed with the SEC on JuneÂ 6, 2022). Â Â Â 2.11 Â Agreement, dated JulyÂ 14, 2022, by and among Quoin Pharmaceuticals,Â Inc., Quoin Pharmaceuticals Ltd. and Altium Growth Fund, LP (incorporated by reference to ExhibitÂ 10.1 to FormÂ 6-K filed with the SEC on JulyÂ 15, 2022). Â Â Â 2.12 Â Letter of Agreement among Cellect Biotechnology Ltd, Dr.Â Shai Yarkoni and EnCellX,Â Inc. (incorporated by reference to ExhibitÂ 2.5 to Registration Statement on FormÂ F-4 filed with the SEC on JulyÂ 16, 2021). Â II-8 Â Â 2.13 Â FormÂ of Representative Agreement among Cellect Biotechnology Ltd, Eyal Leibovitz, as Representative, and EnCellX,Â Inc. (incorporated by reference to ExhibitÂ 2.6 to Registration Statement on FormÂ F-4 filed with the SEC on AugustÂ 6, 2021). Â Â Â 3.1 Â Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on FebruaryÂ 28, 2022 (incorporated by reference to Annex A included in ExhibitÂ 99.1 to FormÂ 6-K filed with the SEC on FebruaryÂ 8, 2022). Â Â Â 3.2 Â Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on AprilÂ 12, 2022 (incorporated by reference to Annex A included in ExhibitÂ 99.1 to FormÂ 6-K filed with the SEC on MarchÂ 8, 2022). Â Â Â 3.3 Â Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on NovemberÂ 3, 2022 (incorporated by reference to Annex A included in ExhibitÂ 99.1 to FormÂ 6-K filed with the SEC on SeptemberÂ 21, 2022). Â Â Â 3.4 Â Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on OctoberÂ 26, 2023 (incorporated by reference to FormÂ 8-K filed with the SEC on NovemberÂ 1, 2023). Â Â Â 3.5 Â Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on DecemberÂ 5, 2024 (incorporated by reference to FormÂ 8-K filed with the SEC on DecemberÂ 10, 2024). Â Â Â 4.1 Â FormÂ of Deposit Agreement between Cellect Biotechnology Ltd. (n/k/a Quoin Pharmaceuticals Ltd.), The Bank of New York Mellon as Depositary, and owners and holders from time to time of ADSs issued thereunder (incorporated by reference to ExhibitÂ 4.1 to Registration Statement on FormÂ F-1/A as filed with the SEC on JulyÂ 26, 2016). Â Â Â 4.2 Â Specimen American Depositary Receipt (included in ExhibitÂ 2.1). Â Â Â 4.3 Â FormÂ of Amendment No.Â 1 to Warrant to Purchase Ordinary Shares Represented by American Depositary Shares (incorporated by reference to ExhibitÂ 4.3 to the Current Report on FormÂ 8-K filed with the SEC on FebruaryÂ 28, 2023). Â Â Â 4.4 Â FormÂ of Pre-Funded Warrant (incorporated by reference to ExhibitÂ 4.1 to the Current Report on FormÂ 8-K filed with the SEC on FebruaryÂ 28, 2023). Â Â Â 4.5 Â FormÂ of Common Warrant (incorporated by reference to ExhibitÂ 4.2 to the Current Report on FormÂ 8-K filed with the SEC on FebruaryÂ 28, 2023). Â Â Â 4.6 Â FormÂ of Pre-Funded Warrant issued in the FebruaryÂ 2024 Offering (incorporated by reference to ExhibitÂ 4.1 to the Current Report on FormÂ 8-K filed with the SEC on MarchÂ 8, 2024). Â II-9 Â Â 4.7 Â FormÂ of SeriesÂ D Warrant (incorporated by reference to ExhibitÂ 4.2 to the Current Report on FormÂ 8-K filed with the SEC on MarchÂ 8, 2024). Â Â Â 4.8 Â FormÂ of SeriesÂ E Warrant (incorporated by reference to ExhibitÂ 4.3 to the Current Report on FormÂ 8-K filed with the SEC on MarchÂ 8, 2024). Â Â Â 4.9 Â FormÂ of Amendment to Warrants to Purchase Ordinary Shares Represented by American Depositary SharesÂ (incorporated by reference to ExhibitÂ 4.4 to the Current Report on FormÂ 8-K filed with the SEC on MarchÂ 8, 2024). Â Â Â 4.10\* Â FormÂ of Pre-Funded Warrant. Â Â Â 4.11\* Â FormÂ of SeriesÂ F Warrant. Â Â Â 4.12\* Â FormÂ of SeriesÂ G Warrant. Â Â Â 5.1\* Â Legal Opinion of Meitar | Law Offices,Â Israeli legal counsel to Quoin Pharmaceuticals Ltd. Â Â Â 5.2\* Â Legal Opinion of Blank Rome LLP, US legal counsel to Quoin Pharmaceuticals Ltd. Â Â Â 10.1# Â Compensation Policy for Executives and Directors of Quoin Pharmaceuticals Ltd., adopted on AprilÂ 12, 2022 (incorporated by reference to Annex B included in ExhibitÂ 99.1 to FormÂ 6-K filed with the SEC on MarchÂ 8, 2022). Â Â Â 10.2# Â Amended and Restated Equity Incentive Plan of Quoin Pharmaceuticals Ltd., effective as of AprilÂ 12, 2022 (incorporated by reference to Annex C included in ExhibitÂ 99.1 to FormÂ 6-K filed with the SEC on MarchÂ 8, 2022). Â Â Â 10.3# Â FormÂ of Indemnification and Release Agreement, entered into by and between Quoin Pharmaceuticals Ltd. and each of the officers and directors of Quoin Pharmaceuticals Ltd. as of AprilÂ 12, 2022 (incorporated by reference to Annex D included in ExhibitÂ 99.1 to FormÂ 6-K filed with the SEC on MarchÂ 8, 2022). Â Â Â 10.4# Â Executive Employment Agreement, dated MarchÂ 9, 2018, by and between Quoin Pharmaceuticals,Â Inc. and Dr.Â Michael Myers (incorporated by reference to ExhibitÂ 10.1 to FormÂ 6-K filed with the SEC on OctoberÂ 29, 2021). Â Â Â 10.5# Â Executive Employment Agreement, dated MarchÂ 9, 2018, by and between Quoin Pharmaceuticals,Â Inc. and Denise Carter (incorporated by reference to ExhibitÂ 10.2 to FormÂ 6-K filed with the SEC on OctoberÂ 29, 2021). Â Â Â 10.6# Â Service Agreement, dated NovemberÂ 1, 2021, by and between Quoin Pharmaceuticals,Â Inc. and Gordon Dunn (incorporated by reference to ExhibitÂ 10.1 to FormÂ 6-K filed with the SEC on NovemberÂ 23, 2021). Â II-10 Â

Â 10.7 Â Research Agreement, dated NovemberÂ 1, 2021, by and between Quoin Pharmaceuticals,Â Inc. and Queensland University of Technology (incorporated by reference to ExhibitÂ 10.2 to FormÂ 6-K filed with the SEC on NovemberÂ 23, 2021). Â Â Â 10.8 Â License and Distribution Agreement, dated NovemberÂ 5, 2021, by and between Quoin Pharmaceuticals,Â Inc. and AFT Pharmaceuticals Ltd. (incorporated by reference to ExhibitÂ 10.3 to FormÂ 6-K filed with the SEC on NovemberÂ 23, 2021). Â Â Â 10.9 Â Supply Agreement, dated SeptemberÂ 15, 2021, by and between Quoin Pharmaceuticals,Â Inc. and AFT Pharmaceuticals Ltd. (incorporated by reference to ExhibitÂ 10.4 to FormÂ 6-K filed with the SEC on NovemberÂ 23, 2021). Â Â Â 10.10 Â License and Distribution Agreement, dated NovemberÂ 7, 2021, by and between Quoin Pharmaceuticals,Â Inc. and GenPharm Services FZ LLC (incorporated by reference to ExhibitÂ 10.5 to FormÂ 6-K filed with the SEC on NovemberÂ 23, 2021). Â Â Â 10.11 Â Supply Agreement, dated NovemberÂ 7, 2021, by and between Quoin Pharmaceuticals,Â Inc. and GenPharm Services FZ LLC (incorporated by reference to ExhibitÂ 10.6 to FormÂ 6-K filed with the SEC on NovemberÂ 23, 2021). Â Â Â 10.12 Â Distribution Agreement, dated DecemberÂ 15, 2021, by and between Quoin Pharmaceuticals,Â Inc. and Orpharm LLC (certain provisions of this exhibit have been omitted pursuant to Instruction No.Â 4 to Exhibits in FormÂ 20-F) (incorporated by reference to ExhibitÂ 10.1 to FormÂ 6-K filed with the SEC on DecemberÂ 20, 2021). Â Â Â 10.13 Â License and Distribution Agreement, dated as of JanuaryÂ 24, 2022 between the Company and E-Log Logistica LTDA (certain provisions of this exhibit have been omitted pursuant to Instruction No.Â 4 to Exhibits in FormÂ 20-F) (incorporated by reference to ExhibitÂ 10.1 to FormÂ 6-K filed with the SEC on JanuaryÂ 31, 2022). Â Â Â 10.14 Â License and Distribution Agreement, dated as of FebruaryÂ 1, 2022, by and between Quoin Pharmaceuticals Ltd. and Er-Kim Ä°laÄ§ Sanayi ve Ticaret A.Äž, and the First Amendment to the License and Distribution Agreement, dated as of FebruaryÂ 17, 2022, by and between Quoin Pharmaceuticals,Â Inc. and Er-Kim Ä°laÄ§ Sanayi ve Ticaret A.Äž (certain provisions of this exhibit have been omitted pursuant to Instruction No.Â 4 to Exhibits in FormÂ 20-F) (incorporated by reference to ExhibitÂ 10.4 to FormÂ 6-K filed with the SEC on MarchÂ 8, 2022). Â Â Â 10.15 Â License and Distribution Agreement, dated as of FebruaryÂ 11, 2022, by and between Quoin Pharmaceuticals Ltd. and Neopharm (Israel) 1996 Ltd. (certain provisions of this exhibit have been omitted pursuant to Instruction No.Â 4 to Exhibits in FormÂ 20-F) (incorporated by reference to ExhibitÂ 10.5 to FormÂ 6-K filed with the SEC on MarchÂ 8, 2022). Â Â Â 10.16 Â Supply Agreement, dated as of FebruaryÂ 11, 2022, by and between Quoin Pharmaceuticals Ltd. and Neopharm (Israel) 1996 Ltd. (incorporated by reference to ExhibitÂ 10.6 to FormÂ 6-K filed with the SEC on MarchÂ 8, 2022). Â II-11 Â Â 10.17 Â License Agreement, dated JuneÂ 14, 2022, by and between Quoin Pharmaceuticals,Â Inc. and WinHealth Investment (HK) Limited (certain provisions of this exhibit have been omitted pursuant to Instruction No.Â 4 to Exhibits in FormÂ 20-F) (incorporated by reference to ExhibitÂ 10.1 to FormÂ 6-K filed with the SEC on JuneÂ 17, 2022). Â Â Â 10.18 Â License and Distribution Agreement, dated JulyÂ 14, 2022, by and between Quoin Pharmaceuticals,Â Inc. and Endo Ventures Limited (certain provisions of this exhibit have been omitted pursuant to Instruction No.Â 4 to Exhibits in FormÂ 20-F) (incorporated by reference to ExhibitÂ 10.2 to FormÂ 6-K filed with the SEC on JulyÂ 15, 2022). Â Â Â 10.19 Â Supply Agreement, dated JulyÂ 14, 2022, by and between Quoin Pharmaceuticals,Â Inc. and Endo Ventures Limited (certain provisions of this exhibit have been omitted pursuant to Instruction No.Â 4 to Exhibits in FormÂ 20-F) (incorporated by reference to ExhibitÂ 10.3 to FormÂ 6-K filed with the SEC on JulyÂ 15, 2022). Â Â Â 10.20 Â Research Agreement, dated MayÂ 20, 2022, by and between Quoin Pharmaceuticals,Â Inc. and Queensland University of Technology, Australia (certain provisions of this exhibit have been omitted pursuant to Instruction No.Â 4 to Exhibits in FormÂ 20-F) (incorporated by reference to ExhibitÂ 10.1 to FormÂ 6-K filed with the SEC on JuneÂ 6, 2022). Â Â Â 10.21 Â Exclusive License Agreement, dated OctoberÂ 17, 2019, by and between Quoin Pharmaceuticals,Â Inc. and Skinvisible Inc. (incorporated by reference to ExhibitÂ 4.30 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.22 Â Exclusive License Agreement Renewal, dated MayÂ 8, 2020, by and between Quoin Pharmaceuticals,Â Inc. and Skinvisible Inc. (incorporated by reference to ExhibitÂ 4.31 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.23 Â First Amendment to the Exclusive License Agreement, dated JulyÂ 31, 2020, by and between Quoin Pharmaceuticals,Â Inc. and Skinvisible Inc. (incorporated by reference to ExhibitÂ 4.32 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.24 Â Second Amendment to the Exclusive License Agreement, dated SeptemberÂ 30, 2020, by and between Quoin Pharmaceuticals,Â Inc. and Skinvisible Inc. (incorporated by reference to ExhibitÂ 4.33 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.25 Â Third Amendment to the Exclusive License Agreement, dated JanuaryÂ 27, 2021, by and between Quoin Pharmaceuticals,Â Inc. and Skinvisible Inc. (incorporated by reference to ExhibitÂ 4.34 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.26 Â Fourth Amendment to the Exclusive License Agreement, dated AprilÂ 19, 2021, by and between Quoin Pharmaceuticals,Â Inc. and Skinvisible Inc. (incorporated by reference to ExhibitÂ 4.35 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.27 Â Fifth Amendment to the Exclusive License Agreement, dated JuneÂ 14, 2021, by and between Quoin Pharmaceuticals,Â Inc. and Skinvisible Inc. (incorporated by reference to ExhibitÂ 4.36 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â II-12 Â Â 10.28 Â Quotation - Tech Transfer and Clinical Manufacture for QRX003 Topical Lotion, dated AprilÂ 8, 2021, by Ferndale Contract Manufacturing to Quoin Pharmaceuticals,Â Inc. (incorporated by reference to ExhibitÂ 4.37 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.29 Â Development and Supply Agreement, dated JanuaryÂ 13, 2021, by and between TopChem Pharmaceuticals Limited and Quoin Pharmaceuticals Limited (incorporated by reference to ExhibitÂ 4.38 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.30 Â Master Services Agreement, dated NovemberÂ 2, 2020, by and between Therapeutics,Â Inc. and Quoin Pharmaceuticals,Â Inc. (incorporated by reference to ExhibitÂ 4.39 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.31 Â Term Sheet for Agreement, dated OctoberÂ 29, 2019, by and between Axella Research, LLC and Quoin Pharmaceuticals,Â Inc. (incorporated by reference to ExhibitÂ 4.40 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.32 Â Term Sheet for Agreement, dated JanuaryÂ 11, 2020, by and between Axella Research, LLC and Quoin Pharmaceuticals,Â Inc. (re: QRX003) (incorporated by reference to ExhibitÂ 4.41 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.33 Â Term Sheet for Agreement, dated JanuaryÂ 11, 2020, by and between Axella Research, LLC and Quoin Pharmaceuticals,Â Inc. (re: QRX004) (incorporated by reference to ExhibitÂ 4.42 to FormÂ 20-F filed with the SEC on AprilÂ 13, 2022). Â Â Â 10.34# Â FormÂ of Non-Qualified Stock Option Award Agreement for directors (incorporated by reference to ExhibitÂ 10.34 to FormÂ F-1 filed with the SEC on AugustÂ 3, 2022) Â Â Â 10.35# Â FormÂ of Non-Qualified Stock Option Award Agreement for officers (incorporated by reference to ExhibitÂ 10.35 to FormÂ F-1 filed with the SEC on AugustÂ 3, 2022) Â Â Â 10.36 Â FormÂ of Securities Purchase Agreement, dated FebruaryÂ 22, 2023 (incorporated by reference to ExhibitÂ 10.1 to the Current Report on FormÂ 8-K filed with the SEC on FebruaryÂ 28, 2023). Â Â Â 10.37# Â Code of Ethics and Business Conduct (incorporated by reference to ExhibitÂ 14.1 to FormÂ 10-K filed with the SEC on MarchÂ 15, 2023) Â Â Â

10.38 Å License and Distribution Agreement, by and between Quoin Pharmaceuticals Inc. and Farma Mondo (incorporated by reference to Exhibit Å 10.1 to Form Å 8-K filed with the SEC on September Å 13, 2023) Å Å Å 10.39 Å Purchase Agreement, dated January Å 25, 2024, by and between Quoin Pharmaceuticals Ltd. and Alumni Capital LP (incorporated by reference to Exhibit Å 10.1 to Form Å 8-K filed with the SEC on January Å 30, 2024) Å II-13 Å Å 10.40 Å Securities Purchase Agreement dated March Å 4, 2024 (incorporated by reference to Exhibit Å 10.1 to the Current Report on Form Å 8-K filed with the SEC on March Å 8, 2024). Å Å Å 10.41 Å Placement Agency Agreement dated March Å 4, 2024 (incorporated by reference to Exhibit Å 1.1 to the Current Report on Form Å 8-K filed with the SEC on March Å 8, 2024). Å Å Å 10.42\*+ Å Form Å of Securities Purchase Agreement. Å Å Å Å Å 21.1 Å Subsidiaries of Registrant (incorporated by reference to Exhibit Å 8.1 to Form Å 20-F filed with the SEC on April Å 13, 2022). Å Å Å 23.1\* Å Consent of Marcum LLP, Certified Public Accountants Å Å Å 23.2\* Å Consent of Meitar | Law Offices (included in Exhibit Å 5.1) Å Å Å 23.3\* Å Consent of Blank Rome LLP (included in Exhibit 5.2) Å Å Å 24.1\* Å Power of Attorney Å Å Å 107\* Å Filing Fee Table Å Å \*Filed herewith Å #Indicates management contract or compensatory plan or arrangement. Å +Exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit to the SEC upon request. Å II-14 Å Å SIGNATURES Å Pursuant to the requirements of the Å Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ashburn, Commonwealth of Virginia on December Å 11, 2024. Å Å Quoin Pharmaceuticals Å Ltd. Å Å Å By: /s/ Michael Myers Å Å Name: Å Å Dr. Å Michael Myers Å Å Title: Chief Executive Officer Å POWER OF ATTORNEY Å Know all by these presents, that each person whose signature appears below hereby constitutes and appoints Dr. Å Michael Myers or Denise Carter, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for and in his or her name, place and stead, in any and all capacities, to (i) Å act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this registration statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to Rule Å 462(b) Å under the Å Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii) Å act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii) Å act on and file any supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed pursuant to Rule Å 462(b) Å under the Å Securities Act of 1933, as amended, and (iv) Å take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his or her substitutes may lawfully do or cause to be done by virtue thereof. Å Pursuant to the requirements of the Å Securities Act of 1933, as amended, this registration statement on Form Å S-1 has been signed by the following persons in the capacities and on the dates indicated. Å Signature Å Title Å Date Å Å Å Å /s/ Michael Myers Å Chief Executive Officer Å December Å 11, 2024 Dr. Å Michael Myers Å (Principal Executive Officer) Å Å Å Å Å Å Å /s/ Gordon Dunn Å Chief Financial Officer Å December Å 11, 2024 Gordon Dunn Å (Principal Financial Officer and Principal Accounting Officer) Å Å Å Å Å Å /s/ Denise Carter Å Å Å Denise Carter Å Director and Chief Operating Officer Å December Å 11, 2024 Å Å Å Å Å /s/ Joseph Cooper Å Å Å Joseph Cooper Å Director Å December Å 11, 2024 Å Å Å Å Å Å Å /s/ James Culverwell Å Å Å James Culverwell Å Director Å December Å 11, 2024 Å Å Å Å Å Å /s/ Dennis Langer Å Å Å Dennis Langer Å Director Å December Å 11, 2024 Å Å Å Å Å /s/ Natalie Leong Å Å Å Å Natalie Leong Å Director Å December Å 11, 2024 Å Å Å Å Å /s/ Mike Sember Å Å Å Å Mike Sember Å Director Å December Å 11, 2024 Å II-15 Å Å SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE Å Pursuant to the requirements of the Å Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Quoin Pharmaceuticals Å Ltd., has signed this registration statement in the City of Ashburn, Commonwealth of Virginia on December Å 11, 2024. Å Å Authorized U.S. Representative Å Dr. Å Michael Myers Å Å Å By: /s/ Michael Myers Å Å Name: Å Å Dr. Å Michael Myers Å Å Title: Chief Executive Officer Å II-16 Å EX-1.1 2 tm2430640d1\_ex1-1.htm EXHIBIT 1.1 Å Exhibit 1.1 Å [\_\_\_\_], 2024 Å Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Å Dear Mr. Å Gordon Dunn: Å Subject to the terms and conditions of this letter agreement (the "Agreement") between Maxim Group LLC, as the lead placement agent ("Maxim") (Maxim is also referred to herein as the "Placement Agent"), and Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the "Company"), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a "reasonable best efforts" basis, in connection with the proposed placement (the "Placement") of up to \$[\_\_\_\_] million of registered securities of the Company, consisting of: (i) Å ordinary shares, no par value (the "Ordinary Shares") represented by American Depository Shares (the "ADSs"), with each ADS representing one Ordinary Share, (ii) Å pre-funded warrants to purchase Ordinary Shares represented by ADSs (the "Pre-Funded Warrants"), and (iii) Å Series Å F Warrants to purchase ADSs and Series Å G Warrants to purchase ADSs (the "Ordinary Warrants" and collectively with the Pre-Funded Warrants, the "Warrants"). The ADSs and Warrants actually placed by the Placement Agent are referred to herein as the "Placement Agent Securities." The Placement Agent Securities and Ordinary Shares Represented by ADSs issuable upon the exercise of the Warrants shall be offered and sold under the Company's registration statement on Form Å S-1, as amended (File No. Å 333-[\_\_\_\_]), which was declared effective by the Securities and Exchange Commission (the "Commission") on [\_\_\_\_], 2024. The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, without limitation, a securities purchase agreement (the "Purchase Agreement"), shall be collectively referred to herein as the "Transaction Documents." Å The terms of the Placement shall be mutually agreed upon by the Company and the purchasers listed in the Purchase Agreement (each, a "Purchaser" and collectively, the "Purchasers"), and nothing herein constitutes that the Placement Agent would have the power or authority to bind the Company or any Purchaser, or an obligation for the Company to issue any Placement Agent Securities or complete the Placement. The Company expressly acknowledges and agrees that the Placement Agent's obligations hereunder are on a reasonable best efforts basis only and that the execution of this Agreement does not constitute a commitment by the Placement Agent to purchase the Placement Agent Securities and does not ensure the successful placement of the Placement Agent Securities or any portion thereof or the success of the Placement Agent with respect to securing any other financing on behalf of the Company. The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Placement. Certain affiliates of the Placement Agent may participate in the Placement by purchasing some of the Placement Agent Securities. The sale of Placement Agent Securities to any Purchaser will be evidenced by the Purchase Agreement between the Company and such Purchaser, in a form reasonably acceptable to the Company and the Purchaser. Capitalized terms that are not otherwise defined

herein have the meanings given to such terms in the Purchase Agreement. Prior to the signing of any Purchase Agreement, officers of the Company will be available to answer inquiries from prospective Purchasers. **SECTION 1. REPRESENTATIONS AND WARRANTIES OF THE COMPANY; COVENANTS OF THE COMPANY.** Representations of the Company. With respect to the Placement Agent Securities, each of the representations and warranties (together with any related disclosure schedules thereto) and covenants made by the Company to the Purchasers in the Purchase Agreement in connection with the Placement, is hereby incorporated herein by reference into this Agreement (as though fully restated herein) and is, as of the date of this Agreement and as of the date of the sale of the Placement Agents Securities (the "Closing Date"), hereby made to, and in favor of, the Placement Agent. In addition to the foregoing, the Company represents and warrants that there are no affiliations with any Financial Industry Regulatory Authority ("FINRA") member firm participating in the Placement among the Company's officers, directors or, to the knowledge of the Company, any five percent (5.0%) or greater stockholder of the Company. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Company's Board of Directors, a committee of the Company's Board of Directors or the Company's shareholders in connection herewith other than in connection with the Required Approvals (as defined in the Purchase Agreement). This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Placement Agent Securities and the consummation by it of the transactions contemplated hereby do not and will not (i) conflict with or violate any provision of the Company's or any Subsidiary's memorandum of association, articles of association, certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien (as defined in the Purchase Agreement) upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect (as defined in the Purchase Agreement). **B. Covenants of the Company.** The Company covenants and agrees to continue to retain (i) a firm of Public Company Accounting Oversight Board independent registered public accountants for a period of at least two (2) years after the Closing Date and (ii) a reputable depositary with respect to the ADSs for a period of two (2) years after the Closing Date, provided the Company is then subject to the reporting requirement of the Exchange Act (as defined below). Furthermore, for ninety (90) days after the Closing Date, the Company shall not, (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, Ordinary Shares or Ordinary Share Equivalents; or (ii) file or cause to be filed any registration statement or amendment or supplement thereto, other than the Preliminary Prospectus or the Prospectus, a registration statement on Form S-8 in connection with any employee benefit plan, or the filing of any amendment or supplement to any existing registration statement solely for the purpose of revising any required disclosure in such registration statement and not for the purpose of increasing the offering size pursuant to any such registration statement, in each case whether any such transaction described in clauses (i) or (ii) above is to be settled by delivery of ADSs, Ordinary Shares or Ordinary Share Equivalents or other such securities, in cash or otherwise; provided, however, such restrictions shall not apply with respect to an Exempt Issuance. In addition, for one-hundred eighty (180) days after the Closing Date, the Company shall not effect or enter into an agreement to effect any issuance of ADSs, Ordinary Shares or Ordinary Share Equivalents involving a Variable Rate Transaction. "Variable Rate Transaction" means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional ADSs or Ordinary Shares either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the ADSs and Ordinary Shares at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for ADSs or Ordinary Shares or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an "at-the-market" offering, whereby the Company may issue securities at a future determined price, regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently cancelled. Notwithstanding anything herein to the contrary, the reset of the exercise price of certain warrants outstanding on the date hereof shall not be a Variable Rate Transaction. **SECTION 2. REPRESENTATIONS OF THE PLACEMENT AGENT.** The Placement Agent represents and warrants that it (i) is a member in good standing of the FINRA, (ii) is registered as a broker/dealer under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), (iii) is licensed as a broker/dealer under the laws of the United States of America, applicable to the offers and sales of the Placement Agent Securities by the Placement Agent, (iv) is and will be a corporate body validly existing under the laws of its place of incorporation, and (v) has full power and authority to enter into and perform its obligations under this Agreement. The Placement Agent will immediately notify the Company in writing of any change in its status with respect to subsections (i) through (v) above. The Placement Agent covenants that it will use its reasonable best efforts to conduct the Placement hereunder in compliance with the provisions of this Agreement and the requirements of applicable law. **SECTION 3. COMPENSATION.** In consideration of the services to be provided for hereunder, the Company shall pay

to the Placement Agent and/or its respective designees the following compensation: A A cash fee of 7.0% of the aggregate purchase price paid by Purchasers at the Closing (the "Cash Fee"). The Placement Agent reserves the right to reduce any item of compensation or adjust the terms thereof as specified herein in the event that a determination is made by FINRA to the effect of the Placement Agent's aggregate compensation is in excess of that permitted by FINRA Rules or that the terms thereof require adjustment. A SECTION 4. EXPENSES. The Company agrees to pay all costs, fees and expenses incurred by the Company in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (i)A all expenses incident to the issuance, delivery and qualification of the Placement Agent Securities (including all printing and engraving costs); (ii)A all fees and expenses of the depositary of the ADSs; (iii)A all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Placement Agent Securities; (iv)A all fees and expenses of the Company's counsel, independent public or certified public accountants and other advisors; (v)A all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Preliminary Prospectus and the Prospectus, and all amendments and supplements thereto, and this Agreement; (vi)A all filing fees, reasonable attorneys' fees and expenses incurred by the Company in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Placement Agent Securities for offer and sale under the state securities or blue sky laws or the securities laws of any other country; (vii)A the fees and expenses associated with including the Placement Agent Securities on the Trading Market; (viii)A up to \$125,000 for accountable expenses related to legal fees of counsel to the Placement Agent and associated with the i-Deal system and NetRoadshow, background check expenses, tombstones and marketing related expenses, including road show expenses incurred by the Placement Agent in connection with the Placement, in the event of a Closing and up to \$25,000 in the event that there is not a Closing. A A A SECTION 5. INDEMNIFICATION. A. The Company agrees to indemnify and hold harmless the Placement Agent, its affiliates and each person controlling the Placement Agent (within the meaning of Section 15 of the Securities Act), and the directors, officers, agents and employees of the Placement Agent, its affiliates and each such controlling person (the Placement Agent, and each such entity or person, an "Indemnified Person") from and against any losses, claims, damages, judgments, assessments, costs and other liabilities (collectively, the "Liabilities"), and shall reimburse each Indemnified Person for all reasonable fees and expenses (including the reasonable fees and expenses of one counsel for all Indemnified Persons, except as otherwise expressly provided herein) (collectively, the "Expenses") as they are incurred by an Indemnified Person in investigating, preparing, pursuing or defending any actions, whether or not any Indemnified Person is a party thereto, (i)A caused by, or arising out of or in connection with, any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or the Preliminary Prospectus or Prospectus or by any omission or alleged omission to state therein a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading (other than untrue statements or alleged untrue statements in, or omissions or alleged omissions from, information relating to an Indemnified Person furnished in writing by or on behalf of such Indemnified Person expressly for use in the Registration Statement) or (ii)A otherwise arising out of or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated thereby or any Indemnified Person's actions or inactions in connection with any such advice, services or transactions; provided, however, , the Company shall not be responsible for any Liabilities or Expenses of any Indemnified Person that are finally judicially determined to have resulted primarily from such Indemnified Person's (x)A gross negligence or willful misconduct in connection with any of the advice, actions, inactions or services referred to above or (y)A use of any offering materials or information concerning the Company in connection with the offer or sale of the Placement Agent Securities in the Offering which were not authorized for such use by the Company and which use constitutes gross negligence or willful misconduct. The Company also agrees to reimburse each Indemnified Person for all Expenses as they are incurred in connection with enforcing such Indemnified Person's rights under this Agreement. A. Upon receipt by an Indemnified Person of actual notice of an action against such Indemnified Person with respect to which indemnity may be sought under this Agreement, such Indemnified Person shall promptly notify the Company in writing; provided that failure by any Indemnified Person so to notify the Company shall not relieve the Company from any liability which the Company may have on account of this indemnity or otherwise to such Indemnified Person, except to the extent the Company shall have been prejudiced by such failure. The Company shall, if requested by the Placement Agent, assume the defense of any such action including the employment of counsel reasonably satisfactory to the Placement Agent, which counsel may also be counsel to the Company. Any Indemnified Person shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i)A the Company has failed promptly to assume the defense and employ counsel or (ii)A the named parties to any such action (including any impeded parties) include such Indemnified Person and the Company, and such Indemnified Person shall have been advised in the reasonable opinion of counsel that there is an actual conflict of interest that prevents the counsel selected by the Company from representing both the Company (or another client of such counsel) and any Indemnified Person; provided that the Company shall not in such event be responsible hereunder for the fees and expenses of more than one firm of separate counsel for all Indemnified Persons in connection with any action or related actions, in addition to any local counsel. The Company shall not be liable for any settlement of any action effected without its written consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior written consent of the Placement Agent (which shall not be unreasonably withheld), settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened action in respect of which indemnification or contribution may be sought hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination includes an unconditional release of each Indemnified Person from all Liabilities arising out of such action for which indemnification or contribution may be sought hereunder. The indemnification required hereby shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and is due and payable. A A A C. In the event that the foregoing indemnity is unavailable to an Indemnified Person other than in accordance with this Agreement, the Company shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate to reflect (i)A the relative benefits to the Company, on the one hand, and to the Placement Agent and any other Indemnified Person, on the other hand, of the matters contemplated by this Agreement or (ii)A if the allocation provided by the immediately preceding clause is not permitted by applicable law, not only such relative benefits but also the relative fault of the Company, on the one hand, and the Placement Agent and any other

Indemnified Person, on the other hand, in connection with the matters as to which such Liabilities or Expenses relate, as well as any other relevant equitable considerations; provided that in no event shall the Company contribute less than the amount necessary to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities and Expenses in excess of the amount of fees actually received by the Placement Agent pursuant to this Agreement. For purposes of this paragraph, the relative benefits to the Company, on the one hand, and to the Placement Agent on the other hand, of the matters contemplated by this Agreement shall be deemed to be in the same proportion as (a) the total value paid or contemplated to be paid to or received or contemplated to be received by the Company in the transaction or transactions that are within the scope of this Agreement, whether or not any such transaction is consummated, bears to (b) the fees paid to the Placement Agent under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act, as amended, shall be entitled to contribution from a party who was not guilty of fraudulent misrepresentation. **D.** The Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated thereby or any Indemnified Person's actions or inactions in connection with any such advice, services or transactions except for Liabilities (and related Expenses) of the Company that are finally judicially determined to have resulted solely from such Indemnified Person's gross negligence or willful misconduct in connection with any such advice, actions, inactions or services. **E.** The reimbursement, indemnity and contribution obligations of the Company set forth herein shall apply to any modification of this Agreement and shall remain in full force and effect regardless of any termination of, or the completion of any Indemnified Person's services under or in connection with, this Agreement. **SECTION 6. ENGAGEMENT TERM.** The Placement Agent's engagement hereunder will be until the earlier of the Closing Date and February 18, 2025. The date of termination of this Agreement is referred to herein as the "Termination Date." In the event, however, in the course of the Placement Agent's performance of due diligence it deems, it necessary to terminate the engagement, the Placement Agent may do so prior to the Termination Date. The Company may elect to terminate the engagement hereunder for any reason prior to the Termination Date but will remain responsible for fees pursuant to Section 3 hereof with respect to the Placement Agent Securities if sold in the Placement. Notwithstanding anything to the contrary contained herein, the provisions concerning the Company's obligation to pay any fees actually earned pursuant to Section 3 hereof and the provisions concerning confidentiality, indemnification and contribution contained herein, as well as provisions in Sections 10 - 14 hereof will survive any expiration or termination of this Agreement. If this Agreement is terminated prior to the completion of the Placement, all fees due to the Placement Agent as set forth in Section 3 and Section 4 shall be paid by the Company to the Placement Agent on or before the Termination Date (in the event such fees are earned or owed as of the Termination Date). The Placement Agent agrees not to use any confidential information concerning the Company provided to the Placement Agent by the Company for any purposes other than those contemplated under this Agreement. **SECTION 7. PLACEMENT AGENT INFORMATION.** The Company agrees that any information or advice rendered by the Placement Agent in connection with this engagement is for the confidential use of the Company only in its evaluation of the Placement and, except as otherwise required by law, the Company will not disclose or otherwise refer to the advice or information in any manner without the Placement Agent's prior written consent. **SECTION 8. NO FIDUCIARY RELATIONSHIP.** This Agreement does not create, and shall not be construed as creating rights enforceable by any person or entity not a party hereto, except those entitled hereto by virtue of the indemnification provisions hereof. The Company acknowledges and agrees that the Placement Agent is not and shall not be construed as a fiduciary of the Company and shall have no duties or liabilities to the equity holders or the creditors of the Company or any other person by virtue of this Agreement or the retention of the Placement Agent hereunder, all of which are hereby expressly waived. **SECTION 9. CLOSING.** The obligations of the Placement Agent, and the closing of the sale of the Placement Agent Securities hereunder are subject to the accuracy, when made and on the Closing Date, of the representations and warranties on the part of the Company contained herein and in the Purchase Agreement, to the performance by the Company of its obligations hereunder, and to each of the following additional terms and conditions, except as otherwise disclosed to and acknowledged and waived by the Placement Agent: **A.** All corporate proceedings and other legal matters incident to the authorization, form, execution, delivery and validity of each of this Agreement, the Placement Agent Securities, and all other legal matters relating to this Agreement and the transactions contemplated hereby with respect to the Placement Agent Securities shall be reasonably satisfactory in all material respects to the Placement Agent. **B.** The Placement Agent shall have received from each of the Company's U.S. Counsel, Blank Rome LLP, Israeli Counsel, Meitar | Law Offices., addressed to the Placement Agent in form and substance satisfactory to the Placement Agent such counsel's written opinion with respect to the Placement Agent Securities, including without limitation, negative assurance letters, addressed to the Placement Agent and dated as of the Closing Date, in form and substance reasonably satisfactory to the Placement Agent. **C.** The Placement Agent shall have received an executed FINRA questionnaire from each of the Company and the Company's executive officers, directors and 5% or greater securityholders as well as executed Lock-Up Agreements from the Company's executive officers and directors. **D.** ADSs sold in the Placement, including ADSs issuable upon the exercise of the Warrants, must be registered under the Exchange Act. The Company shall have taken no action designed to, or likely to have the effect of, terminating the registration of the ADSs under the Exchange Act or delisting or suspending from trading the ADSs from the Trading Market or other applicable U.S. national exchange, nor has the Company received any information suggesting that the Commission or the Trading Market or other U.S. applicable national exchange is contemplating terminating such registration or listing, except as disclosed in the Registration Statement, the Preliminary Prospectus and the Prospectus. **E.** No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or body which would, as of the Closing Date, prevent the issuance or sale of the Placement Agent Securities or materially and adversely affect or potentially and adversely affect the business or operations of the Company; and no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction shall have been issued as of the Closing Date which would prevent the issuance or sale of the Placement Agent Securities or materially and adversely affect or potentially and adversely affect the business or operations of the Company. **F.** The Company shall have entered into a Purchase Agreement with each of the Purchasers of the Placement Agent Securities that at their option choose to enter into a Purchase Agreement and such agreements shall be in full force and effect and shall contain representations, warranties and covenants of the Company as agreed upon between the Company and the Purchasers. **G.** FINRA shall have raised no objection to the fairness and reasonableness of the terms and arrangements of this Agreement. In addition, the Company shall, if requested by the Placement Agent, make or authorize Placement Agent's counsel to

make on the Company's behalf, any filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110 with respect to the Placement and pay all filing fees required in connection therewith. The Placement Agent shall have received from Marcum LLP, or such other independent registered public accounting firm of the Company, letters dated as of the date hereof and the Closing Date, respectively, in each case addressed to the Placement Agent in forms and substance satisfactory in all respects to the Placement Agent and its counsel. The Placement Agent shall have received customary certificates of the Company's executive officers, as to the accuracy of the representations and warranties contained in the Purchase Agreement, and a certificate of the Company's secretary certifying (i) that the Company's charter documents are true and complete, have not been modified and are in full force and effect; (ii) that the resolutions of the Company's Board of Directors relating to the Placement are in full force and effect and have not been modified; and (iii) as to the incumbency of the officers of the Company. If any of the conditions specified in this Section 9 shall not have been fulfilled when and as required by this Agreement, all obligations of the Placement Agent hereunder may be cancelled by the Placement Agent at, or at any time prior to, the Closing Date. Notice of such cancellation shall be given to the Company in writing or orally. Any such oral notice shall be confirmed promptly thereafter in writing. SECTION 10. GOVERNING LAW. This Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements made and to be performed entirely in such State, without regard to principles of conflicts of law. This Agreement may not be assigned by either party without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising under this Agreement or any transaction or conduct in connection herewith is waived. Any dispute arising under this Agreement may be brought into the courts of the State of New York or into the Federal Court located in New York, New York and, by execution and delivery of this Agreement, the Company hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of aforesaid courts. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorney's fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. SECTION 11. ENTIRE AGREEMENT/MISCELLANEOUS. This Agreement embodies the entire agreement and understanding between the parties hereto, and supersedes all prior agreements and understandings, relating to the subject matter hereof. If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect or any other provision of this Agreement, which will remain in full force and effect. This Agreement may not be amended or otherwise modified or waived except by an instrument in writing signed by both the Placement Agent and the Company. The representations, warranties, agreements and covenants contained herein shall survive the Closing Date of the Placement and delivery of the Placement Agent Securities for the applicable statute of limitations. Notwithstanding anything herein to the contrary, the Engagement Agreement, dated October 18, 2024 ("Engagement Agreement"), between the Company and the Placement Agent shall continue to be effective and the terms therein shall continue to survive and be enforceable by the Placement Agent in accordance with its terms (including, for the avoidance of doubt, the indemnification provisions included therein), provided that, in the event of a conflict between the terms of the Engagement Agreement and this Agreement, the terms of this Agreement shall prevail. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or a .pdf format file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf signature page were an original thereof. SECTION 12. NOTICES. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is sent to the email address specified on the signature pages attached hereto prior to 6:30 p.m. (New York City time) on a business day, (b) the next business day after the date of transmission, if such notice or communication is sent to the email address on the signature pages attached hereto on a day that is not a business day or later than 6:30 p.m. (New York City time) on any business day, (c) the third business day following the date of mailing, if sent by an internationally recognized air courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages hereto. SECTION 13. PRESS ANNOUNCEMENTS. The Company agrees that the Placement Agent shall, on and after the Closing Date, have the right to reference the Placement and the Placement Agent's role in connection therewith in the Placement Agent's marketing materials and on its website and to place advertisements in financial and other newspapers and journals, in each case at its own expense. SECTION 14. PAYMENTS. All payments made or deemed to be made by the Company to the Placement Agent, its affiliates, stockholders, directors, officers, employees, members and controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) (each, a "Payee"), if any, will be made without withholding or deduction for or on account of any present or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes on net income or similar taxes) imposed or levied by or on behalf of the State of Israel or any political subdivision or any taxing authority thereof or therein unless the Company is or becomes required by law to withhold or deduct such taxes, duties, assessments or other governmental charges. In such event, the Company will pay such additional amounts as will result, after such withholding or deduction, in the receipt by the Payee of the amounts that would otherwise have been receivable in respect thereof. For the avoidance of doubt, all sums payable, paid or deemed payable under this Agreement shall be considered exclusive of value added tax, sales tax or other similar taxes which shall be borne by, paid, collected and remitted by the Company in accordance with applicable law. Please confirm that the foregoing correctly sets forth our agreement by signing and returning to the Placement Agent the enclosed copy of this Agreement. The foregoing Agreement is hereby accepted and agreed to as of the date first written above. MAXIM GROUP LLC By: Name: Title: Address for Notice: Attn: Email: [Signature Page to Placement Agency Agreement] Accepted and Agreed to as of the date first written above: QUOIN PHARMACEUTICALS LTD. By: Name: Gordon Dunn



required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable after the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant ADSs available hereunder shall have the effect of lowering the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant ADSs purchased. The Holder and the Company shall maintain records showing the number of Warrant ADSs purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant ADSs hereunder, the number of Warrant ADSs available for purchase hereunder at any given time may be less than the amount stated on the face hereof. A 3 A For the avoidance of doubt, without limiting any rights of the Holder to receive Warrant ADSs pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, there is no circumstance that would require the Company to net cash settle the Warrants. b)â€“â€“â€“â€“â€“â€“â€“â€“â€“Exercise Price. The aggregate exercise price of this Warrant, except for a nominal exercise price of \$0.0001 per Warrant ADS, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of \$0.0001 per Warrant ADS) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining unpaid exercise price per Warrant ADS under this Warrant shall be \$0.0001, subject to adjustment hereunder (the "Exercise Price"). A

c) a cashless exercise. This Warrant may also be exercised, in whole or in part, at such time by means of a cashless exercise in which the Holder shall be entitled to receive a number of Warrant ADSs equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: (A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of regular trading hours (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the ADSs on the principal Trading Market as reported by Bloomberg L.P. (âœBloombergâ) within two (2) hours of the time of the Holderâ™s delivery of the Notice of Exercise pursuant to Section 2(a) hereof if such Notice of Exercise is delivered during regular trading hours, or within two (2) hours after the close of regular trading hours on a Trading Day or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is delivered pursuant to Section 2(a) hereof after the close of regular trading hours on such Trading Day; (B) = the Exercise Price of this Warrant, as adjusted hereunder; and (X) = the number of Warrant ADSs that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. If Warrant ADSs are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant ADSs shall take on the registered characteristics of the Warrants being exercised.â-â- The Company agrees not to take any position contrary to this Section 2(c). d) Mechanics of Exercise. A

i. Delivery of Warrant ADSs Upon Exercise. The Company shall cause the Warrant ADSs purchased hereunder to be transmitted by The Bank of New York Mellon, the Depositary for the ADSs (the "Depositary") to the Holder by crediting the account of the Holder's or its designee's balance account with The Depository Trust Company through its Deposit/Withdrawal At Custodian system ("DWAC") if the Company is then a participant in such system and either (A) there is an effective registration statement with a current prospectus registering the issuance of the Warrant ADSs to, or the resale of the Warrant ADSs by, the Holder or (B) this Warrant is being exercised via cashless exercise, or physical delivery of the Warrant ADSs, registered in the Company's share register in the name of the Holder or its designee, for the number of Warrant ADSs to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise, in each case by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the "Warrant ADS Delivery Date"), provided that payment of the aggregate Exercise Price (other than in the instance of a cashless exercise) is received by the Company by such date. Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant ADSs with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant ADSs, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant ADSs subject to a Notice of Exercise by the Warrant ADS Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each \$1,000 of Warrant ADSs subject to such exercise (based on the VWAP of the ADSs on the date of the applicable Notice of Exercise), \$10 per Trading Day (increasing to \$20 per Trading Day on the third Trading Day after the Warrant ADS Delivery Date) for each Trading Day after such Warrant ADS Delivery Date until such Warrant ADSs are delivered or Holder rescinds such exercise. The Company agrees to maintain a depositary (and, if applicable, a transfer agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, "Standard Settlement Period" means the standard settlement period, expressed in a number of Trading Days, on the Company's primary Trading Market with respect to the ADSs as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the that certain Placement Agency Agreement by and between the Company and Maxim Group LLC, the Company agrees to deliver the Warrant ADSs subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant ADS Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant ADS Delivery Date. 5



determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary Shares as reflected in (A) the Company's most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Depositary setting forth the number of Ordinary Shares outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding Ordinary Shares was reported. The Beneficial Ownership Limitation shall be 4.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of the Ordinary Shares underlying the Warrant ADSs issuable upon exercise of this Warrant. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. If the Warrant is unexercisable as a result of the Holder's Beneficial Ownership Limitation, no alternate consideration is owing to the Holder. So long as this Warrant is outstanding, in no event shall the Holder or the Attribution Parties hold more than 4.99% of the voting power of the Company. 8 A

Section 3. Certain Adjustments. A

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise makes a distribution or distributions on its Ordinary Shares or ADSs or any other equity or equity equivalent securities payable in Ordinary Shares or ADSs (which, for avoidance of doubt, shall not include any Ordinary Shares or ADSs issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding Ordinary Shares or ADSs into a larger number of Ordinary Shares or ADSs, as applicable, (iii) combines (including by way of reverse share split) outstanding Ordinary Shares or ADSs into a smaller number of Ordinary Shares or ADSs, as applicable, or (iv) issues by reclassification of Ordinary Shares, ADSs or any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares or ADSs, as applicable, (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Ordinary Shares or ADSs, as applicable, outstanding immediately after such event, and the number of Ordinary Shares or ADSs, as applicable, issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. b) [RESERVED] A

c) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time that the Warrant is outstanding the Company grants, issues or sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to all of the record holders of any class of ADSs or Ordinary Shares (the "Purchase Rights"), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of ADSs or Ordinary Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of ADSs or Ordinary Shares are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder's right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such ADSs or Ordinary Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). 9 A

d) Payments to be made to Holder in the event of a Distribution. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to all of the holders of Ordinary Shares or ADSs, by way of return of capital or otherwise (including, without limitation, any distribution of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "Distribution"), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to receive a payment ("Payment") equal to the amount that the Holder would have received by way of a Distribution if the Holder had held the number of ADSs acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Ordinary Shares or ADSs are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder's right to receive such a payment would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to receive said Payment (or in the beneficial ownership of any Ordinary Shares or ADSs as a result of such Distribution to such extent) and the amount of the Payment due shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). 10 A

e) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the Company's assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares (including any Ordinary Shares underlying the ADSs) are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares

or 50% or more of the voting power of the common equity of the Company (including any Ordinary Shares underlying the ADSs), (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted into or exchanged for other securities, cash or property (other than an ordinary share split), or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding Ordinary Shares (including any Ordinary Shares underlying the ADSs) or 50% or more of the voting power of the common equity of the Company (each a "Fundamental Transaction"), occurs or is consummated, then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share represented by each Warrant ADS that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of Ordinary Shares of the successor or acquiring corporation or of the Company, if the Company is the surviving corporation, and any additional consideration (the "Alternate Consideration") receivable as a result of such Fundamental Transaction by a holder of the number of Ordinary Shares (including any Ordinary Shares underlying ADSs) equal to the amount of Warrant Shares represented by the Warrant ADSs for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Ordinary Share (including any Warrant Shares underlying the ADSs) in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Ordinary Shares or ADSs are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the "Successor Entity") to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Warrant Shares underlying the Warrant ADSs acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary Shares underlying the Warrant ADSs pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term "Company" under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant referring to the "Company" shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of whether (i) the Company has sufficient authorized Ordinary Shares for the issuance of the Warrant Shares and/or (ii) a Fundamental Transaction occurs prior to the Initial Exercise Date. (1) "Change in ADS Ratio." If after the Issuance Date the ratio of ADSs to Ordinary Shares is increased or reduced, then the number of Warrant ADSs to be delivered upon exercise of this Warrant and the Exercise Price per Warrant ADS will each be proportionately adjusted so that the aggregate Exercise Price remains unchanged. (2) "Calculations." All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an Ordinary Share or ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (including Ordinary Shares underlying ADSs, but excluding treasury shares, if any) issued and outstanding. (3) "Notice to Holder." (a) "Adjustment to Exercise Price." Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant ADSs and setting forth a brief statement of the facts requiring such adjustment. (b) "Notice to Allow Exercise by Holder." If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Ordinary Shares or ADSs, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares or ADSs, (C) the Company shall authorize the granting to all holders of the Ordinary Shares or ADSs rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification of the Ordinary Shares or ADSs, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Ordinary Shares are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Ordinary Shares or ADSs of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such

reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Ordinary Shares (including Warrant Shares underlying Warrant ADSs) of record shall be entitled to exchange their Ordinary Shares for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. **12**

**Section 4. Transfer of Warrant.**

a) **Transferability.** This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant ADSs without having a new Warrant issued. b) **New Warrants.** This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto. **13** c) **Warrant Register.** The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the "Warrant Register"), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. **14**

**Section 5. Miscellaneous.**

a) **Currency.** Unless otherwise indicated, all dollar amounts referred to in this Warrant are in United States Dollars ("U.S. Dollars"). All amounts owing under this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. "Exchange Rate" means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street Journal (NY edition) on the relevant date of calculation. b) **No Rights as Shareholder Until Exercise; No Settlement in Cash.** This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant ADSs on a "cashless exercise" pursuant to Section 2I or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv), in no event shall the Company be required to net cash settle an exercise of this Warrant. c) **Loss, Theft, Destruction or Mutilation of Warrant.** The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. d) **Saturdays, Sundays, Holidays, etc.** If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. **14** e) **Authorized Shares.** The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Ordinary Shares a sufficient number of shares to provide for the issuance of the Warrant Shares underlying the Warrant ADSs upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the Warrant Shares underlying the Warrant ADSs upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued, and Warrant ADSs, delivered, as provided herein without violation of any applicable law or regulation, or of any requirements of the applicable Trading Market upon which the ADSs may be listed. The Company covenants that all Warrant Shares underlying the Warrant which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant ADSs in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than any transfer restrictions and taxes in respect of any transfer occurring contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles of association or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the

Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Ordinary Shares underlying Warrant ADSs upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant ADSs for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. 15 f) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. g) Restrictions. The Holder acknowledges that the Warrant ADSs acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state, federal and foreign securities laws.

h) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder's rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys' fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. i) Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at [ ], Attention: [ ], email address: [ ], or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. 16

j) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any ADSs or Ordinary Shares or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. k) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. l)

Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant ADSs. m) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.

n) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. o) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. (Signature Page Follows) 17 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated. Quoin Pharmaceuticals Ltd. By:



a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the "Notice of Exercise"). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver to the Company the aggregate Exercise Price for the Warrant ADSs thereby purchased and specified in the applicable Notice of Exercise by wire transfer or cashier's check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable after the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant ADSs available hereunder shall have the effect of lowering the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant ADSs purchased. The Holder and the Company shall maintain records showing the number of Warrant ADSs purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant ADSs hereunder, the number of Warrant ADSs available for purchase hereunder at any given time may be less than the amount stated on the face hereof. b) For the avoidance of doubt, without limiting any rights of the Holder to receive Warrant ADSs pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, there is no circumstance that would require the Company to net cash settle the Warrants. c) The exercise price per ADS under this Warrant shall be \$12, subject to adjustment hereunder (the "Exercise Price").

cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant ADSs subject to a Notice of Exercise by the Warrant ADS Delivery Date, the Company shall pay to the Holder in cash, as liquidated damages and not as a penalty, for each \$1,000 of Warrant ADSs subject to such exercise (based on the VWAP of the ADSs on the date of the applicable Notice of Exercise), \$10 per Trading Day (increasing to \$20 per Trading Day on the third Trading Day after the Warrant ADS Delivery Date) for each Trading Day after such Warrant ADS Delivery Date until such Warrant ADSs are delivered or Holder rescinds such exercise. The Company agrees to maintain a depository (and, if applicable, a transfer agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, "Standard Settlement Period" means the standard settlement period, expressed in a number of Trading Days, on the Company's primary Trading Market with respect to the ADSs as in effect on the date of delivery of the Notice of Exercise. ¶ 5 A

ii. "Delivery of New Warrants Upon Exercise." If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant ADSs called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. ¶ iii. "Rescission Rights." If the Company fails to cause the

Depository to transmit to the Holder the Warrant ADSs pursuant to Section 2(d)(i) by the Warrant ADS Delivery Date, then the Holder will have the right to rescind such exercise in respect of the untransmitted Warrant ADSs (with the effect that the Holder's right to acquire such Warrant ADSs pursuant to this Warrant shall be restored) and the Company shall return to the Holder the aggregate Exercise Price paid to the Company for such Warrant ADSs. ¶ iv. "Compensation for Buy-In on Failure to Timely Deliver Warrant ADSs Upon Exercise." In addition to any other rights available to the Holder, if the Company fails to cause the Depository to deliver to the Holder the Warrant ADSs in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant ADS Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder's brokerage firm otherwise purchases, ADSs to deliver in satisfaction of a sale by the Holder of the Warrant ADSs which the Holder anticipated receiving upon such exercise (a "Buy-In"), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the

Holder's total purchase price (including brokerage commissions, if any) for the ADSs so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant ADSs that the Company failed to deliver to the Holder in connection with the exercise at issue by (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant in respect of the equivalent number of Warrant ADSs for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of ADSs that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases ADSs having a total purchase price of \$11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of \$10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder \$1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder's right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company's failure to timely deliver ADSs upon exercise of the Warrant as required pursuant to the terms hereof. ¶ 6 A

v. "No Fractional Warrant ADSs." No fractional Warrant ADSs shall be issued upon the exercise of this Warrant. As to any fraction of an ADS which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole ADS. ¶ vi. "Charges, Taxes and Expenses." Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant ADSs, all of which taxes and expenses shall be paid by the Company, and such Warrant ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Depository fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic issuance and delivery of the Warrant ADSs. ¶ 7 A

vii. "Closing of Books." The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof; provided, however, that the foregoing shall not be deemed or construed to limit any rights of the Depository under the terms and provisions of the deposit agreement among, inter alia, the Company and the Depository. ¶ e. "Holder's Exercise Limitations." Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the

(i) Holder's Affiliates, and (ii) any other Persons acting as a group together with the Holder or any of the Holder's Affiliates, and (iii) any other Persons whose beneficial ownership of the Ordinary Shares or ADSs would or could be aggregated with the Holder's for the purposes of Section 13(d) and Rule 13d-3 of the Exchange Act (such Persons, "Attribution Parties"), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of Ordinary Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Ordinary Shares underlying such Warrant ADSs issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Ordinary Shares underlying Warrant ADSs which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Ordinary Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or

Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder's determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary Shares as reflected in (A) the Company's most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Depositary setting forth the number of Ordinary Shares outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding Ordinary Shares was reported. The Beneficial Ownership Limitation shall be 4.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of the Ordinary Shares underlying the Warrant ADSs issuable upon exercise of this Warrant. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. So long as this Warrant is outstanding, in no event shall the Holder or the Attribution Parties hold more than 4.99% of the voting power of the Company.

8. Section 3. a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise makes a distribution or distributions on its Ordinary Shares or ADSs or any other equity or equity equivalent securities payable in Ordinary Shares or ADSs (which, for avoidance of doubt, shall not include any Ordinary Shares or ADSs issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding Ordinary Shares or ADSs into a larger number of Ordinary Shares or ADSs, as applicable, (iii) combines (including by way of reverse share split) outstanding Ordinary Shares or ADSs into a smaller number of Ordinary Shares or ADSs, as applicable, or (iv) issues by reclassification of Ordinary Shares, ADSs or any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares or ADSs, as applicable, (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Ordinary Shares or ADSs, as applicable, outstanding immediately after such event, and the number of Ordinary Shares or ADSs, as applicable, issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

9. b) [RESERVED]

c) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time that the Warrant is outstanding the Company grants, issues or sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to all of the record holders of any class of ADSs or Ordinary Shares (the Purchase Rights), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of ADSs or Ordinary Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of ADSs or Ordinary Shares are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder's right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such ADSs or Ordinary Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

d) Payments to be made to Holder in the event of a Distribution. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to all of the holders of Ordinary Shares or ADSs, by way of return of capital or otherwise (including, without limitation, any distribution of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a Distribution), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to receive a payment (Payment) equal to the amount that the Holder would have received by way of a Distribution if the Holder had held the number of ADSs acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Ordinary Shares or ADSs are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder's right to receive such a payment would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to receive said Payment (or in the beneficial ownership of any Ordinary Shares or ADSs as a result of such Distribution to such extent) and the amount of

the Payment due shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). (e) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the Company's assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares (including any Ordinary Shares underlying the ADSs) are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares or 50% or more of the voting power of the common equity of the Company (including any Ordinary Shares underlying the ADSs), (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted into or exchanged for other securities, cash or property (other than an ordinary share split), or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding Ordinary Shares (including any Ordinary Shares underlying the ADSs) or 50% or more of the voting power of the common equity of the Company (each a "Fundamental Transaction"), occurs or is consummated, then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share represented by each Warrant ADS that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of Ordinary Shares of the successor or acquiring corporation or of the Company, if the Company is the surviving corporation, and any additional consideration (the "Alternate Consideration") receivable as a result of such Fundamental Transaction by a holder of the number of Ordinary Shares (including any Ordinary Shares underlying ADSs) equal to the amount of Warrant Shares represented by the Warrant ADSs for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Ordinary Share (including any Warrant Shares underlying the ADSs) in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Ordinary Shares or ADSs are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder's option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder, as described below, an amount of consideration equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction. The consideration paid to the Holder from the Company or any Successor Entity shall be the same type or form of consideration (and in the same proportion), valued at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Ordinary Shares or ADSs of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Ordinary Shares and/or ADSs are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Ordinary Shares and/or ADSs of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Ordinary Shares and/or ADSs will be deemed to have received ordinary shares of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. "Black Scholes Value" means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the "OV" function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such contemplated Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder's election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the "Successor Entity") to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Warrant Shares underlying the Warrant ADSs acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary Shares underlying the Warrant



Register), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. <sup>14</sup>

Section 5. <sup>15</sup> **Miscellaneous.**

a) **Currency.** Unless otherwise indicated, all dollar amounts referred to in this Warrant are in United States Dollars (U.S. Dollars). All amounts owing under this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. <sup>16</sup> **Exchange Rate** means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street Journal (NY edition) on the relevant date of calculation. <sup>17</sup>

b) **No Rights as Shareholder Until Exercise; No Settlement in Cash.** This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant ADSs on a cashless exercise pursuant to Section 2I or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant. <sup>18</sup> **c)** **Loss, Theft, Destruction or Mutilation of Warrant.** The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. <sup>19</sup>

d) **Saturdays, Sundays, Holidays, etc.** If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. <sup>20</sup>

e) **Authorized Shares.** The Company covenants that, during the period the Warrant is outstanding it will reserve from its authorized and unissued Ordinary Shares a sufficient number of shares to provide for the issuance of the Warrant Shares underlying the Warrant ADSs upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the Warrant Shares underlying the Warrant ADSs upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued, and Warrant ADSs, delivered as provided herein without violation of any applicable law or regulation, or of any requirements of the applicable Trading Market upon which the ADSs may be listed. The Company covenants that all Warrant Shares underlying the Warrant ADSs which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant ADSs in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than any transfer restrictions and taxes in respect of any transfer occurring contemporaneously with such issue). <sup>21</sup> **15** **Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles of association or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.** Without limiting the generality of the foregoing, the Company will (i) **not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value,** (ii) **take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Ordinary Shares underlying Warrant ADSs upon the exercise of this Warrant and** (iii) **use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.** <sup>22</sup> **Before taking any action which would result in an adjustment in the number of Warrant ADSs for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.** <sup>23</sup> **f) Governing Law.** All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. <sup>24</sup> **16** **g) Restrictions.** The Holder acknowledges that the Warrant ADSs acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state, federal and foreign securities laws. <sup>25</sup> **h) Nonwaiver and Expenses.** No course of dealing or any

delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder's rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys' fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. (i) Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at [ ], Attention: [ ], email address: [ ], or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. (j) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any ADSs or Ordinary Shares or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. (17) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. (1) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant ADSs. (m) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand. (n) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. (o) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. (Signature Page Follows) (18) IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated. (19) Quoin Pharmaceuticals Ltd. By: (Name: (Title: (19) NOTICE OF EXERCISE (To: (1) The undersigned hereby elects to purchase \_\_\_\_\_ Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. (2) Payment shall take the form of (check applicable box): (in lawful money of the United States; or if permitted, the cancellation of such number of Warrant ADSs as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant ADSs purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). (3) Please register and issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below: (DWAC Account for Warrant ADSs not bearing a restrictive legend: (DTC Participant name and number: \_\_\_\_\_ Contact of DTC Participant: \_\_\_\_\_ Telephone Number of Participant Contact: \_\_\_\_\_ For Warrant ADSs bearing a restrictive legend: (Name: \_\_\_\_\_ Address: \_\_\_\_\_ Tax ID: \_\_\_\_\_ Telephone Number of Holder: \_\_\_\_\_ [SIGNATURE OF HOLDER] Name of Investing Entity: (Signature of Authorized Signatory of Investing Entity: (Name of Authorized Signatory: (Title of Authorized Signatory: (Date: (EXHIBIT B ASSIGNMENT FORM (To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase Warrant ADSs.) FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to (Name: (Please Print) (Address: (Phone Number: (Email Address: (Dated: (Holder's Signature: (Holder's Address: (EX-4.12 5 tm2430640d1\_ex4-12.htm EXHIBIT 4.12 (Exhibit 4.12 (SERIES G WARRANT TO PURCHASE ORDINARY SHARES (REPRESENTED BY AMERICAN DEPOSITORY SHARES (Quoin Pharmaceuticals Ltd. (Warrant ADSs: \_\_\_\_\_ Initial Exercise Date: \_\_\_\_\_, 2024 (THIS SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITORY SHARES (the "Warrant") certifies that, for value received, \_\_\_\_\_ or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the "Initial Exercise Date") and on or prior to 5:00 p.m. (New York City time) on the date that is the \_\_\_\_\_ 1, (the "Termination Date") but not thereafter, to subscribe for and purchase from QUIN PHARMACEUTICALS LTD., a corporation incorporated under the laws of Israel (the "Company"), up to \_\_\_\_\_ Ordinary Shares, no par value per share (the "Warrant Shares"), represented by \_\_\_\_\_ ADSs (the ADSs issuable upon exercise of the Warrant, the "Warrant ADSs"), as subject to adjustment hereunder. The purchase





was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant in respect of the equivalent number of Warrant ADSs for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of ADSs that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases ADSs having a total purchase price of \$11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of \$10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder \$1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder's right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company's failure to timely deliver ADSs upon exercise of the Warrant as required pursuant to the terms hereof. **No Fractional Warrant ADSs.** No fractional Warrant ADSs shall be issued upon the exercise of this Warrant. As to any fraction of an ADS which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole ADS **Charges, Taxes and Expenses.** Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant ADSs, all of which taxes and expenses shall be paid by the Company, and such Warrant ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Depository fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic issuance and delivery of the Warrant ADSs. **Closing of Books.** The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof; provided, however, that the foregoing shall not be deemed or construed to limit any rights of the Depository under the terms and provisions of the deposit agreement among, *inter alia*, the Company and the Depository.

**Holder's Exercise Limitations.** Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the (i) Holder's Affiliates, and (ii) any other Persons acting as a group together with the Holder or any of the Holder's Affiliates, and (iii) any other Persons whose beneficial ownership of the Ordinary Shares or ADSs would or could be aggregated with the Holder's for the purposes of Section 13(d) and Rule 13d-3 of the Exchange Act (such Persons, *â€œAttribution Partiesâ€*)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of Ordinary Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Ordinary Shares underlying such Warrant ADSs issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Ordinary Shares underlying Warrant ADSs which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Ordinary Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder's determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary Shares as reflected in (A) the Company's most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Depository setting forth the number of Ordinary Shares outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding Ordinary Shares was reported. The *â€œBeneficial Ownership Limitationâ€* shall be 4.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of the Ordinary Shares underlying the Warrant ADSs issuable upon exercise of this Warrant. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. So long as this Warrant is outstanding, in no event shall the Holder or the Attribution Parties hold more than 4.99% of the voting power of the Company. **Certain**

Adjustments. A) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise makes a distribution or distributions on its Ordinary Shares or ADSs or any other equity or equity equivalent securities payable in Ordinary Shares or ADSs (which, for avoidance of doubt, shall not include any Ordinary Shares or ADSs issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding Ordinary Shares or ADSs into a larger number of Ordinary Shares or ADSs, as applicable, (iii) combines (including by way of reverse share split) outstanding Ordinary Shares or ADSs into a smaller number of Ordinary Shares or ADSs, as applicable, or (iv) issues by reclassification of Ordinary Shares, ADSs or any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares or ADSs, as applicable, (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Ordinary Shares or ADSs, as applicable, outstanding immediately after such event, and the number of Ordinary Shares or ADSs, as applicable, issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. B) [RESERVED]

c) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time that the Warrant is outstanding the Company grants, issues or sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to all of the record holders of any class of ADSs or Ordinary Shares (the "Purchase Rights"), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of ADSs or Ordinary Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of ADSs or Ordinary Shares are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder's right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such ADSs or Ordinary Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). A

d) Payments to be made to Holder in the event of a Distribution. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to all of the holders of Ordinary Shares or ADSs, by way of return of capital or otherwise (including, without limitation, any distribution of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "Distribution"), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to receive a payment ("Payment") equal to the amount that the Holder would have received by way of a Distribution if the Holder had held the number of ADSs acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Ordinary Shares or ADSs are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder's right to receive such a payment would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to receive said Payment (or in the beneficial ownership of any Ordinary Shares or ADSs as a result of such Distribution to such extent) and the amount of the Payment due shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). A 9 A

e) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the Company's assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares (including any Ordinary Shares underlying the ADSs) are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares or 50% or more of the voting power of the common equity of the Company (including any Ordinary Shares underlying the ADSs), (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted into or exchanged for other securities, cash or property (other than an ordinary share split), or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding Ordinary Shares (including any Ordinary Shares underlying the ADSs) or 50% or more of the voting power of the common equity of the Company (each a "Fundamental Transaction"), occurs or is consummated, then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share represented by each Warrant ADS that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of Ordinary Shares of the successor or acquiring corporation or of the Company, if the Company is the surviving corporation, and any additional consideration (the "Alternate Consideration") receivable as a result of such Fundamental Transaction by a holder of the number of Ordinary Shares (including any Ordinary Shares underlying ADSs) equal to the amount of Warrant Shares represented by the Warrant ADSs for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one



Shares or ADSs, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Ordinary Shares are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Ordinary Shares or ADSs of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Ordinary Shares (including Warrant Shares underlying Warrant ADSs) of record shall be entitled to exchange their Ordinary Shares for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. A 11 A

i) Voluntary Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company. A Section 4. a) Transfer of Warrant. A

a) Transferability. This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant ADSs without having a new Warrant issued. A b) New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto. A c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the "Warrant Register"), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. A 12 A

Section 5. a) Miscellaneous. A

a) Currency. Unless otherwise indicated, all dollar amounts referred to in this Warrant are in United States Dollars ("U.S. Dollars"). All amounts owing under this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. "Exchange Rate" means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street Journal (NY edition) on the relevant date of calculation. A b) No Rights as Shareholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant ADSs on a "cashless exercise" pursuant to Section 2I or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant. A c) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. A d) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. A e) Authorized Shares. A The Company covenants that, during the period the Warrant is outstanding it will reserve from its authorized and unissued Ordinary Shares a sufficient number of shares to provide for the issuance of the Warrant Shares underlying the Warrant ADSs upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the Warrant Shares underlying the Warrant ADSs upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued, and Warrant ADSs, delivered as provided herein without violation of

h) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder's rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys' fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

i) Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at [REDACTED], Attention: [REDACTED], email address: [REDACTED], or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.

j) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any ADSs or Ordinary Shares or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

k) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

l) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions

Telephone Number of Participant Contact:

For Warrant ADSs bearing a restrictive legend: Name: \_\_\_\_\_

Address: \_\_\_\_\_ Tax ID: \_\_\_\_\_ Telephone Number of Holder: \_\_\_\_\_ [SIGNATURE OF HOLDER] Name of Investing Entity: \_\_\_\_\_ Signature of Authorized Signatory of Investing Entity: \_\_\_\_\_ Name of Authorized Signatory: \_\_\_\_\_ Title of Authorized Signatory: \_\_\_\_\_ Date: \_\_\_\_\_ EXHIBIT B ASSIGNMENT FORM (To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase Warrant ADSs.) FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to \_\_\_\_\_ Name: \_\_\_\_\_ (Please Print) \_\_\_\_\_ Address: \_\_\_\_\_ (Please Print) \_\_\_\_\_ Phone Number: \_\_\_\_\_ Email Address: \_\_\_\_\_ Dated: \_\_\_\_\_ Holder's Signature: \_\_\_\_\_ Holder's Address: \_\_\_\_\_ EX-5.1 6 tm2430640d1\_ex5-1.htm EXHIBIT 5.1 Exhibit 5.1 December 11, 2024 Quoin Pharmaceuticals Ltd. Re: Registration Statement on Form S-1 Ladies and Gentlemen: We have acted as Israeli counsel to Quoin Pharmaceuticals Ltd., a company organized under the laws of the State of Israel (the "Company"), in connection with the registration statement on Form S-1 (the "Registration Statement") filed by the Company with the Securities and Exchange Commission (the "Commission") on the date hereof under the Securities Act of 1933, as amended (the "Securities Act"), with respect to the issuance and sale the following securities (the "Offering"): ordinary shares, no par value, of the Company ("Ordinary Shares") represented by American Depository Shares ("ADSs") and/or pre-funded warrants to purchase Ordinary Shares represented by ADSs (the "Series F Warrants") and series G warrants to purchase Ordinary Shares represented by ADSs (the "Series G Warrants") and together with the Pre-Funded Warrants and Series F Warrants, the "Warrants"), pursuant to a certain securities purchase agreement by and between the Company and each of the purchasers thereof (the "Purchase Agreement"). The proposed maximum aggregate offering price of the securities to be sold in the offering is \$45,000,000. This opinion letter is rendered pursuant to Items 601(b)(5) and (b)(23) of Regulation S-K promulgated under the Securities Act. In connection herewith, we have examined the originals, or photocopies or copies, certified or otherwise identified to our satisfaction, of: (i) the Registration Statement; (ii) the Prospectus; (iii) the Purchase Agreement; (iv) the articles of association of the Company, as currently in effect; (v) resolutions of the board of directors (the "Board") of the Company which have heretofore been approved and relate to the Registration Statement, the Prospectus and other actions to be taken in connection with the Offering; and (vi) such other corporate records, agreements, documents and other instruments, and such certificates or comparable documents of public officials and of officers of the Company as we have deemed relevant and necessary as a basis for the opinions hereafter set forth. In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, confirmed as photostatic copies and the authenticity of the originals of such latter documents. As to all questions of fact material to these opinions that have not been independently established, we have relied upon certificates or comparable documents of officers and representatives of the Company. We are admitted to practice law in the State of Israel and the opinion expressed herein is expressly limited to the laws of the State of Israel. Based upon and subject to the foregoing, we are of the opinion that (i) upon payment to the Company of the consideration per ADS in such amount and form as has been determined by the Board (or its committee), the Ordinary Shares underlying the ADSs, when issued and sold in the Offering as described in the Registration Statement and Prospectus, will be duly authorized, validly issued, fully paid and non-assessable, (ii) the Ordinary Shares underlying the Series F Warrants have been duly authorized, and when any Series F Warrant is exercised pursuant to the terms thereof, the Ordinary Shares underlying the ADSs issuable at that time by the Company will be validly issued, fully paid and non-assessable, and (iii) the Ordinary Shares underlying the Series G Warrants have been duly authorized, and when any Series G Warrant is exercised pursuant to the terms thereof, the Ordinary Shares underlying the ADSs issuable at that time by the Company will be validly issued, fully paid and non-assessable. We consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm appearing under the caption "Legal Matters" in the prospectus forming part of the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, the rules and regulations of the Commission promulgated thereunder or Item 509 of the SEC's Regulation S-K under the Securities Act. This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments that may be brought to our attention after the date of the Prospectus that may alter, affect or modify the opinions expressed herein. Very truly yours, /s/ Meitar | Law Offices Meitar | Law Offices EX-5.2 7 tm2430640d1\_ex5-2.htm EXHIBIT 5.2 Exhibit 5.2 1271 Avenue of the Americas | New York, NY 10020



â€œBusiness Dayâ€ means any day other than Saturday, Sunday, or other day on which banking institutions in the State of New York are authorized or required by law to remain closed. â€œClosingâ€ means the closing of the purchase and sale of the Securities pursuant to Section 2.1. â€œClosing Dateâ€ means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasersâ€™ obligations to pay the Subscription Amount at the Closing and (ii) the Companyâ€™s obligations to deliver the Securities, in each case, at the Closing have been satisfied or waived, but in no event later than the first (1st) Trading Day following the date hereof (or the second (2nd) Trading Day following the date hereof if this Agreement is signed on a day that is not a Trading Day or after 4:00 p.m. (New York City time) and before midnight (New York City time) on a Trading Day). â€œCommissionâ€ means the United States Securities and Exchange Commission. â€œCompanies Lawâ€ means the Israeli Companies Law, 5759-1999, as amended, and the rules and regulations promulgated thereunder. â€œCompany Israeli Counselâ€ means Meitar | Law Offices with offices located at 16 Abba Hillel Rd. Ramat Gan 5250608, Israel. â€œCompany U.S. Counselâ€ means Blank Rome LLP with offices located at One Logan Square, 130 North 18th Street, Philadelphia, PA 19103. â€œDeposit Agreementâ€ means the Deposit Agreement dated as of July 28, 2016 among the Company, the Depository and the owners and holders of ADSs from time to time, as such agreement may be amended or supplemented. â€œDepositoryâ€ means The Bank of New York Mellon, as depositary under the Deposit Agreement. â€œDisclosure Schedulesâ€ means the Disclosure Schedules of the Company delivered concurrently herewith. â€œDisclosure Timeâ€ means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent. â€œDWACâ€ shall have the meaning ascribed to such term in Section 2.2(v). â€œEGSâ€ means Ellenoff Grossman & Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302. â€œEvaluation Dateâ€ shall have the meaning ascribed to such term in Section 3.1(r). â€œExchange Actâ€ means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. â€œExempt Issuanceâ€ means the issuance of (a) ADSs, Ordinary Shares, restricted share units or options to employees, consultants, officers, or directors of the Company pursuant to any share or option plan in existence as of the date hereof, (b) ADSs or Ordinary Shares upon the exercise or exchange of or conversion of securities exercisable or exchangeable for or convertible into ADSs or Ordinary Shares issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price (other than the reduction in the exercise price of [ ] outstanding warrants to \$[ ] per warrant ADS) exchange price or conversion price of such securities or to extend the term of such securities (other than in connection with ordinary share splits or combinations), (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as â€œrestricted securitiesâ€ (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.10(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities (for avoidance of doubt, securities issued to a venture arm of a strategic investor shall be deemed an â€œExempt Issuanceâ€), (d) issuances of ADSs or Ordinary Shares to consultants or vendors of the Company, provided that such securities are issued as â€œrestricted securitiesâ€ (as defined in Rule 144) and carry no registration rights, and (e) Securities to other purchasers in the Offering. â€œFCPAâ€ means the Foreign Corrupt Practices Act of 1977, as amended. â€œGAAPâ€ means generally accepted accounting principles in the United States. â€œIndebtednessâ€ shall have the meaning ascribed to such term in Section 3.1(z). â€œIntellectual Property Rightsâ€ shall have the meaning ascribed to such term in Section 3.1(o). â€œLiensâ€ means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. â€œLock-Up Agreementâ€ means the Lock-Up Agreement, dated as of the date hereof, by and among the Placement Agent and the directors and officers of the Company, in the form of Exhibit C attached hereto. â€œMaterial Adverse Effectâ€ shall have the meaning assigned to such term in Section 3.1(b). â€œMaterial Permitsâ€ shall have the meaning ascribed to such term in Section 3.1(m). â€œOrdinary Share(s)â€ means the ordinary shares of the Company, no par value per share, and any other class of securities into which such securities may hereafter be reclassified or changed. â€œOrdinary Share Equivalentsâ€ means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Ordinary Shares or ADSs, including, without limitation, any debt, preferred share, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Ordinary Shares or ADSs. â€œPer ADS Purchase Priceâ€ equals \$[ ], subject to adjustment for reverse and forward share splits, share dividends, share combinations and other similar transactions of ADSs and/or the Ordinary Shares that occur between the date hereof and the Closing Date. â€œPer Pre-Funded Warrant Purchase Priceâ€ equals the Per ADS Purchase Price minus \$0.0001, subject to adjustment for reverse and forward share splits, share dividends, share combinations and other similar transactions of ADSs and/or the Ordinary Shares that occur after the date of this Agreement. â€œPersonâ€ means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. â€œPlacement Agentâ€ means Maxim Group LLC. â€œPre-Funded Warrant ADSsâ€ means the ADSs issuable upon exercise of the Pre-Funded Warrants. â€œPre-Funded Warrantsâ€ means, collectively, the warrants delivered to the Purchasers at Closing in accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately upon issuance and shall expire in accordance with the terms thereof, in the form of Exhibit B attached hereto. â€œPreliminary Prospectusâ€ means any preliminary prospectus included in the Registration Statement, as originally filed or as part of any amendment thereto, or filed with the Commission pursuant to Rule 424(a) of the rules and regulations of the Commission under the Securities Act. â€œProceedingâ€ means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened. â€œProspectusâ€ means the final prospectus filed pursuant to the Registration Statement. â€œPurchaser Partyâ€

shall have the meaning ascribed to such term in Section 4.8. "Qualified Investor" means any person that falls within the scope of one of the criteria of being a qualified investor pursuant to the First Addendum of the Securities Law. "Registration Statement" means the effective registration statement with the Commission on Form S-1 (File No. 333-[ ]) as amended, which registers the sale of the Securities and includes any Rule 462(b) Registration Statement. "Required Approvals" shall have the meaning ascribed to such term in Section 3.1(e). "Rule 144" means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. "Rule 424" means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. "Rule 462(b) Registration Statement" means any registration statement prepared by the Company registering additional Securities, which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated by the Commission pursuant to the Securities Act. "SEC Reports" shall have the meaning ascribed to such term in Section 3.1(h). "Securities" means the Shares, the Warrants, the Warrant ADSs, and the ADSs. "Securities Act" means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. "Securities Law" means the Israeli Securities Law, 5728-1968, as amended, and the rules and regulations promulgated thereunder. "Series F Warrants" means, collectively, the warrants delivered to the Purchasers at Closing in accordance with Section 2.2(a) hereof, which Series F Warrants shall be exercisable for ADSs immediately upon issuance of such Series F Warrants and may be exercised during a period of two (2) years commencing from their issuance, in the form of Exhibit A-1 attached hereto. "Series G Warrants" means, collectively, the warrants delivered to the Purchasers at Closing in accordance with Section 2.2(a) hereof, which Series G Warrants shall be exercisable for ADSs immediately upon issuance of such Series G Warrants and may be exercised during a period of five (5) years commencing from their issuance, in the form of Exhibit A-2 attached hereto. "Shares" means the Ordinary Shares, as represented by ADSs issued pursuant to the Deposit Agreement, each ADS representing one Ordinary Share issued and issuable to each Purchaser pursuant to this Agreement. "Short Sales" means all short sales as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing Ordinary Shares and/or ADSs). "Subscription Amount" means, as to each Purchaser, the aggregate amount to be paid for ADSs, each ADS representing one Ordinary Share, and Pre-Funded Warrants, purchased hereunder as specified below such Purchaser's name on the signature page of this Agreement and next to the heading "Subscription Amount" in United States dollars and in immediately available funds. "Subsidiary" means any subsidiary of the Company as set forth in the SEC Reports and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. "Trading Day" means a day on which the principal Trading Market is open for trading. "Trading Market" means any of the following markets or exchanges on which ADSs and/or the Ordinary Shares are listed or quoted for trading on the date in question: the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Market, The Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing). "Transaction Documents" means this Agreement, the Warrants, and the Lock-Up Agreements, and all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder. "Variable Rate Transaction" shall have the meaning ascribed to such term in Section 4.10(b). "Warrants" means, collectively, the Series F Warrants, the Series G Warrants, and the Pre-Funded Warrants. "Warrant ADSs" means the ADSs issuable upon exercise of the Warrants. **ARTICLE II. PURCHASE AND SALE** **2.1** **Each Purchaser's** **Subscription Amount** as set forth on the signature page hereto executed by such Purchaser shall be made available for **Delivery Versus Payment** ("DVP") settlement with the Company or its designees. The Company shall deliver to each Purchaser its respective Shares and Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur remotely via the exchange of documents and signatures or such other location as the parties shall mutually agree. Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via DVP (i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers' names and addresses and released by the Depositary directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). Unless otherwise directed by the Placement Agent, the Warrants shall be issued to each Purchaser in originally signed form. Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser through, and including the time immediately prior to, the Closing (the "Pre-Settlement Period"), such Purchaser sells to any Person all, or any portion, of any Shares to be issued hereunder to such Purchaser at the Closing (collectively, the "Pre-Settlement Shares"), such Person shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be a Purchaser under this Agreement unconditionally bound to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement Shares to such Person at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the

Company's receipt of the Subscription Amount for such Pre-Settlement Shares hereunder; provided, further, that the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not such Purchaser will elect to sell any Pre-Settlement Shares during the Pre-Settlement Period. The decision to sell any Shares will be made in the sole discretion of such Purchaser from time to time, including during the Pre-Settlement Period. (2.2) On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following: (i) this Agreement duly executed by the Company; (ii) the Company's wire instructions, on Company letterhead and executed by the Company's Chief Executive Officer or Chief Financial Officer; (iii) subject to the last sentence in Section 2.1, a copy of the irrevocable instructions to the Depository instructing the Depository to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (DWAC) ADSs equal to the portion of such Purchaser's Subscription Amount applicable to ADSs divided by the Per ADS Purchase Price, registered in the name of such Purchaser; (iv) for each Purchaser of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of Ordinary Shares represented by ADSs equal to the portion of such Purchaser's Subscription Amount applicable to Pre-Funded Warrants divided by the sum of the Per Pre-Funded Warrant Purchase Price and an exercise price equal to \$0.0001, subject to adjustment therein; (v) the Preliminary Prospectus and the Prospectus (which may be delivered in accordance with Rule 172 under the Securities Act); (vi) a Series F Warrant registered in the name of such Purchaser to purchase up to a number of Ordinary Shares represented by ADSs equal to 100% of such Purchaser's Ordinary Shares represented by ADSs or Pre-Funded Warrants, as applicable, with an exercise price per ADS equal to \$\_\_\_\_, subject to adjustment therein; (vii) a Series G Warrant registered in the name of such Purchaser to purchase up to a number of Ordinary Shares represented by ADSs equal to 100% of such Purchaser's Ordinary Shares represented by ADSs or Pre-Funded Warrants, as applicable, with an exercise price per ADS equal to \$\_\_\_\_, subject to adjustment therein; (viii) the duly executed Lock-Up Agreements; (ix) a legal opinion of Company U.S. Counsel, in form reasonably acceptable to the Placement Agent; (x) a legal opinion of Company Israeli Counsel, in form reasonably acceptable to the Placement Agent; (xi) an Officer's Certificate, in form and substance reasonably satisfactory to the Placement Agent; and (xii) a Secretary's Certificate, in form and substance reasonably satisfactory to the Placement Agent.

(b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following: (i) this Agreement duly executed by such Purchaser; and (ii) such Purchaser's Subscription Amount with respect to the Securities purchased by such Purchaser, which shall be made available for DVP settlement with the Company or its designees.

(3.3) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met: (i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless such representation or warranty as of a specific date therein in which case they shall be accurate as of such date); (ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; (iii) with respect to a Purchaser in the State of Israel, written confirmation that as of the date of any offer of securities, and as of the Closing Date, such Purchase is a Qualified Investor, that such Purchaser is fully aware of the significance of being a Qualified Investor pursuant to such criteria and that it has given its consent, in form and substance reasonably satisfactory in all respects to the Company; and (iv) the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.

(3.4) The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met: (i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless such representation or warranty is as of a specific date therein in which case they shall be accurate as of such date); (ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed; (iii) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; (iv) there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and (v) from the date hereof to the Closing Date, trading in the ADSs and Company's securities shall not have been suspended by the Commission or the Company's principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred after the date of this Agreement any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.

(ARTICLE III. REPRESENTATIONS AND WARRANTIES)

3.1 Representations and Warranties of the Company. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation made herein, or as disclosed in the Registration Statement or the Preliminary Prospectus, the Company hereby makes the following representations and warranties to each Purchaser:

(a) Subsidiaries. All of the direct and indirect subsidiaries of the Company are as set forth in the SEC Reports. The Company owns, directly or indirectly, all of the capital shares or other equity interests of each Subsidiary, free and clear of any Liens, except as set forth in the SEC Reports, and all of the issued and outstanding shares of capital shares of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. There are no outstanding options, warrants, scrips or rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any capital shares or equity interests, as applicable, of any Subsidiary, or contracts, commitments, understandings or arrangements by which any Subsidiary is or may become bound to issue capital shares or equity interests, as applicable. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.

(b) Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly

existing, and, if applicable under the laws of the jurisdiction in which they are formed, in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. No proceedings have been instituted in the State of Israel for the dissolution of the Company or any of its Israeli Subsidiaries. The Company is not currently designated as a "breaching company" (within the meaning of the Companies Law) by the Registrar of Companies of the State of Israel, nor has a proceeding been instituted by the Registrar of Companies in Israel for the dissolution of the Company or Subsidiaries. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective memorandum of association, articles of association, certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company's ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a "Material Adverse Effect") and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. Â

(c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors, a committee of the Board of Directors or the Company's shareholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable

generally, (ii), relating to the availability of specific performance, injunctive relief, other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. (d) No Conflicts. Except as set forth in Schedule 3.1(d), the execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company's or any Subsidiary's memorandum of association, articles of association, certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect. 9

(e) Filings, Consents and Approvals. Neither the Company nor any Subsidiary is required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state (including state blue sky laws), local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus, (iii) notices and/or application(s) to and approvals by each applicable Trading Market for the listing of the applicable Securities for trading thereon in the time and manner required thereby, (iv) filings required by the Israeli Registrar of Companies, (v) filings required by the Financial Industry Regulatory Authority, and (vi) such other filings required to be made under applicable state securities laws, the Israeli Securities Authority, the Securities Law and the Companies Law (collectively, the "Required Approvals").

(f) Issuance of the Securities; Registration. The Shares and Warrant Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company. The Warrants are duly authorized and, when issued in accordance with this Agreement, will be binding obligations of the Company under the law of the jurisdiction governing the Warrants, duly and validly issued, and free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized share capital the maximum number of Ordinary Shares issuable pursuant to this Agreement and the Warrants. The Securities are not and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company, except as have been waived. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on [ ], 2024, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Company and the Depositary have prepared and filed with the Commission a registration statement relating to ADSs on Form F-6 (File No. 333-212698) for registration under the Securities Act (the "ADS Registration Statement"). The Registration Statement and ADS Registration Statement are effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Preliminary Prospectus or the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the

rules and regulations of the Commission, shall file the Preliminary Prospectus or the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement, ADS Registration Statement and any amendments thereto became effective as determined under the Securities Act, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Preliminary Prospectus, the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. A Any "issuer free writing prospectus" (as defined in Rule 433 under the Securities Act) relating to the Securities is hereafter referred to as an "Issuer Free Writing Prospectus". Any reference herein to the Preliminary Prospectus and the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein as of the date of filing thereof; and any reference herein to any "amendment" or "supplement" with respect to any of the Preliminary Prospectus and the Prospectus shall be deemed to refer to and include (i) the filing of any document with the Commission incorporated or deemed to be incorporated therein by reference after the date of filing of such Preliminary Prospectus or Prospectus and (ii) any such document so filed. All references in this Agreement to the Registration Statement, the Preliminary Prospectus, the Prospectus, or any Issuer Free Writing Prospectus, or any amendments or supplements to any of the foregoing, shall be deemed to include any copy thereof filed with the Commission on EDGAR. A 10 A (g) A A Capitalization. The capitalization of the Company as of the date hereof is as set forth on Schedule 3.1(g). The Company has not issued any shares since its most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as set forth on Schedule 3.1(g) and as a result of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any ADSs, Ordinary Shares, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional ADSs, Ordinary Shares or Ordinary Share Equivalents. The issuance and sale of the Securities will not obligate the Company to issue ADSs or Ordinary Shares or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. Except as set forth on Schedule 3.1(g), there are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company (other than in connection with a stock split, recapitalization, or similar transaction). Except as set forth on Schedule 3.1(g), there are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any share appreciation rights or "phantom share" plans or agreements or any similar plan or agreement. All of the outstanding shares of the Company are duly authorized, validly issued, fully paid and non-assessable, have been issued in compliance with all federal and state securities laws where applicable, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Except for the Required Approvals, no further approval or authorization of any shareholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no shareholders agreements, voting agreements or other similar agreements with respect to the Company's share capital to which the Company is a party or, to the knowledge of the Company, between or among any of the Company's shareholders. A (h) A A SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the 1 year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such materials) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Preliminary Prospectus and the Prospectus, being collectively referred to herein as the "SEC Reports") on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with GAAP, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. A 11 A (i) A A A A A Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC Reports, except as disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) neither the Company nor any Subsidiary has incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and strategic acquisitions and (B) liabilities not required to be reflected in the Company's financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its shareholders or purchased, redeemed or made any agreements to purchase or redeem any of its shares and (v) neither the Company nor any Subsidiary has issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company share option plans. The

Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on Schedule 3.1(i), no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made. (j) Labor Relations. Except as set forth on Schedule 3.1(j), there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company or any Subsidiary, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an "Action") which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents, the Shares or the Warrant Shares (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Except as set forth on Schedule 3.1(j), neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty, which could result in a Material Adverse Effect. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Israel Securities Authority or the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act. (k) Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company's or its Subsidiaries' employees is a member of a union that relates to such employee's relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign (including Israeli) laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. (l) Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case of (i), (ii) and (iii) as could not have or reasonably be expected to result in a Material Adverse Effect. (m) Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such certificates, authorizations or permits could not reasonably be expected to result in a Material Adverse Effect ("Material Permits"), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit. (n) Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of Israeli, federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance in all material respects. (o) Intellectual Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the "Intellectual Property Rights"). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Intellectual Property Rights used by the Company or any of its Subsidiaries in their respective businesses has been obtained or is

being used by the Company or such Subsidiary in violation of any contractual obligation binding on the Company or any of its subsidiaries in violation of the rights of any person. The Company and its subsidiaries have taken all reasonable steps in accordance with normal industry practice to protect and maintain the Intellectual Property Rights including, without limitation, the execution of appropriate nondisclosure and invention assignment agreements. The consummation of the transactions contemplated by this Agreement will not result in the loss or impairment of, or payment of, and additional amounts with respect to, nor require the consent of, any other person regarding the Company's or any of its subsidiaries' right to own or use any of the Intellectual Property Rights as owned or used in the conduct of such party's business as currently conducted. To the knowledge of the Company and its Subsidiaries, no employee of any of the Company or its subsidiaries is the subject of any pending claim or proceeding involving a violation of any term of any employment contract, invention disclosure agreement, patent disclosure agreement, noncompetition agreement, non-solicitation agreement, nondisclosure agreement or restrictive covenant to or with a former employer, where the basis of such violation relates to such employee's employment with the Company or its subsidiaries or actions undertaken by the employee while employed with the Company or its Subsidiaries. The Company has no knowledge of any facts that would preclude it from having valid license rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business. **13** **(p)** **Insurance.** The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost. **(q)** **Transactions with Affiliates and Employees.** Except as set forth on Schedule 3.1(q), none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, shareholder, member or partner, in each case in excess of \$120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company or a Subsidiary and (iii) other employee benefits, including share option agreements under any share option plan of the Company. **(r)** **Sarbanes-Oxley; Internal Accounting Controls.** The Company and the Subsidiaries are in material compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management's general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management's general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. The Company's certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the "Evaluation Date"). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries. **14** **(s)** **Certain Fees.** Except for fees payable to the Placement Agent, no brokerage or finder's fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents (for the avoidance of doubt, the foregoing shall not include any fees and/or commissions owed to the Depositary). Other than for Persons engaged by any Purchaser, if any, the Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents. **(t)** **Investment Company.** The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an investment company within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an investment company subject to registration under the Investment Company Act of 1940, as amended. **(u)** **Registration Rights.** No Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company or any Subsidiary. **(v)** **Listing and Maintenance Requirements.** The ADSs are registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the ADSs under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth in the SEC Reports, the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the ADSs are or have been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance

requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The ADSs are currently eligible for electronic transfer through The Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to The Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer. (w) Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company's memorandum of association, articles of association or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company's issuance of the Securities and the Purchasers' ownership of the Securities. (x) Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Preliminary Prospectus or the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve (12) months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof. (y) No Integrated Offering. Assuming the accuracy of the Purchasers' representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated. (z) Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company's assets exceeds the amount that will be required to be paid on or in respect of the Company's existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company's assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. Schedule 3.1(z) sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, "Indebtedness" means (x) any liabilities for borrowed money or amounts owed by the Company in excess of \$50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others to third parties, whether or not the same are or should be reflected in the Company's consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of \$50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.

(aa) Tax Compliance. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all Israeli and United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges, fines or penalties that are material in amount, shown or determined to be due on such returns, reports and declarations, other than those listed on Schedule 3.1(aa) hereto which are being contested in good faith and for which adequate reserves have been provided and (iii) has set aside on its financial statements provision reasonably adequate for the payment of all material tax liability of which has not been finally determined and all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim. (bb) Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA. (cc) Accountants. The Company's independent registered public accounting firm is as

set forth in the Prospectus. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company's Annual Report for the fiscal year ending December 31, 2024. (dd) Acknowledgment Regarding Purchasers' Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm's length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers' purchase of the Securities. The Company further represents to each Purchaser that the Company's decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. (ee) Acknowledgment Regarding Purchaser's Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.12 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or derivatives based on securities issued by the Company or to hold the Shares for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or derivatives transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company's publicly-traded securities; (iii) any Purchaser, and counter-parties in derivatives transactions to which any such Purchaser is a party, directly or indirectly, presently may have a short position in the Ordinary Shares and/or ADSs, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm's length counter-party in any derivatives transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the ADSs and Shares are outstanding, and (z) such hedging activities (if any) could reduce the value of the existing shareholders' equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents. (ff) Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the ADSs or Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the ADSs or Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company's placement agent in connection with the placement of the ADSs and Shares. (gg) FDA. The Company does not have any pharmaceutical products approved for marketing by the U.S. Food and Drug Administration (the FDA) under the Federal Food, Drug, and Cosmetic Act, as amended, and the regulations thereunder (the FDCA). The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with the FDCA. The Company has not been informed by the FDA that the FDA will not approve an application for any product proposed to be marketed by the Company in the United States. (hh) Stock Option Plans. Each stock option granted by the Company under the Company's stock option plan was granted (i) in accordance with the terms of the Company's stock option plan and (ii) with an exercise price at least equal to the fair market value of the Ordinary Share on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company's stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or the Subsidiaries or their financial results or prospects. (ii) Cybersecurity. Except as would not, individually or in the aggregate, have a Material Adverse Effect, (i) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of the Company's or any Subsidiary's information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, IT Systems and Data) and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification; (ii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iii) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with commercially reasonable industry standards and practices. (jj) Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (the OFAC). (kk) U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser's request. (ll) Bank Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the BHCA) and to regulation by the Board of Governors of the Federal Reserve System (the Federal Reserve). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. (mm) Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting





Affiliates has acted as a financial advisor or fiduciary to such Purchaser. Â  
(f) Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the definitive pricing and other material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser's assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser's assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser's representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future. Â

(g) No Voting Agreements. The Purchaser is not a party to any agreement or arrangement, whether written or oral, between the Purchaser and any other Purchaser and any of the Company's shareholders as of the date hereof or a corporation in which the Company's shareholders are an Interested Party (as defined in the Companies Law) as of the date hereof, regulating the management of the Company, the shareholders' rights in the Company, the transfer of shares in the Company, including any voting agreements, shareholder agreements or any other similar agreement even if its title is different or has any other relations or agreements with any of the Company's shareholders, directors or officers. (h) No Governmental Review. Such Purchaser understands that no Israeli or United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities. (i) Brokers. Except as set forth on Schedule 3.2(i) or in the Prospectus, no agent, broker, investment banker, person or firm acting in a similar capacity on behalf of or under the authority of the Purchaser is or will be entitled to any broker's or finder's fee or any other commission or similar fee, directly or indirectly, for which the Company or any of its Affiliates after the Closing could have any liabilities in connection with this Agreement, any of the transactions contemplated by this Agreement, or on account of any action taken by the Purchaser in connection with the transactions contemplated by this Agreement. (j) Independent Advice. Each Purchaser understands that nothing in this Agreement or any other materials presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal, tax or investment advice. 22

4.2. Furnishing of Information; Public Information. Until the earliest of the time that (i) no Purchaser owns Securities, or (ii) the Series F Warrants and the Series G Warrants have expired, the Company covenants to maintain the registration of the ADSs under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act, even if the Company is not then subject to the reporting requirements of the Exchange Act, except in the event that the Company consummates: (i) any transaction or series of related transactions as a result of which any Person (together with its Affiliates) acquires then outstanding securities of the Company representing more than fifty percent (50%) of the voting control of the Company; (ii) a merger or reorganization of the Company with one or more other entities in which the Company is not the surviving entity; or (iii) a sale of all or substantially all of the assets of the Company, where the consummation of such transaction results in the Company no longer being subject to the reporting requirements of the Exchange Act, provided, however, only in connection with subsections (i) and (iii) of this Section 4.2, that such limitation shall not apply on or after the date as of which the Purchasers may sell all of their Securities without restriction or limitation pursuant to Rule 144. A 4.3. Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. A 23 A

4.4. Securities Laws Disclosure; Publicity. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission, and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b). Â

4.5. Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an "Acquiring Person" under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers. Â

4.6. Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or that the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have entered into a written agreement with the Company regarding the confidentiality and use of such information including to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company delivers any material, non-public information to a Purchaser without such Purchaser's consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, and of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. Â

4.7. Use of Proceeds. The Company shall use the net proceeds as disclosed in the Preliminary Prospectus and the Prospectus. Â 24 Â 4.8. Indemnification of Purchasers. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a "Purchaser Party") harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys' fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against a Purchaser Party in any capacity, or any of them or their respective Affiliates, by any shareholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a material breach of such Purchaser Party's representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such shareholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). The Company shall indemnify each Purchaser Party, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys' fees) and expenses, as incurred, caused by or based upon (i) any untrue or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereto, any Issuer Free Writing Prospectus, the Prospectus or any amendment or supplement thereto, or caused by or based upon any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding such Purchaser Party furnished in writing to the Company by such Purchaser Party expressly for use therein, or (ii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder in connection therewith. If any action shall be brought against any Purchaser Party in respect of which

indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company's prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party's breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.

4.9. Listing of ADSs. The Company hereby agrees to use commercially reasonable best efforts to maintain the listing or quotation of the ADSs on the Trading Market on it is currently listed. The Company further agrees, if the Company applies to have the ADSs traded on any other Trading Market, it will then include in such application all of the ADSs and Warrant ADSs, and will take such other action as is necessary to cause all of the ADSs and Warrant ADSs to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its ADSs on a Trading Market and will comply in all material respects with the Company's reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to use commercially reasonable efforts to maintain the eligibility of the ADSs for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.

4.10. Subsequent Equity Sales. (a) From the date hereof until 90 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, Ordinary Shares or Ordinary Share Equivalents or (ii) file or cause to be filed any registration statement or amendment or supplement thereto, other than the Preliminary Prospectus or the Prospectus, any post-effective amendment to a registration statement declared effective by the SEC, a registration statement on Form S-8 in connection with any employee benefit plan, or the filing of any amendment or supplement to any existing registration statement solely for the purpose of revising any required disclosure in such registration statement and not for the purpose of increasing the offering size pursuant to any such registration statement. (b) From the date hereof until 180 days following the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of ADSs, Ordinary Shares or Ordinary Share Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. "Variable Rate Transaction" means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional ADSs or Ordinary Shares either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the ADSs and Ordinary Shares at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for ADSs or Ordinary Shares or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an "at-the-market" offering, whereby the Company may issue securities at a future determined price, regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently cancelled. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages. Notwithstanding anything herein to the contrary, the reset of the exercise price of certain warrants outstanding on the date hereof shall not be a Variable Rate Transaction.

(c) Notwithstanding the foregoing, this Section 4.10 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.

4.11. Equal Treatment of Purchasers. No consideration (including any modification of the Transaction Documents) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of the ADSs, the Shares or otherwise.

4.12. Certain Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company's securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules. Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no

Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser's assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser's assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Â

4.13. Exercise Procedures. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant ADSs and/or Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents. Â

4.14. Reservations of Shares. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of Ordinary Shares for the purpose of enabling the Company to issue ADSs pursuant to this Agreement and Warrant ADSs pursuant to any exercise of the Warrants. Â 4.15. Lock-Up Agreements. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements without the prior written consent of the Placement Agent, except to extend the term of the lock-up period, and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific performance of the terms of such Lock-Up Agreement. Â ARTICLE V. MISCELLANEOUS Â 5.1. Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser's obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the 5th Trading Day following the date hereof; provided, however, that no such termination will affect the right of any party to sue for any breach by any other party (or parties). Â 5.2. Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Depositary Fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers. Â 27 Â 5.3. Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, the Preliminary Prospectus and the Prospectus, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. Â 5.4. Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m.Â (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m.Â (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Report on FormÂ 8-K. Â

5.5. Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers who purchased at least 50.1% in interest of the sum of (i) the Shares and (ii) the Pre-Funded Warrant Shares initially issuable upon exercise of the Pre-Funded Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing the Company and each Purchaser), or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought; provided, that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of at least 50.1% in interest of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company. Â 5.6. Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. Â

5.7. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred

Securities, by the provisions of the Transaction Documents that apply to the Purchasers. No Third-Party Beneficiaries. The Placement Agent shall be the third party beneficiary of the representations, warranties and covenants of the Company in this Agreement and the representations, warranties and covenants of the Purchasers in this Agreement. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8. 28 A Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. A

5.10. Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities for the applicable statute of limitations. A

5.11. Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, by e-mail delivery of a .pdf format data file, by other electronic signing created on an electronic platform (such as DocuSign), or by digital signing (such as Adobe Sign), such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf or other electronic or digital signature page were an original thereof. A

5.12. Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. A 5.13. Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights. A 29 A

5.14. Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities. A

5.15. Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. A 5.16. Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. A 5.17. Independent Nature of Purchasers' Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or





?JB1X5\_],]OO!^5/\_!>;\_E&E\8\_~QK^#W\_JT?#%?P5W' M\_(D:-\_V,\_?BC\_-,N@5\_>I\_P7F\_Y1I?  
&/\_L:@]ZM'PQ7\%\_=Q\_R)&C?]C'XH M\_P#3+H%\_!NMOZ[YBBBBB@85]?(\Q9Z3:\_M\A/QYX\UTY\_L70Q\_U\*?\_"-//ZXKQ?  
X/?"7Q'\;/B#X?\_>'/LUM<:IG[9JU MW\_R#=!TOIKNM:YT\_S^GJ[2WQ4].>,=9\ PY^,'JF "?X2V?\_C'@<  
M\3[5/^8[XTX\_Z&S"KZ4\_9\_Q.\_9U\1Z#\_7\_#\_@#P!8W7C;1\_BU:>7 PI/5K3 M\_B9'QYI7CK60^)%]?\$0\_MROU/^,O[  
7\_/[DWP7\5?LY\_C7+CQM^W]^R7X:'Q M.^\_]GI%V?^\$:^)6F:[G\_(3OP9X.(<>(?\$/PH!T\$ !01CQ02QW^+ZS^P?%KG  
MP'\_9"t?XF?>?P5?\_#XM67Q/T;\_ (P:3XXLB?V@ZI\_8OB#\_A.O&@/T#P M]Q\_Q1\_!R.X!%?AO)?C9\6\_V\_CQX?^  
/A75\_=T3XL>\_&\_JM7GJJ\_A.U M3'\_]T7QR?\_J;\_/YX7\;\_?SQ0!X?17Z6?M\_P#P5!WT7@OJM?]G:TE7]G?  
M]I%\_2U;5M"@[M(2/@A\8C%?)X[\_#NL%"V/AY-[MXC%"6.WD\_X1"&0K%Y!AEE M\_-.@#])O^"2?  
PA^"7QQ\_J^%WPZ^+7A+3\_@C5/#OQ.O-9.ZH=6&FWPT/X M9Z]KFAL3H3\*-L?B+1#(\_XJ\$"5W\*JW S?M=6,,O\_  
"9;^R7\_.\$'9/\_)G M?OSCO7T1\_P \$-\0\_!(O@OZ\_(W\9.I%\_W0\_ %SSTKQ>;]OS]O:&6XQ\ M1M;\_/#5?  
#0=3\_A6\_UZ\_C0!3^//\$/L'C#Q;X@20>?#\_@G^U+S[\_PB?A.  
MSUG3O#. @P#8#\_X2#Q)XN^@\_M7'UU'C#6/%7B3Q1X@\_5>\_?M-SXH4:SJ?B M?6+N[L\_--\_JFNZT/[=UK^P\_?  
\_Z\_UY>@#]#\_(-?"SP!KW\_!C]MCXM:YX6T MS4OB1\OBI^SIHO@\_P 5W?\ R%-"TOQSK>NC73GT\5YP>.XY7H?  
SPK]4@!\_MRB@\_X\*#?]EL\_9+\_J/6OU^5!]7[3\_P#!,+Q'\+/VD?VB\_AM^SU\3?V6?V>=0 M\+CX;^.KZ\166C?  
\$K3?'6OZGX#^&>O:\_H6L:[KC?=\$O^" &1:%M; BCLA6) M4JV&XL5^L/\_1( P"4A/@# LG'QW\_J4MXJH  
^'OC#/\_>\*V5O\$GAZ[O\_ PC6A?LY^\_@? G@7T'A[\_13\_B1^\*/3G MQ.10!^+]+%\_>X?M(?!\7/V; CQ\5\_@1XCG%SK'PO\  
&&J>\_&#JV#\_Q/M+ZZ%K7\_M'\_?AP:'XHKP^@#]@/\_FO?#\_+JF\_JC+]@?QCI7[OP!^)C#XW>#\_(\_ZUX\ M0\_W1\_&6I:I?  
ZIX%\_W)@Z%SX?\ B1X0S Q3GX=/Q\_>\_=\_^"GPL-\_!S]D' MIGX6>\$\_^%66 [5/A'XH7GB/X.G6-8U3/"GB?  
X4>,ET/^V]"&OD^\*!X=6,3 MXFP><@D#14G[X?\_ST3]E\_JC[\_@E#>+\_@)%?CCX\_U;PS>KSQ=IOQ\*!:  
M'XE4IIFA\_&\_P+K?B173P^RG7-PWHZ9'S\*PX/Q\_P#/%+/AOXX;\_UX7\_+M\\* \$:Y^\_O[+\_9#]B^%?B&TLCIO\_ A^\_,\  
#/OC?P1X?\_ ",\_>/\_\$7A/C.,C MQH<@X.: /RHHHHH \* 2C\_@CS\_P I)OV3O^QP\4 ^H5X@K\UZ\_2C\_(\_\ P#\*  
M2;]D[\_L]HYHV>)D=@GEL(\_G\_>AC^XOTJAJ-U:-65WLOA\8M8 MJ^\_>\_&J#P/H;:@=9^%FB\_\"\_!-7#ND4AU?  
P;X='@^"IMHE)+@VRL@\$! MN0\_3X-VOQ,NOC!/\*[A];%?N[^6^)T'A'1AX]NR-\$7P]AO&8C'B)XSX%\_M!^K?  
\$'2]6TK66D^\_7C#X0\_&=6%K8M?)K\7-T#0O#VKZ1\_&#\_VS7M:U>)RP+ M'\_A'6(["MM 'I\$\_P;^%T\_A/Q#VY/ 7@EO  
\_C&^U/5\_ \$WA\_ (1K10\ A&M< MU37);?Q!KNK:[HQ)CUF7Q'KI\$TWG\*YD)"9&!4E\_ \OAEK4GB^?6/ 7A'4;KX  
MB:3I6C^\_O[4].Z3J\_7:7H0D\_&@Z1XA#[AK<7AKYA#'\*SJ 5\*,75=G\$:\_+^TA\ M--8\1^\_O#D>J7?  
:7@[2=+\_3 Z%I.JZDFN>%M9\_&>\_\$\_<>M:\_&=64Z[\_&3XX MT2\$^1\$TB:>B]BF2.C\3?VD\_ 'PW\<  
(>\$/^"J6VH^\$ '\_VCZQK/AW6!J.E.;I MM\FD\_ #?7OB'I"+)KGDN/^\$JV:\_\*ZP, '0!2"-SA@#T#5?@S\\*\_%\$]JM[KOP] M\%:]:\_?  
^%\_W6;K5O#.D7U]?ZEX&NSK/@M]7ED0R3R^\$6?S/!9D^,PSE9;8D MRFNO/3%="^56.GZ?K,  
N8-.12^%\_ \$]JI8(1JG@K7)\$\1Z+(K-QF/Q#HFER[ M2,MLP/60G[QQ^TQ8>+\$+KQ!!!X>NM;@\_>\_&?BEXFNS:7BZ<<\_D>  
1KFD?,K? M.H>(\_-\*^-=0M\_ \$%\_GQ\*X)?\_N^\$60%XTV4Z+XD#N'\-7\$2 ';>.OAMX!^\*&@77A7XA^#? M#?  
C[PMJK:=>7?AWQ9HND^(\_#EW)I4AFTQI-%UI)[=G5SN0^5M%#E:0\*\$S\$U\_ # MGPN^?  
@V+3;;PIX\)>'+\_0O#8%:1!H7AK2--:P\B0:JV@:0(5/D^\_6DR? M[ 5/(5F%5R\_FRUQ5I>J0V-  
JOACQWX^\_H0:WHW]J7FK>.M:T/P\_MHUQK>D;1\$ M9M-L=6U'6].U2Z &B:9H;>/\_EUJ4KY>W1"PN\;O'(NXN- N  
50A2X!W0^\_&O M@\*\_#5!^L1>\_#D&H?#\_2-0T#P%=\_+H6EB\):-K TG2]8TGPOTD>%T>:+1=\$ M-  
Q!N5XH4#MLC53TGA;PMX<#Z!IOACP\_KHNF>&!]TFR^QZ7H>@V4>F:98Q1A  
MG,>E:5&OEQ\*I8G"[@XZ]">2V\_ %3P)XTN+\_P+Z\_ %K= \_?>=%-\*:QV5E;ZDUX M/"VNZK=>M&UF=-  
L3Z1#\_+KVB:O;8=73'Q\$9-0USX9Z!6753HH>,2>\$\_#\_&NNWC7S-B^%90# MOB\*YGBB3S4 />^%5\_#'\_ A/O^%I?  
\_\*^%\_ \\_+\_L\_ ^QO^%A\_ (QI\_ "9 P!D MXS\_8 P#PD?E V\_C;VSSL;\_>N\*^W=\_+^Z%I6H>(K[3]-T\_3[\_P 3:DFM^)+J  
MWLEM+[7-531-T%\_6U?8[?VQ\*OA[0\_#\_@M+,F\1Z\_&\_((5%\_ \$B/\_TK\+OA MQX\_?>\*\_ 6#?  
S\_#FXURUU70+6QU.TU.^U+0\_ "6O>\*\_TG1]ZJL4Z3)H&M/\_D M6\_PL3H6OR>%H13%Z3\4\_B\_#?  
PE=>\*8[:\_>\*VUCPKI/^EW:Z=IT7]O>+\_ M-H^J:O+O6W .M!E#(ZLP=65BQ(-^#PGX?L]\_U#PW:Z-  
IUIH&IW6J7USIMM! M-&\_O9/\$.KRZ]KXDA+\_5D\0ZUK&K2S#=Y;-<.Z( W-^\*O@Y+?7A72\_!7C;  
MX<>\_O&GA#0\_+\_C^%?%OA+1O\$?AO3I\_11I/]G:-K<\$\_UM') BHL;L!B,1E] MF<\_AX<^/\_P/M7\->\_O\$>HZL?  
#DVM\_ "L\_ &:[L=7M=12+3/ R)H.YVR32+N4QQ"-YI(K.G\_ +17P:UCP]IGBO3?\_G7F@:\_EXNTK MP7;:NEGJZ6  
4ZZFAC1]UEU@7^P)Y3KVC+N\3+:!IP%.V@#3/6? 7X)>\_M1\*>\_(&WPF^7B\_6?  
:Y'ZGXB':+JFH>%0PSNT%M:@E;0R.H\$#(+(\_%: MD7PJ^%J\09\_BQ;^ ?L7Q-NK%-  
'O/B\*GAG2AXTNM)1!I0T=O\$:\_Q\_P#0"+ M5& F:\_E\_=\$\$,RUP4?QXT5\_AI<\_SPOI6JZEI\_ \ PF+^#K\*VUZR?P8]\_JX^)  
M8^\$OFD:\OE)X>/B0&0>)/,9)XF4&7=&JS^\_@\*\_WA@/B36K?PJJY\Z1XFG MM79]0TXZ=J^K:-H2'1O\$422>\_O\$\*?  
V\_KVA0O+X=F?>VO>\_1Y1\Y!(>T5YV MWQ" T2X^\_G\_ "S=&D&L>&CPE)XTL+FS();=I  
T=];C<8)VF2+!QU7+6/#WQ(\4\* M\_FZ!H.M,6)/XP'F825[\*]TE17R#X:\_;\_V^([+\_P!J\_P#PA\_B73M)>Z4F MM'5\_MO@[4]-  
)\QZU<>[CP^FOOH?B29V'B=O!FO\_>\_F\7K;\$>\_5M%/\$>\_C\_M+4\_A+6=&^\$\_BN'0?%/\_CWQ7>66LVLG@W5\$+\_  
[]1\_ ^ M\$E\3Z[HGAR(>\_4/71P;XU\GP: E50#["HKPOX' !@T+X[ ^#XY\ V=YIVF MW5REC:VMU>Z'J#?-  
HFAZV7,OAWQ!XJ\%@NLHNY+AI#A0R#\_+YVC?M\_ #R\T M^\_U?6M5G\_.+I>C>\_?\$.^MR:O:ZJ-  
,T#PUX\$UGQ'H6M:IKNLHA\:@^#\_&F\*R MS1J@T/Q\8=S&8D  
^A:\*\_F^/WPCMEU26;QC#;VF@:1I>LW;76C:U8"JTW75T M,:/HI?1=WB\$2G7M =#X92X9#K>@(\_Q8W,>\_J\_ ?C\_3/B  
VOW.D&VN-/TK4-& MMK+5K.Z\_>\_OZ9K?@\_P\_XTVC6=\*\_D'#H\B!%5#\_&&41%MSX4( >FT444 %%% M &7?  
\_P#'\_G=\_]>I\_ ^@FN4^%G\_)-\_8D>%\_3;UU=\_P>=W\_UYZG\_ .@F MN4^%G\_)-\_&\_A7\_TSV]  
"Y4\_ \%YO^4:7QC\_ [&OX/?^K1\5\_!7; E&E\8\_ ^QK^#W\_JT?#%?P5W^ (D:\_V,\_?BC\_P!,  
MN@4&ZV\_KLCF\*\*\*\*!G8\_&\_GC'P8>-\*\_\*ZY\_ '&I:WX@!^&\_ ACP'\_ P#\$FTW\_ M (1+POX%Q\_86BZ)H?A\_ )%  
[\_^OZ\_A\_&WC;Q)\0O%&H>,O&J\_P!M^(-4\_P"0 MQJWV/^S?\_0\_SG?\_W5RJ%\_J AOXX\_ %/PK\*\_B!\$=\_\7ZC?\_GXGW>F:SX[  
M\%?8M&U'3==U/1#H>L@?#\_ (A)4%@."0I.<CRBBB@#T?X3?%KXF\_ P; MZ\\$/SX2^,-:\_>\_&J#2/%?  
A\9U\*Q&O:+\_&\_!K!P((4'!!&#Z\$5]=?V5O M^"A/\_1VQ9\_ \ K\J\* /8/C9?\_C%\_T5XGT\_P)/B3XHTO1O^\$8L  
M]6\0WG]I:G8:4/\ B?#1,?\_ <A^ M\*M2TWX;^/-8\+ZUXP)VG\_ ,U[5/O\ R O[<\_/%OT]L9KS^BB@\_KT#X8\_ \$  
M[Q\_ \\_ %L'C\_X9\_,-\$>,+L4L/Q%X>O/\_U.PTO7=% L?7?\_ RW/RKS^B M@\_HHHH [CP1\3O\_,-\_>\_H\_X0#QCK?  
A+ A/\\_J\_ #[\_Q@/#U[9O]O> M= Y M#NBZY\_U+OT"MQ7#T44 =Q2/B=X\_P#BUXH\_X3'XF^,=;\_>\*\_+JSTO1;SQ#X  
MAO!J6IW^E:\_H%O)@Z\_.^\_B1X\_8>%\_ @?Q'XJUO6\_ \_POL4 MLO ?AZ(O^/9X2TO7=::OZZ#\_)?^\*D\_SQFM#P?\\  
&\_XJ>\_!OCCX<^#O" B3 M1/\_Q0L]+LO'GA.TO/\_BF?%\_O]A?@(\_+^W#\_ /K=>\_O/F%\_ 1110 5^E\_ ! M'G\_E\_>\_R=\_V.BG\_  
-0KQ!7YKU^E\_ !G\_E\_>\_R= P\CAXI\_ J0KQ!0\_ HRQ\_ M<7Z5R'B+6H-(.ZIj=\_J-E,6UI?L\VF:/^=)4LD"?  
\*RZ'H\B!]7D#\_?\_Z" MW<%1M:-&>W9\_ H0/\_0AW\_K0%/#7P-T?PQ\ MOBSIGB/Q9+X9T+2/A=V\_AKK&J:+J]@^O Z-  
KWPB^%O]MZ\_AR/Q&LC?\_+4U M]8F=O"4:R>(%EECD0/>TE\_94\_!7&N>(\_O%I/!X\$+9.YUD\\*?L9ZIX7LV M6;QG!J-  
RNL?LYZS9W26FMJ3IOP/UCX"ZWK>BG1E\0MX;1?%;?!+<98P"AUW) M.U9%/UU=^"-6\02?  
#O6=;UN^T[6!/NH)K.J6OAR^U?3#?VN:B=UG07T]1I M2^\_0U\_MJ252X+L;MQRX/CO6\_A]^S-X>OOB-  
=ZYXH\8B+P+X1V>/'FDV MVD:YXJTP\_19TCX1L!CXPC+\_+O!WD\),OCF)\$\ M4.D?HL@GX(W\_@?3O@[\_#J>NSZ?\  
L^\_ #H^%[VSM=\*UA=5'A76?AGXA^\$JN#\_ MX<>(5D\).K+;?"C GQAH6)%5MT5;&J?L:\_?J/CGXF>(I)1D\_L?XD?\\_6=

MWX6:'6]0THZ=HFM>']=\;1:TI\2GP\9/%Z:\*\_AMC'#X36"&&=KG\_(2L[ W9 M:%//\$/FF>)/BKXIO]=T34=1\??  
V99Z0MYI&K' A'M+T#2/\$\$6B:'E?[\$"70\$ MGUS60\$#QVY\*2+/XD\1(5 D5B >>&M(? M1QK@6\_7XK:1X#T+746,>))-  
"D6'P3H6#XH3'A\*0;?W?RJF9X2TK]GGP=>Z- MJ. @Z^O=^/?C5X^^(.CK8:3'IK7OCMO&WCK0O'2:[K&A:  
OB!M#Q\$(C1M"7\_ (2(GP^C?(5\_P (FSR-XMV>\$->1Q\*K-, "#1/V< %%G=^&J?QA MHTWJA \$#XR>, +Q6\ZKF\_P!-  
^\*W[0N@?M(KI&!XF)QX9\0:"X;C!8EHMI,: M.S!P"YJ\7P@^)UJH\_BK7O&VM7< QXF\Z5=68\-'0 \ A5/Q-^'\_(\UU\LP  
MYX2\3JJ^)/!@G(\6.Q"KE=Y; \MTWX=?LQ^.[JP\.\V6O:WJV M>DW%KK!<:3KWCQC[K>N-K@1>'-  
!1>\$O\$' "UO#O@S\_A+"KJO\_DL<<L%R?C%\_YMO#NJ@.GQ6V-(V@8\2N?#P'B+/B4[U\ M7988#\*K++/P3^SGX@V?  
\$K3\_B%J?C+3-3FNM7U'6 \_FF6GA\_5; 27XUGX\ MHIT,OXED;0DV?/6ED;8V1HR%7!8N@!Z/X0TOX?>?\$  
&%UXT/[;XQB^"A: MSEM+#PU)IOANP+Z%K/CE=&57\.>'80AMHDZ!HCKIUA:/?Z)M\_LU\_AIH'P^UK1ACPZ2R^,/#^  
MB1^)O& P&F\<3>(/&@"228&J1\_@A^,J2\<>(K;638:YXL\#>" EO!>1:S M?Z2NDZ#XW\0>(-1]  
(37XXROB6+78K>&60! \_D,2R@R8D:N#^?/[7C3X,7V MJZA)X[L?&=WJ7@WX->]:AU72M8;  
["/A7X.T3PYK>LZ0J^(I637?&D4WB)G M,9 \OP\I,3A0"KXG\_91^\$&E^%\_BQ>ZUXF\1Z'I/B\_6?'GQ \>:\_.EZ M%?  
B)XGU'QII\_B77-4\::3GP!K8T^>\^!&NO^.-\$!%F/#,L>OZ\_P%">+;P0 MN@>,O";D>-'?  
0 \$,2PPRDR+ZJOPET\_4+XKV^K:SKNLZ=\5+74+[+4M#U6^U M\*\\_#FFZ7K@Y!/;Z1I6BC;%"J[[A0BL\-.  
/[&U[Q(RZ^P\1ZUH3JD MK(S)H#E2?^\$HF6, XBQ^&?P&TNZ\+^.9/\$WBV\X6+\*F 9^\.:IJM1^IR' MPQK9/Z\$-  
"UK6V/1^)/#\_B\*;Q#H6C(K>+IE">.&\1%U/CGQ<^S\6\_!KG+ M2)3P?K6O^^(HM\ AS\5?  
AA\0=1%U?;GL/2ZKX%T+P)HT&M-X99'D>4>H MQ'X8E@8HGB-Y#.3XJ5)?;-9^"&HZGX#^%7@NWUG3--  
M\_AXSP"\^+[R[F:U MJ%\_J+> ?&>A>(& L\$GQ,0C^)\_P"PI1\*WB@>,' UQPX8Q)MX\_XB\_LU^)/%OBO  
MQ\_XIT3QGH^@W'B]\_#!%O>>M2U#\_HZ)KWPUS.NA?L:Z^ENGPMV^"3A'\&K MXY\4%!(3M< 9/JGP8T'PIXP^>.  
>:S:6W@WXAZ?KFJ:I::=.:[X+2Z]XWU MWXL:(B>#X;A0^(!U(RRR6L@@71UA\;R/YDQ/.>\_@K^S]X)\56E]I/B7  
M7KCQ!H&L>%\_@R/[58[CXIT'2/A#XXT31'UI?#B^(2OE\_[P1XK423'P83K\_B M9T@= %?R]-X@\_9Q\0:EH\_P 9="A\8:);V?  
Q/74[&SOKGPAJYU/P\_I>N^?-? MCK7F\*IXC U[7(O\$/CK?X/F<11Q+H46T,7Q'V0^#GB4^(&NKGQ)H3)XR^W@ M?  
XXI\$\_AO5WEL=)=(%^\_A\_P")#1SXD)&OR'P\$KMXE7;?&[93";(DV@0 "?  
M0+1 #VI:X:\7W&M>=" XHSPA:"R4ZC7@/A&V:XDFNA?7O\$" \_1QZP6 M#KS2=%\6Z#KM];:EI\_B;Q'X[  
MUFV6SM/[/-9)\<:YKVN'26:0JQUQ?[:?\*1\P&[UKXC'[#7B?\_A (-!Q4; M (3D>,\^\$U\_X2W^PWV?VK\_PAFW:-\_X2(H?  
#\_P#PNK\_BY^Q6+Y,,9R\* /T'3 M @\_%X,@N(M2N-;1ZD)\^L:IXF\16%[>:9^+M3DE\0ZS&NMG1?#:@^Y?&>  
MM);CPL\2.^T,25\*BA:?LS^!K/2!/6AC5/\$ESI\_@N]U&[2\*ZN-%=M>\*:WH?B' M1EUUQH813X9U[0!=  
NWAA8% B.B1&0R, YA7F/ O[,\_M^"/C1KWQ\*T\_P 5V=UX M8O+76-/.^"[K2-:9^'M.U?6="UYO\*9M>DBDFBN-;^  
P|M]F#X[.N06MWC/ MF&G\_+\$J;:X'N/"D'C\*SMI=3LO"]EK%Y:Z5J^EMK \ PCW\_S.+AM970?<  
M(W+XF/P1\9^8PDP/^%@,IV/&4E /H\_P#X8LO 7B+3O"NA>.KO![\H\_B2S\;P MSK\$&BIJ&O:IHFC "CP\_HNM(B^/"Q?  
0!/WAK0D).>7X:@\$,C>(.9A(98?)J'Q M?W/[,PV\4V]E87[;I]ETS2 B5H\H;9=%;5!Q7TSQW'KVDKKS:"\$/\_,^  
M7XXUJ1?"8=/2-X;D6WED\\*I&>"\5\_LL:GJM]8:OX>2:I)=SI>\_CZIHEFFO M^&G\2ZG\I6NZ-  
M#U@2:VVOQ217\$L7P5U9V\0R .I\0[(U?:7:T]FKQ1H M'PN\<> +7QAI;:Q\1? ^E #W6/%G]CZLNIZ?IFB?  
L\_Z#)=&8\$>(SET1:)) MXH; W,==6(8LU &MXJ\_96^%7C+7 &WB/6[>]GU#QW/X9N=706GA\^9\_8&L^ M  
]=T,G\_BGF\_M!]XB/#Z)\*45MXN)@1A>&TD:\$=\*=#C>\*/^\$67KXNU M\_P 23!G5T= 6/V: @\_K+?"!>J^#9]4MM3-  
UJVGWXN[2R\_L\9B](>&).%!Y. M=\$^0CE2.F3B@#Z/HHHH \*\*\*\*,N\_P"/[,\_Z]3\_/\_037?\*S\_DF\_@#\_+\$C  
MPK\_Z9[>NKO\ CSN\_P#KSU/\_-!\*,?9+/\_\*@N@#W] M<^WZU\_HG\_P#!3\_/\_9D^(\O[77]'/Q  
^!/PLFT.#QGXKUCP+=V4FO7AL-\*[GP] MXWT+Q#JP>0 X/EZ1\N4-P2SG)Y\_EPA\_X-W?V8?]1XC^#F>W %>:R/K\_,RW  
MC?]Z4 ?@] 8^M \ 0)U' P C1\_8^M\_ G4?\_ (U^V\_ !#R?MZ ]#'\?' MPO=: P#FZU\_\SE 'X/?V/K?\_0)U' P"-]CZW\_T"=1\\_  
C7[P\_\0\G[>O\ T,?P= \ M"JUK\_P"9RC\_B'D\_,U\_Z&X. ^%[K7\_S.4 ?@] 8^M \ 0)U' P C1\_8^M\_ M G4?\_ (U^V\_ !#R?  
MZ ]#'\?' PO=: P#FZU\_M\SE 'X/?V/K?\_0)U' P"-]CZW\_T"=1 \ C7[P\_\0\G[>O\ T,?P= \ "JUK\_P"9RC\_B'D\_,U\_Z&X. ^%[K7\_S.4 ?@] 8^M \ 0)U' P  
C7Z0\_P#!(NSOM-X M\*.?LKWVJV-SINGVOC#Q1]LN[J\&FZ;G\_(007>V?KP?P-?8\$\_/)\^WK\_P!# M'\?  
"JUK\_YG^\*^NOV?"^\*G[7G-[7GP2^.'Q'U;X7ZAX\*!^([3UGQ!::5 MXOU?4=3>PD\%>(/#4<>B2^'(X9)7?6]JH9%  
)4.5# T?UA1^\*#/A0'\_A)- M\$]A\_&E=/3Y74#IC:7\_A\*/#? T,NB?^#C2O\ X[6C\_9UA\_P^5K\_X!\_ MUJD\_L^Q\_Y[7\_P !4\\_  
B:#G,K\_A\*/#?\_0RZ)\_X.-^T.?!)1X; P"AET3\_M ,&E? QVM7^S['GSM?\_5/\_B:/[L?^?U\5/\_F@#\* X2CPW\_P#!#  
M+HG\_(-.\*\CM\_ E'AO\ Z&71/\_!QI7\_QVM7^S['\_)\[7\_P%3\_XFC^S[ M'\_GSM?\_P%3\_.)H RO^\$H\ P#0RZ)\_X.-  
\* P#CM' "4>& ^AET3\_P<:5 \ M=K5\_L^Q\_Y[7\_P !4\_B:/[L?^?U\!4^)H RO\ A\*/#?\_0RZ)\_X.-^M^T.?!)1X;\_Z&71/\_  
<:5 \ 'U?/[L?^?U\_P# 5\ XFC^S['\_)\[7\_P%3\_XFC^S[ M'\_GSM?\_P%3\_")H RO^\$H\ P#0RZ)\_X.-^M^T.?!)1X;\_Z&71/\_  
,=K5\_L^Q\_Y[7\_P%3\_XFC^S[ M'\_GSM?\_P%3\_")H RO^\$H\ P#0RZ)\_P#C2O\_([1\_P) M1X;  
.AET3\_P<:5 \=K5\_L^Q\_P"?U\!4^)H\_L^Q\_Y[7\_,!4\_P#B:,K M\_A\*/#? T,NB?^#C2O\ X[1\_P'EAO\_H9=\$\_!&E? '\_U?  
/[L?^?U\ 5/\_M (\FC^S[ M'\_GSM?\_5/\_B:/[L?^?U\ 5/\_F@#\* X2CPW\_M\_P#HG\_(-.\*\CM\_ E'AO\  
Z&71/\_!QI7\_QVM7^S['\_)\[7\_P%3\_XFC^S[ M'\_GSM?\_P%3\_")H YO4/%'AP6-R?^\$DT3\_CU)\_Y#&D\9'?'+\$ GRAPHIC 12  
tm2430640d1\_ex5-2img004.jpg GRAPHIC begin 644 tm2430640d1\_ex5-2img004.jpg M\_JC\_X 02D9)1@ !0\$ R #( #\_VPI# \$! 0\$!  
P0%!@<("0H+\\_0 M1 @\$# P(\$ P4% M! 0 %) 0(# 01!1(A,4\$&U%A!R)Q%#\*!D:\$((T\*QP152T? D,V)R@@D\*  
M%A<8&1HE)B7J#A(6&AXB)B1\*3E)66EYB9FJ\*CI\*6FIZBIJK\*SM+6VM[BYNL+/#Q,7& MQ\C)RM+3U-  
76UJC9VN'BX^3EYN?HZ>KQ\O/T?;W^/GZ\0 'P\$ P\$! 0\$! M 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!  
M Q\$!2\$Q!A)40=A<1,B,H\$(%\*1H;"!2,S4O 58G+1"A8D-.E\1<8&1HF M)R@I\*C4V-S@Y.D-  
\$149'2\$E\*4U155E=8651C9&5F9VAI:G-T=79W>'EZ@H.\$  
MA8:'B(F\*DI.4E9:7F)F:HJ.DI::GJ\*FJLK.TM::WN+FZPL/\$Q<,'R,G\*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ\_JH # ,  
(1 Q\$ /P#)? @EC^ MQ,W[=&8T'XH:EX TV'PRGAR>R&G:9X6%ZZ+V]%/ID MJ3@ZQ>6<NV)-  
X=MVR+9^E+TA\WP\_JU\_H@O M4["TO'FV6DJS;/H,BW200) ICO\$F0QA,/3EMOYO\_!&7X@\_MO\ A?\_ 9P\?  
M;:\_S+/#/A\\$\_GP9\A:M:GUW7O'7CW6/#&L67B9?\_!PZ\*650INFZ+-!QLK:WMD358WA@BVVS  
M1TO^".WB/7 \_WA3]LEO\$6HW6I3!:^W\;/#6EI=^6!DZ0NA)9Z39K\$D:K; M6+WEY%#.0UQ<1N);B::1M]<\_P  
\$C=5^#":)\<]&TS4O'=Y^U3?>-]3\:\_M6 MVGQ6TK3!:\_MXSUN>EL19Z9H6HZEH9#J=F7\*2:LK[F-M;>\_Q?\\  
^"H\_B;XA\_CJX?/M]@OX!)'\V C[QY!KOQ;^\*OB73;2VNK\_P (?#KP?I&I\_P#"-1SO/;7\*6R^) M%/,26.X>5,)+(\$?82K?  
2G\_!+#]HW5?VA?V3\_RGBTQ;&R^\*P>U75?@A\4K" MQ\$<4-GXN!%-'BOFM/\*22,ZS\$89KB0(L3:G:Z@D!0P/R/\

\$\_T\_B\%X(^,GQ M3:\_8;Y^\*7Q\*!;3XG^./C\*7X9?#+0;[Q9X=TBZ\+\_KX;3VEIX?N(+6ZU"S MN(%UO51':WC7-LUS=SZ5?/-.;N>:XYCX<>./W!]W\_!6GQ7X9\(^/#^I? M;J03PW9>(-/LO".OZ7K^D^& CGX=:YN[T7,6GZM>-IMYKVM/JEJ852&UN+WQ M;HP>"6\*\*T\$'2Y+DY\$FG=-/9:7T '\#? P""[= X\_ X5+^S)HGP[UI #WB?Q  
MI^T5H\_A2VODALYY!J7A7Q):1@W=M8]M\$T7VS\_P M3Q:[E\_,^%% P#"?<:^?VB @\_JTOPL^/?  
@N9K+=\_2 &OAB0Z7=:[6&V. M67PWKPM8]4%W;0BV@EOWMK3[/\_QVZ1\_\*!\_3C3\_-@^4J@E3]M?P "5RR>8  
M\_=U>"8A7&"\L-M93MD D'[U1)5; @\_H)\$O'W[;7QET7 @\_I;^R HAO? \$?A4: M;X? &E?  
AE80SL/BA\\*X)GN/\$'B2UL[7?]JH4>]\*MX[DW31K=Z@]NWVN>X\$ MD@:HM)W?8SDKI+Y\_UYNYJ\\_\%]-;U?0?V?  
VE=" ?P9GUS2;M98I+JV6YN-(DETW5HD+&RU&UO5N+ M6[M" L;6UQ;R0\*JHH4?)W[8DWE?\!  
SP5,S+YYE('E6\,GB7X>+< M2.02WG0,&D1 =C94,K\*<4Y235E?<48M-/Y6/VE^!NJQP? /X-.KJ=W#YOPK  
M"\:AJU[\_. \$W[+/"#"+P+IUQ)X<:\_:KU\*RM[KP-X6M1)%]I\,> ;JXLKJR\ M4^++F.0PVTEHDMK\$RR>:ZB&1E^\$?  
BQ\5OVXOV/[V6X]\_9=\.YX/\_9>^#\_P  
MX\*>?'.I:IJUQX0^(\_[1C^&#/AZQ\4>\$)!6WM8[R#PO931:K&K:2O\$OPPC0\_VQX" M\86K2W&J6GB1IY/M]UJ4EZ+@?; [N62ZD0J[S%P2LHXQG2CB(>WA+5R@U)4U%"VJ[I2;:2Y(R=[I\_#?\_!1/X.V\_P"S M-\_P3Y/\#\_M"\>\*?EQ+]0DLY?  
%&J'Q+XBCM5O\$G@DTZR>X M:]8):6EK;PQ(L8VF<22R=WI\_!3P/=V%O=R\_M"?&"6ZA2Y>\*&T\#\_JP/  
M.:%7 \_LE7\*PLYCWO&SMMW.7;<:[G\_6]:XM?V0\_#SIMDUY>?\_+X^%-W!8!H MXI=0N=.UL:S;6UK),#'+/(<)QK5\*?L  
MHM0A>4DTTKM-XYC7JK( M)5J]&KF66JA2E\_K!AZD)T8RJ0=1X9\_6H-6A>DY,^1\_C=^R7\=@G[X#\0\_MM)?  
L?';Q'XYTDX?V>M^-OA[\-2].SV&L-&M,D6XUF[TZ^L-(AO[&\_^R\L;  
M=4AEAA8@RI^\_1F^\_P#Q\_P#MX>\_AY^Q=X;\_&L:\_L91-X\_>\_?@ZVED MN=1U;QEXUCCA\,^'+>S2M!>:I\*EO-/DS00;G#,Z:\_K]J;JKOJH?XSVWA[ M]F[XP?\_4OV^\_A)9=0T[PQXL\^7CK4)O'MMK-C?7T45SX3\ZQX+TZ3P\_16  
MJZK\$#")-6O2%,TGSQR A>\_V\OA\_P"!&!'C\K\_@EM\!M-650@YI'Q?T?3[B. MFD:\*)A\ (V6B2^')+R=O\*FS=SSRS6J;U0M<+@2;4(Y:E:<,:J&J0C1G"-HU M.;F4W4C&  
[3;C'25VTG%NT59\*509PG!^\*XJK<\$4^+YX&KQ/G6/XFS6EBLOI5Z  
M='Y;PCD699CC\OS"OA+99.KC:N%Y,A,+AI8B52,9UYT:MMHS7^J7&G MV2VL%W.9A,+Q9PUS.5+O8O\  
@E]1\_V3].O\_B;^PE\8\$\_VF>+-\|4+CX>? M\$#^P[WPWXRT^\*(VEOJ%KHJ:E:-  
\$5=XI5G0RXV32.@@);]Q+.TD@B4"0+:A)% M2#RT4;Y9=& "Y\$GS;W8-O9B69V8DU<%G#&DGWWC)G#C>\DC'<(\-  
(6D9EURV?Y='Q8XLJ1  
MQ.#6\*P/^JV)^K5JW"\\$GRZEEZP/M:DZN&Q]:A0EBX8GV.%K4DZ%6+?"OQ'\\$RLK2^\$\_&EZ9)J-B  
MB,6E2VN)KLFTE90[P 3O(AY7/XF\_P#!';JH#Q[X0^,?A+XO:[<:IX,\_?T M[Q5!/+==OUM8XX?B+\.M%Q#;Q/  
7T!1/:PH\_ERLPV1>82Q^S\_-D> MV7PE^VK\_,%4?!?AR?/[X4:QTQ3#91A6L8?%NHZ)J\NMLN\.(IY@;B>2-&\$  
M:\_XE2\*,\Q!/AOX,\_!/6/&\ P2FV\_&KP#\\$'Q7\_&9OCY2/BAX,O; S/>W M&G:+XKLEUJVW%W-  
!\*-3TZ"XLY\$GM[A9%#L%P;C\Y/\$XF57#>R\Y2I5TI)? M\*%-R3E\*WN-6O9WDM-4S]YR\_(>,&DPOB=P54R\_#9;D/B-C?  
#>.5\*LXXFOD^&X MVR;,(;6>8;62?2+^UO-.EA)"  
MQ.@[613N/PIT3P[J'QD\_92\_X\*3\_MY>/,\*=]4^\_7@GQ+X5^&4=PDVZQ^\$7PZO  
M+NVT5[!6V111:I,LL\DJQ\_:\_]QFYGG01?!6SF<<3AW1P]7EFJ%7%--V?LL-1 ME5FTHOKR.\$>13:O9)V\_-O!K+\*7#\_&  
<.)L\_R^CB/2^\*\*O\$.E\_P#!\$S1\_=%A? MF+7Y@;\*KYM5BM[2VO!<3ZAI4=Q>V]O#\_EJ)IFGFFQY&V227.\_ACVO&NH?  
M%?&&UO\_!=X\\_.>:ZVM;3PNE#=:YI-KJ4ZQ?"29)E M4RW+,5<%F\$8"!5!&.^T4C-  
\_P0PTQ0R#P^&^\$8M7>ZBMV;9J7A^1+J:2:&2.W M4NT8:5%D1M=&H)VK["%OCC\_P%-.3X0\_#\*V\\_-LD?"#6#UMX  
\\6NB:UJ M/QC6PO=1TVWT&QAM+R>V6VV6[S0HD@CR=JE<@'Y1Y)4ZN)P87\$8:IAAXNNZE&%/EKI1FU3]C&  
[8W\_!&7P5& MTKQ\_M\_".>2(0P2HOA%;?S"Z2J93!\$-U'&1\$T#,)1S.'0AEB\*E>T>?\$C1  
MP4KU+Q/H5KXP\_9/^\$.A>';G6=.M=;UFP^,1U>^TS1Y[B!KS5K;3E@>@6:6W\A M%6&>24-Y(.  
C,M%>G1H82M%\$AA>E>VL+/1=E\_=OF[]>S/S7B3.N/8Z\$LSX MFX8S"O.A&4:V6<0<5\.H.3]QSA@V" G3UDE#K=-  
GYI\_&\_VD\_@3(?V5\_B M5X;^\*?Q8\$>/\$=[\>];UNPT;Q-K5KI%T;6\!^";-HA;/?7DV+270]1M)4>  
M\DBDF@D\N7C25\_+C\_&@1?!\!0G]B?PSI-YK.L\_M)\_^RL+\_,PSW,'B6":5+ M: -+OCMK%\_M\$/\\_&"NVC\_/\_W\_TD?  
G32>K/[C/V!/\$5Q^TK\_,%!/VL/VX? GAW4 M]+\_9\_P#&OPV?\*!SPCXGU6!M. X6!K7A:Y\&OJGB^V\L)(Y;V]M;!=.U\*"\&Z#  
MP6TBWS12B4PVX3A?^"47[1'P/^#>B?ME>%?B?\5!P]2ZC^W;\=;RPT3Q-\\_MK%AI5S/\_:=!LC';-  
>WA\$(NK.YM+=WO7:5(HYI0)Y)%3[%\_X(^?F!?"\_MZ]/&O\_J1ZG7\\_.7[0O\_)P7QF\_[+Q2O\U8EQ5&E/5S7]U?FF?  
Z%R\_MW\_+R M0).?VCOA/#;+#'-(+CQ58+\*J2JK1Q1JKKN(#!<\_.V<9+\FO@C\_@JK^T:OC3) MG?X9?L\_+/.NZ?XJ\=?  
MV>,Y?A#X'U[0[ZSU"&+PK8S0/XZU:T\$=Y:3R6]I MYECILDEK+(YKBY5U6=": AXVW MOY \_G\_ CD\_P"7?\VD#U  
M; U9/Q7K^P\*V P!8\_P#V%;O\_-%/0.2NK;=3^2\_1OWP#X\_X)P^%OVC?A7X1  
MMI]6\_8U\_:\$T/6;PM86S2S0\_!KXK6T8U9=\*\_BN+ZWB2PT[Q":1LMM\_:\_EY:32 M2272VT5]/="OL7]L8B3  
((^#H;CR+9Y/A#^S5;FSD,=M;O(\_BGX:S7%O); M7\MM+>FVMTO;3>+ZR9G1KF)I1Y,M2?\\_!Q\\_,F1>#?  
^RO:/ P"B;RM/JKW\_M)06:= V3CX" P#1^#T"O?ETWE^29^R/I-VCZ9?L]?!\*RM-.AL84^#O@#" M[-!"+.W62?P?  
I/VV2.TAE>&&6ZG::6>:WEF:1I'N)2YD;\> P!L'X\*?7]@ M/XUZE\_P4  
9;T][WXWTZ6SMO.\$N(%MRD: LU^S\I\_R07X,?\_DO"?^HSIM>7?MF?\_)N'0\\_) M)KO\_\*  
I\6/E),A '2726(PZ=V\_LUX=?\_.U\_IGY;\_!4'XT #GJH\_@G\\_\*O MC!\_.]>M=<'\>+/C3\\_-1L\B/4--  
CGBD7Q%#)-874QN[BT6^LIXYQ/I2\$:\_A(D M87\*HZ\*/W,T81OZ=:01HL\_KMC2+S%:@:(B,[2!T95G4,!YA88=&H\_D]\?  
M\H@/\_]G=Z7\_ZD^LU\_6'X6\_P"0#8?I07\_I9<5RJ4J>8N2=U/#R35M+\*4U MNU9J]D;L^HS?  
\$3K<'\XJ/LL/G\_!U:TESQFZF\_PLO=BG3<)QLDI\T%915 MV?FW\_P%:O!NG>) V&OC>\UA&U\H>DVOBJPNF:"Z?  
W%E<1;O;9Y"2S+<>;(%9 LDK@?:7\_4- M\_P"3-OVHO^R\_..(W@G[2O\_) 'C7\_+\*Z\2.SK"^\#G\_)^?PV[\_  
M'71O\_233JXX8S%2ITZ#G!Q=;XI0UTG;Y]G@!>^&H\0X3&U  
M,)B\*E#\$4GG.\*P'MZ\_=AB\*E'')"RE#N<<+ZU4L]JOF'L.D74-K=Z9\]GR  
MZ\_JJO/%"9+NWD<\_.>'>2RL6\*B7YE\*)^IGCK\_DC7B\ L2Y\_ \$B2OSI\_". MG\_)FOAS\_+'XH?  
^K"\1UW83#T K56+C&2^HU7%2C?EDYT >6MKJ\6VS>M]3 MYO->\*LPS?A7C1XM [3FG&"5#"\#8NG-QJY/A.'&+:]61^  
'OCM3\&=;RR1Z-(OC#\_J VI\_MQ'9Z>62[FUI\$U&RD>W0S6Y3<)OVI7F;]F\_P!KWX<^O@1 P\$O\_C9\O#  
M[2:1HW@G]GR318HY9O-\$M+>WE=VOGA5(9;N"XEGFO&\_U=//0'D4QFOS, M:H Y3F LS \7CX1\_P#1\$M?  
KO\_P4B Y,7 :2 P"R?^O\_1JUPT-L5GF,X#Y<#A:5LGX\_SN M6#O&>:\3\_47/\$ MB  
>X3W\*>8A\*M; \VGX4:/Y\]KM);5X,S0RB[D#PMO;RY&D1/N+X"?MI?LL:+ M\$?A+I.K?'CX96&J:=\.?UI?:=?>\*=.B-  
G!IT:U)0D MY\DU%J2=K\GSS!9Y?A2I>9]FD)99BL+A:C  
MQ.9>SAB'4>\*R[PDFJ<7[M.\$N9)R2Y\HTG\N\DJ3[W\0'POB@8/F1?&M@  
MMO((Y;F40S;Y0S6\4,DY@:W=Y2GEQ[MPVE?YRF@\_P#(5O\ L-1\_Z:9J\*[\_M<%F^(E15XP5G9\*/E;?O?  
[V^W0^>XHX(X7R/&?"83^WYTYX2%63KYCE-2?. /YN+LUPY%)-.UM]=#\_9 end GRAPHIC 13  
tm2430640d1\_s1img01.jpg GRAPHIC begin 644 tm2430640d1\_s1img01.jpg M\_IC\_X 02D9)1@! 0\$ 8 !@ # VP!#  
@&!@<&@'P<)"0@\*#!0#\_L+ M#!D2\$P\4'1H?AT!:P@)"XG"  
(L(OP<#7#A(6&AXB)BI\*3E)66EYB9FJ\*CI\*6FIZBIJK\*SM+6VM[BYNL+/#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?  
HZ>KQ\O/T?;W^/GZ\_0'P\$ P\$! 0\$! M 0\$! 0 \$" P0%!@<("0H+\_0 M1\$ @\$"! 0#! <%! 0 0)W \$" M





\U:1 T'[W +\I1 PS5I' \$'[W ORE>UT4>TGW#V< M>QXI P ,U:1 T'[W ORE' #-6D?]!^] [I7M=%'M)]P]G'L>\*?  
\U:1 P!! M^] [I1 PS5I' 0?O?\ ORE>UT4>TGW#V<>QXI PS5I' 0?O?^ \*4?#-6D M?]!^] [I7M=%'M)]P]G'L>\*?  
\U:1 T'[W +\I2+^S7I\*# ;]R, ZE\*] MLIL?^J3 '11[2?UT4>T MGW#V<>QXI PS5I'  
\$'[W ORE' #-6D?]!^1 P" \*5[711[2?UT4>TGW#V<>QXI PS5I' 0?O? ORE' M #-6D?\ 0?O?^ \*5[711[2?  
UT4>TGW#V<>QXI PS5I' \$'[W ORE' #-6D?]!^] P" \*5[711[2?UT4>TGW#V<>QXI PS5I' 0? MO?\ ORE' #-6D?\ 0?O?  
^ \*5[711[2?UT4>TGW#V<>QXI PS5I' \$'[W ORE' #-6D?]!^] P" \*5[7 M11[2?UT4>TGW#V<>QXI MPS5I' 0?O? ORE' #-6D?\ 0?O?^ \*5[711[2?UT4>TGW#V<>QXI PS5I' OXF/V:!]0?V >\"^12E X9JTC H/ MWO\ WY2O:5^ P#O?  
T%.H]I/N'LX]CO3 AFK2\ H/WO ?E\*/^&:M( Z#)] M -^4KVNBCVD^X>SCV/%/^&:M( Z#)] WY2C (9JTC H/WO  
'Y2O:Z\*/:3[ M A/.8/4 X9JTC H/WO\ WY2C AFK2\ H/WO ?E\*]KHH]I/N'LX]CO3 (9J MTC H/WO  
'Y2C AFK2/^@ > ^4KVNBCVD^X>SCV/%/^&:M( P" @ > ]^4I/ M^&:](W\$?V > \ '4I7ME-'^M; =']:/3[A/.8/6 X9JTC  
\*#)] WY2C A MFK2/^@ > P#?E\*]KHH]I/N'LX]CO3 AFK2/^@ > ]^4H P"&:M( Z#)] P!^  
M4KVNBCVD^X>SCV/%/^&:M( Z#)] -^4H X9JTC \*#)] WY2O:Z\*/:3[A/. M/8/4 P"&:M( Z#)] P!^4H X9JTC H/WO ?  
E\*]KHH]I/N'LX]CO3 AFK2\ MH/WO ?E\*/^&:M( Z#)] -^4KVNBCVD^X>SCV/\$ ^&:](W ?V > \@G 4I2\_<  
M,U:1 P!!^] [I7M] UJ P"Z?Z4ZCVD^X>SCV/%/^&:M( Z#)] WY2C (9J MTC H/WO 'Y2O:Z\*/:3[A/.8/4 X9JTC H/WO  
WY2C AFK2\ H/WO ?E\* M]KHH]I/N'LX]CO3 (9JTC H/WO\ 'Y2C AFK2/^@ > ]^4KVNBCVD^X>SCV  
M/%/^&:M( P" @ > ]^4H X9JTC H/WO\ WY2O:Z\*/:3[A/.8/4 X9JTC H/W M\ ?E\*#^S7I O P 3^]Y Z8I7M= <  
(> J 6CVD^X>SCV/%/^&:M( P" @ > ]^4H MX9JTC H/WO\ WY2O:Z\*/:3[A/.8/4 X9JTC H/WO ?E\*^ AFK2/^@ > \ M?  
E\*]KHH]I/N'LX]CO3 AFK2/^@ > P#?E\*^&:M( P" @ > ]^4KVNBCVD^X>MSCV/%^ AFK2/^@ > \ ?E\*/^&:M( Z#)]  
[ WY2O:Z\*/:3[A/.8/4 X9JTC M \*#)] WY2C AFK2/^@ > P#?E\*]KHH]I/N'LX]CO0 LUZ0/^8 > ]^4H P"&:M: M( Z#)]  
[ P!^4KVNBCVD^X>SCV/%/^&:M( Z#)] -^4H X9JTC \*#)] WY2O:Z\*/:3[A/.8/4 P"&:M( Z#)] P!^4H X9JTC H/WO ?E\*]KHH]I/N'LX]CO3 AFK M2\ H/WO ?  
E\*/^&:M( Z#)] -^4KVNBCVD^X>SCV/%/^&:M( Z#)] WY2NF  
M%\_P]X.U9=3\$L^HWD8\_=BT4G4DU:X\*\$5T"BBBH+"BB MN;:=^--/P'X8?6+Z%[C]XL44",%CG.!D]. 3^%  
'245XG)\5/B3IMDOB#? M T\*>F^8^6S"=\$/0M(Q^I0#Z5N^-/B;JUKH?A6^#6=I>R>  
(I/+ABO5.FVFLVMJ?"VIA4BOTC8/#(>.Q;:@GH/E/L: /1J\* M\ V\* \$V\4ZUK^HPP06 @ 1XF(O)(7\Z=E&20=VT  
\$XQG!7/7CF( CAXE3R M/\$-[X56+P;<7/D)= DS\* <%B=V.Q A)! .. /<\*\*\U=:\$77M\40>& FC M0:OJ1M/MLYF8[4C]  
R\X&>O<8!S3+XOMJ'PM/BBST&XN;X7)LOL%N3)B4# M.20,A,8/3N!T >FT5YGX&^(^OZEXQF\\*>.-"CT05?  
(^TPFW/R%, X(+S[@ M]B, BO3\* "BBB@ HHHH \*\*\*\* "FQ P"J3 =%.IL?^J3 '10 ZBBB@ HK.L] M?TO4%U!K.  
[67^S9G@NP%(.3J,L", B.#VJS87UOJFFVU 8R>:W4\*30R,2N M]&  
93@X(R",#0!8HJG&KV&E6\I\_ YI(4E118P"Z!@67/3([9P: 'T444 %%85YXU\?:]3V5Y]\*Q2ON\$DD M,;^5\$QQA7E V(>1PS  
\BMW KTH \*\*\*JWNI6FG-;+>2^6;J=;>'Y2=TA!(' XX M4\GB@"U1110 444CNL;[L%51DL3@ >M  
"T52TK6+/#6[1KG2[E;B%9'B9E!& M&1BK @]5/UZC@U=H \*\*\*\* "BBB@ HHHH Y[6 &G^'M0^RWL-R\CH) 8E4C  
M!X[L.>#6= PL[10^?:^ [I \77.?\$O )&B+ KU7 T]Y"OJL)E>&JT(U)) MW:[GS^](Q:G5E".R/4O^%G:- P  
^U1 W[3 XNC A9VC?^U1 P!^T \ BZ\ M MHK\ L?"IG]YA :6(ON/4O\ A9VC?^U1 W[3 XNC A9VC?^U1 W[3 .+K  
MRVBC^Q+V?WA :6(ON/4O\ A9VC?^U1 W[3 XNC A9VC?^U1 W[3 .+K MRVBC^Q+V?WA :6(ON/4O\ A9VC?  
^U1 W[3 XNC A9VC?^U1 W[3 .+K MRVBC^Q+V?WA :6(ON/4O\ A9VC?^U1 W[3 XND'Q,T;>3]FON0! JT \  
MBZ\NHH L?"IG]X?VEB/+[CU+ A9VC?/M??]^T ^+H X6=HW /M??^?M/ M (NO+\*/[PO9 >'I8CR^X]2 X6=HW #  
[7W ?M/ BZ/^%G:- S[7W '3 M P"+KRVBC^Q+V?WA :6(ON/4O^%G:- P ^U1 W[3 XNC A9VC?^U1 P!^ MT \  
BZ\MHH L?"IG]X?VEB/+[CU+ A9VC?/M??]^T ^+H X6=HW /M??^?M/M/ (NO+\*/[PO9 >'I8CR^X]2 X6=HW #  
[7W ?M/ BZ/^%G:- S[7W M '3 P"+KRVBC^Q+V?WA :6(ON/43\3-&W@ 9K!@#\$ZM/ (NE P%"G:- MS[7W ?  
M/ BZ\MHH L?"IG]X?VEB/+[CU+ A9VC?^U1 W[3 .+H P%"G:- MS[7W ?M/ BZ\MHH L?"IG]X?VEB/+[CU+ A9VC?  
^U1 W[3 .+H P%"G:- MS[7W ?M/ BZ\MHH L?"IG]X?VEB/+[CU+ A9VC?^U1 W[3 .+H P%"G:- MS[7W ?  
M/ BZ\MHH L?"IG]X?VEB/+[CU+ A9VC?^U1 W[3 .+H P%"G:- MS[7W ?M/ BZ\MHH L?"IG]X?VEB/+[CU+ A9VC?  
^U1 W[3 .+H P%"G:- MS[7W ?M/ BZ\MHH L?"IG]X?VEB/+[CU+ A9VC?^U1 W[3 .+H P%"G:- MS[7W ?  
!=>6T4?V/A>S^/[2O'E]OZE PL[10^?:^ [I \71 PL[10^?: M^ [I \ %UY:11 8^%  
/[P M+\$>7WJ7 "SM& Y]K\_ OVG\_Q=:VA>+M\03R M0VGFQ2H,A)P 6'J,\$Y07B]/@GEMITFMY&BE0Y5T."#6=3)<.X-  
0NF5#,ZRDG M+5'T#17-^\$/%4>OV?DW!"7T\*CS% YZ#^VZCM725\I6HSHS=.:U1#3J1JP4 MX,\*\*\*\*R!-&Z?B\*6D;I^(I:  
"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "O(O MVBM-N;GP5I^H01F>#3[Y9+B(#C8P'W'VS@?  
"KUVFR1I+&T!VD=SZ7T+@@XAP.? M0!=^2K6G^!/#^G:IEBEFY6DS&:R-PYD!:BV[0].>P% SP\_5O#+>\$OB1  
MUO\5-8U#Q%HLSYL[VXNF/F\\_)GZWX?TGQ'8K9Z[80WUNKAU29AY- M067A+0M.UIM7L]ACU!X \*\_YY9RN,\_9)]%  
^@H @\!W%R?A?XK^%U8-:> (MM/L[G;X;&D2\*2",=3E@,]PR<^G-W?BS2; ]G73?"5G.TNO/<+ +!(V,FX3E  
MO3'(O^)Q7T0WA01V1+KOL(AJBIY?VH9#E<8P<=>/6]B! #\$>O'6H]"LEU\$ MR> II\$0W: [WU]YZT>8'4/[P)^T!  
<7WBBX6SM+OP %%X)5F7RP1QWS\$WZ M>M9OPP[5CP)\*K O??:>75E?:TX7R /W:[%&]L]MP\* 45[3KGA700\$RQ#7]  
M\*M; ,G/E:&,\$IGK@10#@<>U6\$T32X%!.D1Z?;)J0QFT6)1%M/4;>E 'B?A  
M'5K"V^/B#PEJC^)+76K9I+^ZN(MTML0%.%D\*@A1M0;>F"!U Q[U61H?A/0?# M1E.@Z3:V#38\QH8\,P'0\$]<>U:]  
@HHHH \*\*\*\* "BBB@ IL?^J3 '13J; M \*I/|T4 5-5BNYK\$K8.4ER#P<\$CT![5-8I/8Q)=OOF ^9JGHJN9\O\*9>S2J  
M>TN]K>1Y\$:6[TB#Q#XFT:T^T\$:E?VVJ0)P\UON)5QV+1DDX[JS#TJM;ZK)9> M'!=!BU&]^PV:^&[\$63G5]  
[&4QG>5\$2,"R?\*WM@<:]FHJ34@/51H(+X:I  
M>RC5+W1M\*/RSRH)76Y82LD;8QC\*E05+9P"QS\27.MZ3JOB#30#]S?26<. MG3.)+J65X(WEE\$[J:G4;\$.2N<#)  
S7JE% 'DUEJ-I? &HV>M/-H]QJ.G11 M"TU"Y9,9:7\*JW+HA96&,A68J<1,BC7D.C^)->@TZ]U\*^>4?:8;B::867F  
M19Y54L2=HX+ \$KDXZFO6:/\* /'=8UBXFDE X1S6;^709=4TN&[2D?+O\*RSQ MI\*6+ -NS(R0"  
<>HKLO!EO<+XG\6Z9)=7\$]K87L\*VRW\$S2M'@1F&YR6(R2>3 MQ7844 >1)]I;&^U9=^UMK6ZEFE::POJ=B+J+43R  
8UQNVR Y7(!)SCFMK4 M[6E\3)X=B^T6:ZX;>ZMIE=L6R1?M4\*D?=^5%QC',IKT.LQ=@ X20ZU-/<  
M3W"O&".1QY=NIV[MB@#EMH))R>,PXH Y# 28HK#5%U'4#<2^)IK9E:D,?D M :I8 +\O.W&U1CC(1:R'N[>I[U?  
08[W4 YM?AUXM>6;2RLD2E10N8R=B+M\*!6 M &??)->LT4>965R;?P;H.HZOJNHI975T[:G>->S?\*H67RP6#?NTW;  
2N,X7 M)YY+XDU+7-)M;75=4ET6YU.Z%O+JJE1KB!,96 \S= E\\$N\!LYPO4CKZ;10!  
MY=I\ M\_9S%^+F#4M1GFN]3OK66,XO9)\$FC19+4JS\$<>6GS=>,DDDT>#=3N; M  
%C2K:34M]X('K6S:EIQDGN&M6UG7DN--M/.B6!4+>8BX;+')J\*YS A!/\$G 0. M\CO %5]M@<30AAH1E-  
J\VIH^6O="K\*O]J:+:OV9SU%# =# ,(OJD Z!W D>\ M^\*H X03Q) T#O\_ (? O5=GUS#?/R/WHYOJU? D?  
W,YZBNA X03Q) T#O\_ M "/ P#%4? \ ""> /@= P"1X \ XJCZYAO^?D?O0?5J P#( N9SU%# P ( M)XD Z!W  
)C P#BJ\ A!/\$G 0. P#(1\51)/^@= Y'C /BJ/KF& P?"D?O0?5J M\C^YG/45T\ P@GB3 H?'^1X P#XJD X03Q'G]G<  
7>/ .H^N8; GY' M\T'U:O\ R/F< 170 \ ""> /@= P"1X \ XJC (03Q) T#O\ R/ /%4 M?7,- P ( >@^K5 Y]S.>HKh?  
A!/G 0. P#(1\51 P@GB3 H?'^1X M P#XJCZYAO\ GY\T'U:O ( N9SU%# =# OXD Z!W D>\ ^\*H X03Q) T# MO ()?  
Q5'US#? (\ >@^K5 Y]S.>HKh?^\$2? [ R' \51 P@GB3 H'? M^1X BJ/KF& Y^1^!]6K R/[F<]170 \  
(XOZ!W D>\ XJC A!/\$G \_#O M (\ P 51)@^K5 Y]S.>HKh?^\$2? [ R' \51 P@GB3 M H'?

^1X\_BJ/KF& Y^1^!\_!6K\_R/[F<]170 \0XD\_Z!W\_D>/ XJC\_A!/\$G\_M \$#O\_(!? P 51)/ P\*\*H^N8; GY[T'U:O\_ "[F<]170 \_\0XD\_P" @= Y'C \ MBJ/^\$\$2?|\_ P\_CQ \ Q5'US#?(\_>@^K5\_P"1\_ \ ^\*H^N8;\_ )^1^!]\_!6K\_R/[F<\_170 P#"">)/ M^@= Y'C /BJ/^\$\$2?|\_ R'/ \51/\_ XJCZYAO^?D?OO?5J \C^YG/45T/ "">)/^ M@= Y'C ^\*K8-#VZ>^\_OB"RH(\%8A(I,JRI\_.!6=3'X:G!RYT=FFRX82O M.2CRM>J&>!O" <|W=1.M=EX+>MT(4E6E(|\_O[Z].IL<:11K'&H5\$ 55 P ! MVIU?&8O%3Q53GE\cz:#8>.'ARO"BBBN0Z1&Z?B\*6D;I^(: BBB@ HHHH \* M\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HH MHH \*\*\*\* "FO\_ZI/|T4ZFO\_ZI/|T4 .HJO?7T6GV G3[BN< \*\_DFGVUREW;) M#G8XR,C!|KM? H1[2//R7U]:\*GN %\#: .V|@<'078W/C>WL8[QKK3[R0:7"DFIRVX1DM"R!R#E@S84Y.T-Q^5(L MZ>BN:N?.G07%XL5M>75M82107EY B&\*!G"D Y8,>]48 \$TT/B\* M>"^N[@QIJ-S%#%#&5..U23.S!&"6((Y)X/% '9T5RL'Q!TUM-BU"!LKZP\_MLI]/?489[A(R)8456; 1V8'#!<#/KFG>\*X|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|319^/4>XKFO.34\_9WH?%^900S.?/KL>V4 M55TW4K;5M/CO+)T4@XSU! [@[CUJU7RLHN+<9:H]-25T%/%(84444 -^M7 M =/I\*=33\_K5\_W3\_2G4 %%% !1110 4444 %%% !2'JOUI:0]5^M "T444 M%/% !1110 4444 %%% "-T \$4M(W3\12T %%% !1110 4444 %%% !11 M10 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %-C M -4G^Z\*=38 ]4G^Z\* '2)-D\*2HKJ>JL,@TJJ\*%10JC@ # %+10\*ROF- 8MO>2)@ C\$ESB,[G'R]=Z#HH Y\_4]U235I=0T'6 MQ827\*)<0W-K|IB8+G#\*NY2C?.03D@<<51E^'FGW%C96EQ. [QVEMJ> M\$-2OX[ZPB\0-'H^H&3[1:36:RR\*)"2XCD)&T\$DXW\*V,!=?<^I9/6@VFE M1W4&EZ3:\*E\|D1SK'M:V16/WV5\L<=. <|17>44 W\!S6=W:16>LM'I%IJ!U"&O-N"PD9F9E,F[E,N MO OD=R<5V5% '+2^"Z/8P6^H& TZ|EO+2[GTGX=1N3>OSJ|VZZE,(193)F>W5\$4Y%"N#U8\B@#CK7P L% MKIL#ZCYBV6K7&I'QCS!)Y?WN,>|[G.WH,1^'OAS!H&IVDL<|G):V (M M8UTN%9;=H|R<@LO /5=A?/-=K10 4444 %%% !1110!Y5\2 ^1HB\_Z5\_M":N0KUGQ)X\* P"SCU47?V [-LC\$6SR=^<\$G.=P\_O5D?\*K .HS P"2O\_V= M?78/. <+2P(3E9I=G D?.8G!8B16E\*='YH\|HKT+ A5? 49 P#)7 [\_.A5 M? 49 P#)7 [\_.NO\ M7! S @\_ \CG +/O\OXK\_\|HKT+ A5? 49 P#)7 [\_.MC A5? 49 P#)7 [\_.C^U<^# R#^S13 +^\* P\_SSVBO00\ A5? %&?)7 M .SH P%"5 \ 49 \E?\|C^U<^# R#^S13 +^\* P\_SSVBO00\ A5? M %&?)7 .SI/^%6?1 :0 P#K \ 9T?VK@ Y\_P 49 P#)7 [\_.C^U<^# R#^S13 +^\* P\_SSVBO00\ A5? M %&?)7 .SI/^%6?1 :0 P#K \ 9T?VK@ Y\_P 'D\GXG^7\5 F>?4 M5Z% PJO \*C/ DK /9T?\*K P"HS Y\* P#V='|JX\ G ! Y! 9^) E %?Y MGGM:&BZ+=Z|J"VMFON\A^!&QJ:[+ A5? 49 \E? +.NQ731+30M/6ULU|Y) M#|Z1O4URXG.\*:? [EWEZ/3[S>AEM64\_WJLA=\$T6UT+35M+, <=7<|7;U%-%M?)3G\*J6)U&Q."R>6=P8'L? 8U+8VWV.QB@+ER@ON/>JLN6]3+ MFG[3EMI;5=:C;VN^VMVXR&..?ES\O ('<!\&M M#7 %6F^'+K3+?# (9=3N1;PB, [?5VR1A!D G :%<=J|IM=(V)7&D)K^@ZTM MO\*=Q8O275I?/ !(62\$ATP,E%W)+.7QA- X<2.2&EA\$4;>C^5&N1UR#Z4 ;FO>+K?0[Z.R33M2U6)>+SFM]-@(\$KO1YOO;) ) M! [G!P#BM73- 2MM7TNWU"PD\RWNS#HV,"H1V(Z\$=C7\*)>K6.X\2LUS:ZOIK MBT5.;6M'\R5W^9B89(T1N%)W#<"#N..<6\O->T70- #\4ZE;2W&M1QSZ:T\* MH%>Z\$K?Z.77HK%TBR.WF-]\* /3ZH:Y]OH&@WNK7B2;/V4+32+\$ 6\*J.G ) MS^ (KSF7P)%]MUN"[T]L6F@6JV]9?B31KW4=- M2MXAT? 5=1U"73H1HTD=O+,\$)MP'5=@/EMYF[&P6SWZ4#/9H95GMXYD!"R\*& M /7!:&?7D>I>&M2D7Q7J-CIEX- 1\^Q%O+\$#'.\D6XG6%CCDJJK<.1CJ\*,J M>AW#?VS!X6TJ M/#|EG:#|]GEAWW7VI69TC8!@1&!N8 #CO- CUZBO)& ( M&UUGQ=]CTBYC@L;FRGT18XW"1.40S/.F2P^8K[@TW5=^UE \$V7/|G.V?V MBIT^&I/+)'#E- HCD'[I4QD,K/\_XL@YY /7:\*\*\* "BBB@ HHHH \*\*\*\* "BBB M@ HHHH \J^? (T1?>J P#H35R=? \$O\ Y&B+ KU7 P!":N0K|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| ^@?/(CKW\_0+G (4? "):G!]ESY^@KH?^%HWO M 0.@ P"VH X6A>[B?!.@Y&OFCCV9?^X ? P \$/9X+^= = P YI A\$=> MZ!< Y'C (1'7O\ H%\$ )NA X6C> 1Z# +[:C A:- T#H/^ VH]MF7 M#[C] \ P0]G@? YW|W .> X1'7O^@7/^0KNO!W@Q-+6/4-27=>\$92-AQ# 1M>L: (6C> \ 0. @ [NP\^)K7Q%:6H P!W;"?X?<N\*X.? 6Q L??BH MQZV.O!T\|7W)7?F=%%%-?N!1110 4444 -\ K5\_W3\_2G4T ZU? =\ M2G4 %%% !1110 4444 %%% !2'JOUI:0]5^M "T444 %%% !1110 4444 M %%% "-T \$4M(W3\12T %%% !1110 4444 %%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%% !1110 4444 %-C P!4G^Z\*=38 ]4G^ MZ\* \*NJ7DEC8//#YC @<|[F1:= [FRFBFDC\MG7)7T]>BJNN6UC/EE[3FOI; M;]3R5+24X \$L<>CZO=ZJVIW<=K>6\|C(D;:CY?S[P%"G' UZO^, B!J0@^0+ M)>:6M;6.26TG=VNKOL97\$ITX2EOFYX\*9P.O(XSD)I/CGO.]IIUFRTH6EQ\ MVBS?96D\SST\ S|ZN[@(?+ (VGGOGM780^%).@U9]219/M#W\*W3\$OOYBVYMP<> MGED>O-1CPA12B !)? 1]4DU9/WG\_+=RY8\_3]XW% S TGQAKUW+I.JW=II\_M@:W/Y-JL<74 8,8WD).UL[>0 -NX'0\$?BBYN-%N?L].BT\_6H\6XM M'291OW<\$J.<#[O R>M:=GX(TBRO[.XB^U-9RM-:VCW+&W=L@E\$S@ M?> Z# /%5?"7@F#0]TB6\ENYKZRM%C\$.@QU=-!+.- \$EA.%9=1@ADM(K M.\*\*]>-9HXTV\*&P>?EX/KWS5J7P-H\|OK4 JS%)/\$6G:UXSEFOM(^R6- U;PVOV^5H8K'3H[B!]5M9%F52K@,=W!;GJ#C@UU&I!\_)U2\N[J9KN\*6[E MAG2XN6D9IHP I).. #'3C MC% \$7BFY0+P;;3W\*?>1WEAYL=EHD?|5" &5-QZ'D#)Z'FL+3=?6QTWQ+XI MU[32:OI7F1SZ>^6T11OCCC[Y&3@|1D\T"//:#XO74] MKJ=N)-&U'4;>R% I;R->TGD8WIC1/N\_X "P^8< \$H\_8 CYK!^)2"5A% .YY M8CQ%@>-HW V;K!

(XHPO8<#ESD9/05TJ^!M+\BYCN9]0NS<0K SW-X\A6-6# M!5R<#D#G&3W-  
/UGP3I6N:A/>7;WD4EU;"UN1;W3Q+/\$"2%8 ]/F;ICK@/4#. M8M %WB2:IN-8MTLIM-N=(T^YM-  
:/>L@DN6=8P7SM'S\;F,2&TD62-G\$BC,X\$8P5)/W3SR".G'@#1FBO M!W4MY%,]Q/=TJ219\MT?JA&3C&/YU:@)  
(Z="L6^6\N)([U;[S;BY:1V ME52HR3V /08% "7OCSQ787FIUEI% S::9J4&GRHIDCDF>5(\%220H#R=2#D  
M<<\$9.K=^\*=?TOPY?R:H^@6^H6>H"U>YFG>&T5&B20/ACN9@' V@Y)&\*V[CP M9I-T+  
[S4E TZ^BOYL28S+'LVD>@ =KQ2ZOX/TO66\RZ^T1S"\6^2:"8QO^\*L M8C!!::H#D4#.8TO6M>\?]  
A"Z@1O(N!&JRHRJX+ \$M&" M#VW=1C/2II&LKXP M%M6W:<:7R6MBJ[M 4.#M]2? P!7%6M!\.V7AR\*[2P>X M?  
[9<&YF:XF.K-(552VYN>0H I6K0(Q/"ND:AHFE26NJ:@;^1IWF\$A &W>=[# MH.-/[C\_9Q]\*VZ\*\* /\*OB7 R-\$7\_7JO\Z\$UO%DG1DL8S^?IO] JE:OKU\*=.FY5 M=C6E="\*H"!O,=<+UQP1W)JK P@GAO H?'^1Y/  
M\_BJWU^\_\1\_04ZNB.)KP7+&:2]68RH4I.[BF 1'/?\O(X: Z!W D>3 XJC A M!/#? 0. \CR? %5T-%/ZYB?^?DOO8OJU#^?1  
& \H?'^1Y/ (JNAHH^N8G )^2^A]16H?R+[D<] P@GAO \*!W D>3 M P^\*H X03PW - [ P CR?\ Q5=#11]"& P#H'?  
D>3 .\*KH:\*/KF) Y^2^A]16H?R+[D<] M P (X; .@= P"1Y\ XJFCP)X<[PC^SN,# EO] [5='31 K6 W1 6CZYB M?^?  
DOO8?5J'B^Y&! P@GAO \*!W D>3 P^\*H X03PW - [ P CR?\ Q5=# M11]'K45IR;]7=&:Q=J M'A7PC NARF'4-  
0N1;OR!02BX)8C/ /091 :MMD9;L]#HKO?5 A5K,@^\$Y=@/4D'N.>,KOMXG/B'P/X!U36=0N-/M|ZX== M0GLV9&"J0KL ?  
0D#!^E\*X[OM%,&L:EH^D:AI4OPM\8Z|JVJO=JAM;LN4; M/3|R(#DX&.N 3GYJY66V M0Z?;.+XGIXEOY-5DN -  
FMY)"8&0R% NT8XXY'3!P,47#E/H^BO'/\$\*W?O\$ M^+0\KJU]IFGV.D"\Q9R["\C]?"  
7'F)^1OC.:Y|3 \$GB 4 @3>"ROK]:ZTW M4F@OKE)G%H\$W\$ACR<\$XR.<#TS1<.4^A\*\*\6^'UVL Q+CC)  
:IJ6I> &%M\_ZH MU^[\\$.E(9?MW@\$.2%Z#^]VZ>TTT[B:L%%%,04444 %%% !2#H\*6D'04ABT5 M6OKO;&V\UE+X  
'SZY3?:EB9695?:D8"X6.NHKD++OS)\*;^)M4O->T&[O+ "33=^N(Y|A'6[\SSH ]W+YB #:V.0/F[\Y%PL  
M=W17%V/O%"S'+)/8PO\*]E+>V:QWRRM\*B\*&\*R #]VV" #CYAUZR,5-)XNU@6JH MT/AV-Y|NVFNXHFU  
\*%AC(KEFV '#S?NC."N#D%PLSKJ\*Y'0?'"\$NM7%HKZ-) M!%J&GM?V)\$ZN\JKL#\*R\!&S(N/F((ZD=?HOC.6 \6/X?  
U+3X;.^RM=)]GO M5N \$#!2KX V\PXY'7FBX6.KHHHIB"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* M .9\1^,/^\$?  
U)+7#]HWQ"3=YYW&21C&T^E9/ "S/^H3 P"3/ V%9 Q& P"1 MC@ Z15\_1":N3KZG!Y?AJE".Y1U?  
F P#, \#\$XRO" M\*,9:+R1WG "S/^H3 P"3 M/ V%" "S/^H3 P"3/ V%<175 9F\$ D % YF'U!\$?S?@O\CO/^%F?]0G P F M?  
L\*/^%F?]0G P F? L\*X.BC^S,) )^+ P P^O8C^;% D=Y P +, ZA/ DS M P#84? \ "S/^H3 Y, \V%  
<'11 9F\$ D % YA] >O'WX+ (1#L B;/S721WE M@UO\$OP9%EW[?J-HXKM%8.H9"&5AD\$'@BO\*["P3XDN(+V+2KC?-  
;RG;%@9,9 M P#B?Y5Y^.RN\$8>TH\*UMT=F%O\G+DJ]>IZ/2=Z6D[U\>V+1113\$%% !11 M10 4444 %%  
"=Z6D[TM(84444O!1110 4444 %% !24M)0 M%% !111 M0 4444 %% !1110 E+24M !1110 4444 %% !1110  
4444 6T U: 044 M) JU^@HK V^K P"l;ZFN#^+?@N\:>\$8X-(V?VC9W"SP;GV;N"&7:/@Y^H% = MX\_<  
K&^II\*VW1ELSY^USQ9(6=5M)]-AF^MLV4D%YBTW12\\$,Z,5X8@]\_]  
MA5J/0AJWA#X8V]AIMUJ% C;7^+>B9<>O!&-F]<,G@@5[O12L/F/%"G@ MZ\#>=^7>  
J&>>T9PFHZ;90\|C/5(P.,C/(Z'V)J7Q;:ZU\2\_5AX>^P:C M8^%+8+>P&2H9@/[P4#UW'G  
KUZBBP7/&O#/AO60#]UXB^=Y#>S M:.%J-M\*= -U\$6[-\$74C:[@84XZ@9^USS1TCX@7\_ (2M/AG+X;:""X'F:L0  
M3"8JY<\$-C;P3G@Y( & :^BJ\* 4.8@/6:?XB\\$ .\\$!%?A?09], M[??UXKZ  
HHY0YCQ[0M+U3Q!\_6M\1Z9X8N?"^E?:F&Z2YB%NUPO5^ @^L MHSTP,^@KV&BBFE83=PHHHIB"BBB@ HHHH  
\*0=1!2T@Z"D,1T212LBZGJ&&12 MJH50J@ #H.E+13%97N<]X.M (O;6UU\* M+&^>1Y(.\\$O>63) K,%D+\*&R20  
M&,&G\*&6Y\&V4TUX;>[O:&^"IM[6152;8H4O-#12'M;6D>%/16M&MIKF5K6\*> M-6F<-N\YT=B>!WC7 &  
!D8Z8V]\*+!\*&STR73\$(E"LT4FS<2 M0!W|L8(P.3O2Z1X&L-&UV'5H:JZEN:(1K1%-8D3RR5/W8T49RHZ^N>,-=1  
M18+L\*\*\*\*8@HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@#S/XC?C! UZK .A- M7)U[N.]>7MX?-O8TE3Y+V\ ^  
>76R[VE1SYM + @G@%>450 ;? 3O?^ 9 M?V7 ' P P">#T5[Q11 ;? \$! ! X?V7 ?\ P X)X/17O%'\M ]. O \_MX ?  
V7 ? X)X9;6LUYR+B63.0/9?;^ M=,U%<.,S\*>)CR)E\>4>@+1113\$%% !1110 44 M44 %%  
"=Z6D[TM(84444O!1110 4444 %% !24M)0 M%% !1110 4444 M4 %% !1110 E+24M !1110 4444 %% !1110  
4444 6T P!6OT%?"ZM M?H\*\*P-B-H,L3NZGTI/L ^U^E3457.QWUM;R'#!99E0D8ZX]C4? PD&C?]!>O \ E\>:M0JM72?  
W\$.5-S9: ^S M .U^E'V : 2JO\ PD&C?]!>O \ E\>:A(-& P"@O8 ^!\*>XT 9U?Y7] MPN>GW7WEKI/\_+7Z4?9 \_JK]\_>  
"0:- P!!>O \^4 OH X2#1O^@O8 ^!\*>MXT>SJ RO[@YZ=?>6OL ^U^E'V? &OTJK PD&C?]!>O \ P# E\>:C A(-&  
MZ"IC P"!\*>XT>SJ RO[@YZ=?>6OL \ M?I1\G VOTJ\*WU;3KR816FH6L\A& M0D4RL?  
R!JW42YXNTM"ERRU1#]G VOTI!!\Y&[L.U3TT?ZUO]T?UI3P7IE^B^:;V6H\*T\?8AE(!/X)?\H K\9\_&A9QZOJ P  
M GM\\$8JS3AV#(C\\$8;7WXR #QS71^>OB=<:-T'AV^)6\\$6LC7I-ENK,REL@:  
M0!ZY\_.&LOO=:\!LOA.\LK>>2Y M'3)5A,2JRJI(5\$;KNW(0<=5 ]:X?4]&  
MO9 AS\*=,6[ETZZNKUA%=1YWP>9(&1Q@@Y 8\$[IRS?QOX+;2 M]N)UA>Z#M\|F>IZ\$\$@ G'&0#73^(/B-  
<^%OB)I^D:W8Q0Z#J2@0:KN.%?"W6 M[?>Q1 P/K7DVI^%KS1?BCHVB?\$\_Q#J6L:/ M>O/ < "58=9AL/  
&E6PO-.6,\$8%N@) ^/8G! ^B[B>V0#H/#7Q+'B?Q' MKKV<\$2>%!B+-JS;OWK@ L .F -  
QSSP!ZUR\QVU\$W<&IW7A;6#PG<7?V=-4 M9FR%W% =YXQV'L1DD5G> KTO\%?O@9[\$VNO:5:W:S08YFW!L-  
GN< +Z8^"M M<[?^\*]\$N?V9=.(V\|)J[3+"[\$G,@83E\1T!!&WSCK0!ZKXZ^)>HZ#XCM MM  
\*:. ;NHR6QNYD5S^ZCSQP!R3R?RZYJK\_ !1USQ!X!L=>^> &[1NY+E[ M]>[L -+>05&<[AC.^8G M& Y^M2?  
JZ LOX8^ (M;E!^RK>W%RB'C\*I\$) 3'X4 70?"Q0\7:YX C\ZIX M4BLC&N^]=9&9K9" I\*ENPR<<GFO6:\^#\_C, A"?  
Q)J#B34?5U)?7# 8"C< M551[ D#MNO7H= @HHHH \*\*\*\* "BBB@ IL?^J3 =%.IL?^J3 =% "NZOH7D8  
M\*HZLOP!2@A@#D'D\$=ZJ;E8#4/R#(8 F#!@, I4EE:BSLX[=6+A!C<>]5:/ M+>^IGS3]I:WNVW\SGM'\  
<6NK77B" T\$!AO-%FE0PL^?C3(@..A\*L,8G(/88(ST8 D52B)>(:/3M.5K%KC'A^SL98%BM MIO+DC1A)&3\*X  
4EARN<YZ#,FIUNO^/-)T2: ^LTG@N-2L4@DDL M'HVV60)[  
MG(!#8Z,O]X5M6>M:7J%I+=6&I6=U;P\\$B6:"=72,@9@<# ]:X35O"6J2Z3 M-  
9)IANY])TVV:4RQ>9!S2ABQ!.581Z|]\$NEC4HM5L7L<"Z6Y0Q\$YQC? MG'ZU3T[QEX?U:4[RQT[5].XFLX5GE,6P  
MN41I(TCN%@D!D@.3D\$CGD;3CDT =G'XAT6;3TOH=7L)+.240I<+%M\$N]\*5>\*KB:V6"SOKR&6TV MLN'  
A56.TCY@>H:& \*]WXWU\*/4+TZ=X7NM2TO3[@VUS=6\ZM-O&-VR #=);+68H;Z^"-@  
MK)9EE/J"6"ZG9M>/N\VVXN\$]OMI(;YR<\$\$'T(-9^I  
M>+;"PU,ST^WFMKN[GO8[2:!+A?,MPZL0S\*,G^H<9SUK'.PM<"SLGCTZ(7B> M(I;Z60; DFYE8.6SS^>[9>,N..  
<8JA%X;U)=\\$M7/AYM/UE[J:53+#AXRTA MWCYMY#KD\$#H>N!0!V9\1Z(+>XG.L: ?Y-J%: >3[4FV\$,J6.  
<+D=,]:=+K^C MP6\$=1-JUC:2J7CN'N4\$;J.I#9P0\*Y&P\,WFG> & #@?1TN9;"Z>6[LD:+<^Y  
M90'R6",REP>3W/.2S\,7DWB2POY%CM+(:GIH [&VUS2;VZ6UL4LKBX>(3+%%<(SM&>C@ YVGUZ4MIK.F7][/9V.H  
MVES=6QO/#!.KO% O#D?C7\$6W@R]MSX9:WT^\*VELM3O9KF6/RPT44BSA&X/. M=/? SVSTXC) ^=&=J P#H35R%=?  
\$O\ Y&B+\_KU7 M\_P!":N0K[W\_ />A\CC\ >) ^H4445W'(%%% !1110!)<2VMPD]O(T05WG@7PC-) <0:S?SQQ+A[= M%+/GU/H/Y 3KY.:TJ\$J-5=FMO\ (I'+ZE6-7EAJGN>D4T?ZUO\ =!:=31 MK6 W1 6OBCZ@=1110 4444 %% !1110  
4444 -^M7 =/!\*33 K5 W3 2 MG4 %% !1110 4444 %% !1110 4444 %1W%M!>6 M[P7<,<,@P\A\X-/R/44;AZC\Z .);X- & N)I\_P#A'(\  
[RLK8EDVC M=UVKNVJ?0@#':K]EV- M-/T>TEBN;T:+;:BOEN;IV>)JV1T(! P 1C Z5T



M7QM^S5KR2>'+L7^@NV:S0[LDPLN>?+ NM]\* 7'!G3]K'P3^TCH:SZ!>"SUJ- M  
UUHMX0)X3ZX\_B7W%.KAY4VPIUXS2:/F^9<9Q]17BO[67QVOOV>:#2 M8]:F@N8[<6=O,8U.\D<\$ ^E>S+  
("0#SGGI7R9 P5"7;^RJ// ,4M?YM6-%7 MDDS6JW&T>+?# \X\*I> ("C[PYX=?P#I]HFJW\DTJWKNR\*! \$@>M?I"O  
M'3ITK^?OX%C (O=/SW76K:![\R+7]H|UU8JE&G\*)AAJDJD=2K>7!LK2Y MN"NO(T@7UP"  
<5 /O/6/%5WXV^\*OB 7=18O=WFI3LQ8Y\*\*CD ]B% ?T&7\$ M2W\$\$.L+9V2\*5/L",5^ OQX^'JY,?C5XT\W\;1/%J\$MQM?  
K+%(Q=77VP16N! M232FF?:+F%N=@ST\*^G?-?H6K< M@\$C=TYX?F D&2,=AD=\* -OXL?\$B^+^'Q\$0>--5C(N-  
6NFF6+ GFG2-#[ MA<"OUJ\_X)S\_!2Z^\$/P!MKO5H3!KGB,4ZI<1,NTO(P\_=H1[#^=]>SB9+V\*3W/\*  
MP]W5:6QS/\_!5A\_ LTOV\Q2\_K7YM\_LVR/VB/AJS\*=G]M0 XY[FOTM\_X\*G: M9=:A^S#<36\1DBM-0MY9V\"  
[L9\_.ORZ^"N6WAGXR>!=80"R6MKJ]O)(P/R MJN[&3^=&%CS46@O% )G]!1.\*;N/I4<=S'+#'(KAD= ZE>\*/>  
<:V;"A1ZDY/%?A#!:R26L%ILR[A(\$3NQ;H\*IC!>"39Y6, MO\*44C^@:X#S/M?M)\.-.71\_A]X:L0A3I-IMNFWT(C7-?CE^WY-  
:KX;?M/> M(Y61DTWQ"5U2VF\*X5F,/@4|R#6.\$K:W\.-M; MO8[./5)EO]\*EF;"23'AH@>@; !P: 3\_!O4\_6N?  
&\*2J^+^;86WL[5HPW\4\*F MW+VSVILDB11L\CK'&HRS,< #U-U\.:F>,[.NG\$ 1CX9 X4KXY M[!5Q P"@&OY^5 Y  
X\_W\* H(^// I3QQZ?V3<8' #7\^P P"0\*?W\*G + MW9&F?O1/Z\$/@?: ^#O@P/)^5: /H K\U ^"LW\_=O"O\  
V!F ]&BOTE^ MKB3X+^"F7D'2K? 1%?FU P5F Y+MX4 P" P,W HT5SX6 UC0VQ\ 9S M &?  
-2 :2U[O!H,BZC'8:MIMC]MM -7\*3' C9OX?K7(ZOH C;X! \$!8=074O M!GB[39=TEI/ C%OJ\$7RW-  
NV.&1^OX5V5L3RU7&6QRT?+?O&5Y',KX:W^IMJWA\*XFCFMX[AB\]E4)P(V/.SGITK&.'C4ES  
M4RYUY4URS\*GP+ Y+=X! [#5M P"C%K^@2OY^ @7@ '#P1SK5MCG IHM?T! M@Y!K/&Z31OA7[I&^3KC%?  
\*G[;O!&%K^TAI-OKGAI]#3/6G1E(Y67:E %U\ MB1NW/1NU?5N/EQ36X;KO]\*^G-QJ^?"S\_@H[7 AS86^GW5[9^+K&\$  
1\_VPA[T M+Z;UP3^/?KUXP"^?E@UAZCT.SUJS=>8[R!7 JLGD?A7SYXD X)O \* M274UROA?  
2I)!TTVY;5J!@UZ7UJE)6J1U./V\$X\_!+0^3]= P""M7C^+L6B MTGP=H^F7!&=7\$CRIGV4'-?\*/Q5^?-?  
C:XW:XYJ,>:GUAQQ'9JO2VA]DC \ M9NM?IC\_PZG^#W>^2'NQ&H?I]VG?I.J?@Z&^6^1J# "NH? \_&-5"KAHLATZ  
MTMS\WOW= \$7@3PC\8= U?XD6=UJ/ARSF6?RX4W(LP/R.Z Q\*II=V5^Z'@?QE MH7CW0+;7#/>I6N]::=  
(@&GM'#\*1CVZ>F.U?\* #J7X/8.:WQ&1T/ \$P ^QKT M\_P" G&WA7]FW7910\*.:YX@:>  
(QRZ=>WQEMG1&V8X(J)RQ5:G62<=UT-/" M=)-26YZO[3A]IGO3\ ZWX3UB/?8:I/;L^ .8R1A77W4X(^E?AI\=@!XJ\_9  
MW\5W. @^)M.F2Q\$FW3\64'R+M0?E(/I&.^?O:N[>.25;D,> MBL7Q5X-T/Q MWH^E^(M)M=:TZ4 \_;7T8=?  
P]PKGH5W1LGJF;5J7M;RVL?E3^SI\_P%)O%G MP?T.S. ^\*M+;QEH-J?\*M[B.4)=11^C,W7'YU[U??%\=/!T=G\*+/P-  
K4MX\ M5++-&%;ZD#@5VGCW @EY\ \$CS7&D+JGABXD;E;Y/D#Z)C^M,OVE;J&WUCRM&,\V\O MF0:3  
25W]F=OXF'8!S7HWI"?['FN?%[QUI?C?O#I\EE&TB9;A&O%P^IS\*< MIY8\ (!+=#7W+-  
P#@GC%OAO=0W@T&3O#>O>DFLS&95;U"XP\*^E,2U@T M^WCM[.):((UV)%&H54'8  
#H\*53%0C%PIJR" &'FYJ51ZDD:B.-0HVH \$/:O M\$ VJOV:= % :6 R:3?G[!K5BWFZ5JL2[G@D/;IT]#^=>W=6  
()QWI.6,T^H MKSXRB=LHJ6C/P" ^+P\.:? 'Q5\_9?BS2[C3;F"4RVVHPY6"9@>)87'5O; MK7T5%\?^"G/Q"^.G6VE^\*  
[\*'QML2\*J7#9=A1T!/0GZU^J\_BKP;H/CS29= M,\0:19ZU8/PT%Y\$"X9Z?A7RYXV\_X)>\_!OQ1/+I-OJ7A>9B6VZ?  
G45JJU..#V4Z;]QGGM] P %="O"XTT:->-8;4\_K#+<1A!ZY.\*^7\_C] M\_P % OB/\_.  
[&XTJ.1!/WAF7AK73&/G7^DDAY [YQ7U4O !(WP5O7=XUUUX\ M\_ /G&XCTS7J\_P] X)S\_!/P#=PW3:-  
XBO(ONOK, QF7/J%P!4V&CLAN%>3>NQ M^8WI\_!+^CC|HC7+>UT+39M/QR?Z7KLRE8(T)Y\*Y^ \_(?2OV>^"GP:/? K  
MX:>7X2\0F.RLT^>=^9)W)RS,?4G/TKL-+TFRT&SCM-.M(.^\*SB&\$M[:(H\_M5<7I@Y/N17-  
5K2J>2.FG2C3W.\$^/A\_XLKXW .P3J:>O(MKJ%N]K,T/#A&#&@]J^1/^3\_P &S9\_9S>>)"N.+  
MG4\_8XO\_=K7"XB%&)=3+\$T74::Z'TQ^S[ R1'P1\_V" H/ 0!7Y0?%9?^2[>% M?  
^P,W HT5^H7@ PW9^" #.F:8&5K'3H\$MX3,VY|JC R>]-?M ?L5> P! I M#Q5I^O\ BBXU:\*= LK? [+@N?  
\*39NW4:E2Z-;7/\*RM?Z?;A:2VUW;QW5O, NR2"6,&V>H( M/!%?GO\ M6?/\$X-  
3>]\5?"54LKTEIKCPW(V(ICU)@;^\$ [/2OT2]5'YTGW< M #@=Z\*=65^-Z\$Z<9;H\_KX3Z/?\br/>AWJHCP5HVL6%QIFJ6FN6PN+\*B/MT/F" MOWY(&O)OBC^S7X\$^+7B30? \$6MZ5MU\_1KE+FTU\*UO'\*&1@P#?  
>&1WKUE?N\5 MIB\*WMFI6L11^S5KB5Y\_XBUR"U/.:A?RV]FMBLZ1Q\$@[S(5).:/O0<>]<^ MWALR^+)=3E\$ZN[VU  
ME5C=13 F.-1C#;CR#[#K4C>,H=)\.:K;7]LM1#&T\$>TG&1R?SKM?LL28V\*L M841%&.>L\*S,21^\*M3U&  
<12PW,:\*BL@)4J\_=?2MU4IROS+I^-R'3FK>&O,2:5J\$"Q1OVJRX5.%MX [>F\*IZUX)'B;7X+C4VWZ?9IFWA5B  
MI\$IZR\$@<UM?4257ED4\_ =WJ6B:G\_8VL7)NYKE//@GVX! OI^" MJE^ (VKOI=CIC :FMHI+^>67AMA!R!CO4>J?  
#&S6.\*ZTP-:G;R"2VFDE=PI M[@C/0C@UJ>(/#1QK5KI63'OMKJ\_XD61=P; (( 6M'\*DZBJ?>1RUI0:9RFJ:I  
M9>5\$NBZI>3ZI&04A#,Y8\$!&IJ>:7Q" N; ^'PO +[:PNYIHHVGC7)3/7 \U M?USPHTY:ZAI9CLJ2@8'<%  
61">5;\\*L>+M'N?-TRVAA98I8KB.? OD\BCVE M+F@[:+!/U! GQ67H.M:S'C MBVGN'M!O+518K!U&44')/N.?OKKM6\  
(Z;KUQ93W\LMQ):-OBSQ@^ J/8\ M55F\ S'OA:ZFK\*+>.V:\$I[DYS6<:E)I^9LVY\*B:LOOC#7)=)TQ4M!OOKIA!  
M;1\Y9S @,G\*S " =Y?:3?3Z#J-S]LNX@)XKJ1<&>(|3QW!XJ74O :>)/#7^ MJL9+>W01V<;LNPG[!'Y)XQ4%]\-::SF-  
0T@O:;I:N"DC2,RE<.A!/0C/ MXU494N3E> ZD\ M;FN+J&I7WB#O!-HMG&+QM436+N(:^,8BGAD&8Y4'(S\_M#  
MG!]Z2TD\4W4\0N([\*PA1LR-NPR+Z#2HE:4==D7%23]XH\_ \$'6O[ -NM\$66Z  
M:SM;BX\*2[ Y9<=.\*DT>T75+T06M &1EBGGD25>NY1&2/UJ3QY]S^G^%;VZMIC#,H4I(O^\*?XG\ S:[ ]CFM[@6U  
M[93":!R,<893ZY&169>:3KWB:\$66]QVMEIV[]Y3,FE4'(!\*SI\]EJ?\_TW\* MDZEY6ZG4WEBE]#\$'DE4 ?LW\*GII5R?  
(@>UDOUOU)KJ\N9GANGB3,IQM!X!>N MWV\8'-8?A30YM%ANTE8.9KAI@0,8SVK\_,K1:-I1;DF5/\$FI7-IXFT& /\*9T@  
MF+B11C#8'-07U1>Z\_X@ET>QN?L5K:Hkw=P@S(6/2.9Z</JLK>8KCTP:T]0O(I-LY:F9MJ0H78)#@." VY7S 6C#>X'4  
M5SQ\]V5S>3?\*SMQ:VL\$6\R"-%3<>IP,9-56MRJS(H\W5' 9 end